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Introduction
Parkinson disease (PD) is a progressive neurodegenerative disorder that mainly occurs 
at older ages and is clinically characterized by resting tremor, rigidity, bradykinesia 
and postural imbalance. These clinical manifestations of PD are caused by a selective 
degeneration of dopamine-producing neurons in the substantia nigra in the brain 
stem and the consequent dopamine shortage in the striatum.1 Recent discoveries, in 
particular the identification of several gene mutations that cause familial forms of 
the disease, have led to new insights into the pathogenesis of PD. Of all PD cases, 
monogenetically inherited forms nevertheless make up only about 10%, and the 
majority therefore are sporadic. It is commonly thought that sporadic PD results from 
a complex interplay between various genetic susceptibility factors and environmental 
exposures, which induce neurodegeneration through various pathways, including 
dysfunction of mitochondria, oxidative stress and aberrant protein degradation.2-5 
However, the exact mechanisms underlying these processes are still not completely 
understood and therapies for PD are as yet only symptomatic.
Reliable estimates of the impact of PD in terms of incidence and prognosis in 
the general population are of importance in the light of the worldwide aging of 
populations. Well-designed epidemiological studies that quantify the problem of PD 
therefore are needed, but only a few large prospective population-based studies 
on PD have been conducted worldwide, and many of them were register-based. 
It is known from prevalence surveys that many PD patients, in particular those 
with mild symptoms, are missed when no direct screening is done, which may 
have led to underestimation of the incidence and biased estimates of the prognosis.6 
Prospectively designed epidemiological studies may also add to and strengthen 
the knowledge on pathogenesis and risk factors for PD, which is relevant for the 
development of better treatment. Much of the current knowledge on PD pathogenesis 
has been derived from animal models and genetic research on rare familial cases. 
Whereas animal models often focus on single risk factors and short-term effects, 
observational studies are well suited to study multiple potential risk factors and their 
interactions, which is of particular interest when studying complex multifactorial 
diseases like PD. Epidemiological studies with a long follow-up period probably also 
more accurately reflect the pathophysiological processes underlying PD, as these are 
thought to develop over a long period. 
The objective of this thesis was to study incidence, prognosis and potential risk 
factors for PD in the general population. This was done within the context of 
the Rotterdam Study, a large prospective population-based cohort study in 7,983 
participants aged 55 years and older.7 Many potential risk factors were assessed at 
baseline and participants were followed with repeated in-person screening for PD 
12
Chapter 1
for up to 15 years. In this thesis, I will first review currently available epidemiological 
evidence on diagnosis, frequency, risk factors and prognosis of PD, with special 
attention to methodological issues (Chapter 2). Next, I describe the age- and sex-
specific incidence of parkinsonism and PD in the general population (Chapter 
3.1) and the relationship between subjective motor complaints in the absence of 
clinically obvious abnormalities at baseline and the risk to develop PD during 
follow-up (Chapter 3.2). Because recent evidence from animal models suggests that 
alterations in fat metabolism might be involved in PD pathogenesis,8-10 I evaluated 
the association with PD risk of dietary intake of various types of fat (Chapter 4.1), as 
well as serum levels of total and HDL cholesterol (Chapter 4.2). Animal studies have 
furthermore indicated that high homocysteine levels might increase the risk of PD, 
as homocysteine administration induced mitochondrial dysfunction and increased 
oxidative stress.11 Therefore, I investigated the influence on PD risk of the TT variant 
of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, which is 
associated with mild hyperhomocysteinemia (Chapter 5.1) and dietary intake of folate, 
vitamin B12 and vitamin B6, essential co-factors that are required to keep plasma 
homocysteine levels low (Chapter 5.2). The role of oxidative stress in PD was further 
explored by examining the relationship between serum levels of the antioxidant 
uric acid and the risk of PD (Chapter 5.3). Subsequently, I studied the prognosis of 
PD patients in terms of risk of dementia and mortality compared with participants 
without the disease (Chapter 6). In the final chapter, I aim to put our findings in 
a broader perspective (Chapter 7). I reflect on the relevance of our observations, 
discuss how they fit current knowledge on PD pathogenesis and give suggestions for 
future research.  
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Introduction
Parkinson disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer disease and is expected to impose an increasing social and economic 
burden on societies with aging populations.1 In recent years, the interest of the 
scientific community in PD has grown considerably, triggered by the discovery of 
several causative monogenetic mutations. However, these mutations likely explain 
only a small proportion of all PD patients and about 90% of cases are sporadic. 
Despite insights derived from genetic research, the exact pathogenetic mechanisms 
responsible for the selective dopaminergic cell loss underlying PD are still not entirely 
understood. Current thinking is that mitochondrial dysfunction, oxidative stress and 
protein mishandling play a central role in PD pathogenesis,2-4 and that in sporadic 
PD these processes are induced by non-genetic factors, probably in interaction 
with susceptibility genes. Insight in non-genetic causes is needed to further the 
understanding of the pathogenesis of the disease and to develop effective therapeutic 
strategies. Large, well-designed, prospective population-based cohort studies are the 
only studies suited to examine the effects of multiple potential risk factors and their 
interactions, as well as effects that develop over a longer period.
In the past, numerous methodologically limited epidemiological studies on PD have 
been carried out, mostly small case-control or register-based studies and based on 
prevalent cases. Only in the last 5 to 7 years larger prospective studies have come 
to a stage where they have identified sufficient numbers of PD patients to examine 
incidence and potential risk factors of the disease. In this article, we will review 
what is presently known about the frequency, risk factors and prognosis of PD from 
epidemiological studies. Special attention will be given to methodological issues, 
as the usefulness of epidemiological data and interpretation of findings are largely 
dependent on the quality of the studies they were obtained from.   
Diagnosis of PD in epidemiological research
A reliable and easily applicable clinical test or marker for PD is as yet not available, 
in spite of the development of promising sophisticated imaging techniques such as 
PET and SPECT scanning that might discriminate between PD patients and normal 
controls, or between PD and other parkinsonian syndromes.5 Although potentially 
useful in a specialized setting, the value of these techniques in epidemiological 
research, in particular in low-risk cohorts, is limited given that they are costly and 
not yet widely available. Thus, PD diagnosis in epidemiological studies is still based 
on clinical manifestations. According to currently applied diagnostic criteria, the 
clinical syndrome of parkinsonism is characterized by resting tremor, bradykinesia, 
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rigidity, and postural imbalance and is diagnosed when at least two of these so-called 
cardinal signs are present.6 A diagnosis of PD furthermore requires that parkinsonism 
is idiopathic, i.e. that potential causes of secondary parkinsonism (dementia, use 
of antipsychotic medication, vascular disease, head trauma, infections and other 
neurodegenerative diseases that involve the nigrostriatal system) are excluded. A good 
response of the symptoms to levodopa medication is often considered supportive for 
a diagnosis of PD, although not observed in all patients.7 
One of the problems in epidemiological research on PD is that clinical criteria at 
best lead to a diagnosis of probable PD, while post mortem confirmation is required 
for a diagnosis of definite PD. As in epidemiological studies neuropathological 
material is usually not routinely collected, a certain degree of diagnostic uncertainty 
is inevitable. 
Clinicopathological studies have shown that in less than 80% of the cases the clinical 
diagnosis of PD was confirmed at autopsy,8 although the use of more strict clinical 
criteria in a specialist setting has been shown to improve diagnostic accuracy to up to 
90%.9, 10 The meaning of such pathological validation studies is nevertheless unclear, 
as universally accepted neuropathological criteria for PD are lacking.6 Besides, post-
mortem examination is only performed in a minority of patients and atypical cases 
are likely to be over-represented in pathology series. 
Clinical diagnosis and differential diagnosis of PD may be difficult, especially in the 
early stages of the disease that are usually studied in prospective population-based 
research. In the elderly, frequently present conditions such as arthritis or neuropathy, 
that may resemble some of the cardinal signs or affect their presentation, may 
complicate diagnosis.11 Furthermore, the clinical distinction between PD and other 
neurodegenerative diseases (dementia and disorders that involve the nigrostriatal 
system such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA), 
dementia with Lewy bodies (DLB) and corticobasal degeneration (CBD)) can be 
hard because parkinsonian signs as well as non-motor manifestations, including 
cognitive, sensory, and autonomic disturbances, may occur in all these conditions. 
To distinguish PD from other neurodegenerative disorders the order in which motor 
and non-motor symptoms appear, as well as evaluation of disease progression and 
responsiveness to levodopa therapy are of importance. Most clinicians therefore 
consider a single visit not sufficient to make a definite diagnosis. In contrast, diagnosis 
of PD in epidemiological research is often based on a single assessment, increasing 
the possibility of misdiagnosis. A study design that enables long term follow-up of 
participants after an initial diagnosis is made, either through direct contact or medical 
records, is thus preferred over assessing disease status at one point in time.
19
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Frequency
Methodological considerations
It has been noticed previously that results of studies on the prevalence and incidence 
of PD appear to vary according to applied methodology, which may complicate 
comparison across studies.11-13 As in virtually all epidemiological studies diagnosis 
is based on clinical assessments, frequency estimates are affected by the set of 
diagnostic criteria that is employed to define PD. Not surprisingly, the use of stricter 
diagnostic criteria has been shown to yield lower frequency estimates.11 Estimates 
of frequency measures are influenced even more by case-finding strategies. Studies 
performed in a clinical setting or those with record-based case finding methods fail 
to include patients who have not sought medical attention and thus underestimate 
the prevalence or incidence of PD in the general population. This has been illustrated 
by the results of several door-to-door prevalence surveys in which a considerable 
number of PD patients was detected that had not been diagnosed with the disease 
before.12-16 Most incidence studies with in-person examination also yielded higher 
incidence rates than record-based studies and identified a noticeable amount of new, 
not previously recognized PD cases, who would not have been included in a record-
based study.17, 18 
Many authors present crude estimates of the prevalence or incidence for an entire 
population or a section of the population above a certain age. These are of little use, 
since they strongly depend upon the underlying age-distribution. Age-standardized 
rates are also of limited value, as differences in age distributions used for standardization 
may hamper comparison. In this review we therefore only summarize age-specific 
prevalence and incidence rates in the given figures.
Prevalence
Many epidemiological studies have been conducted in different settings worldwide to 
estimate the prevalence of PD in the general population. Crude prevalence estimates 
derived from these studies range between 55 and 900 per 100,000.14-16, 19-26 In general, 
the prevalence of PD in industrialized countries is now estimated at 0.3% of the 
entire population and about 1% in those older than 60 years of age.27 In figure 1, we 
summarize age-specific prevalence rates obtained from population-based surveys. PD 
clearly is an age-related disease, being rare before the age of 50 yet with prevalence 
estimates increasing with age,12, 13, 15, 20-23, 26 up to 4% in the highest age groups. The 
importance of in-person examination for case-finding in epidemiological research is 
demonstrated by the high rate of newly diagnosed patients in prevalence studies with 
screening of all participants. The proportion of patients that were identified with PD 
who had never received this diagnosis before ranged from 24 to 42%.12-14, 21-23 
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Figure 1. Prospective population-based prevalence studies on Parkinson disease; 
age-specific prevalence per 100 persons
Figure 2. Prospective population-based incidence studies on Parkinson disease; age-
specific incidence rates per 100,000 person years
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Some of the studies reported a higher prevalence of PD in men,13, 15, 20, 24, 28 although 
in other studies estimates for men and women were not significantly different.12, 14, 21, 23 
Neuroprotective effects of estrogens have been suggested as a possible explanation for 
a higher risk of PD in men, but the role of estrogens in PD is still controversial.29,30 
Incidence
Incidence rates may provide better tools to compare occurrence of PD, as they 
are theoretically not affected by differences in survival of patients. Given the low 
frequency of PD outside a clinical setting, incidence studies of PD in the general 
population require large cohorts and long follow-up periods, and incidence data 
therefore are relatively scarce compared to prevalence figures. Reported standardized 
incidences vary from 8 to18 per 100.000 person-years.31 Figure 2 shows age-specific 
incidence rates, restricted to those from prospective population-based studies with 
either record-based or in-person case-finding.17, 18, 24, 25, 32-36 Onset of PD is rarely 
observed before the age of 40 and a sharp increase of the incidence is seen after the 
age of 60. However, results on the highest age groups are conflicting. Some studies 
reported a drop in the incidence for the highest age groups,36, 37 while others report 
that incidence rates continued to rise with age.17, 18, 24, 34 The decline at higher ages has 
been suggested to be an artefact caused by increased diagnostic uncertainty due to 
presence of co-morbidity in the elderly and the fact that people at higher ages might 
not consult their physician for parkinsonian signs when they consider these part of 
the normal aging process.26 Selective non-response or lost to follow-up in the highest 
age groups and impreciseness of the estimates due to low numbers may also have 
played a role.
Table 1. Age adjusted male-to-female ratios with 95% confidence intervals for the 
incidence of PD, derived from prospective incidence studies
Study (ref.) PD cases / study population Male-female ratio
   
Rochester33 138 / 53,885 1.6 (1.3 - 1.9)
China35 566 / 3,869,162 0.9 (0.6 - 1.4)
Manhattan24 83 / 213,000 1.6 (1.3 - 2.1)
Taiwan25 37 / 11,411 1.1 (0.5 - 2.7)
Central Spain17 30 / 5,160 2.6 (1.2 - 5.4)
Rotterdam18 67 / 6,566 1.5 (1.0 - 2.5)
Italy34 42 / 4,341 2.1 (1.1 - 4.1)
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Most studies on the incidence of PD applied record-based case-finding methods, 
which is less costly and time-consuming. However, the value of in-person screening 
for epidemiological research again is proven by the proportion of newly diagnosed 
patients in studies that involved examination of all participants, ranging from 39% to 
53%.17, 18 As shown in figure 2, estimates of the incidence rates were higher for all age 
categories in studies that applied in-person screening methods.17,18,34 Like in prevalence 
studies, several of the prospective studies found evidence for a higher incidence of PD 
in men.17, 18, 24, 28, 33, 34, 37 Age-adjusted male-to-female ratios of prospective population-
based incidence studies are presented in table 1.
Non-genetic risk factors
Methodological considerations
Many environmental risk factors have been hypothesized to be related to PD risk 
based on presumed underlying pathogenetic mechanisms of the disease. Much of 
the epidemiological research on risk factors has been conducted in the form of 
retrospective case-control studies, which are prone to several kinds of bias. Because 
potential risk factors are retrospectively assessed, recall bias may occur when PD 
patients are more likely to remember exposure to these factors than control subjects, 
due to increased awareness and better knowledge of the disease. Furthermore, 
controls are often not selected in an appropriate way, or ascertainment of PD is 
incomplete or inaccurate resulting in selected case-series. An important pitfall in 
case-control studies is the issue of reversed causality, i.e. the question whether 
observed differences are really causally related to PD or rather are a consequence 
of the disease. This latter issue holds particularly for studies on dietary factors, the 
majority of which is retrospectively designed. Dopamine shortage might affect food 
preferences,38 and altered intake of certain nutrients in PD patients may thus be 
erroneously considered to have played an etiological role. Dietary habits are usually 
assessed by means of food frequency questionnaires. A certain amount of error 
and thus misclassification of intake is unavoidable when using such an instrument. 
Furthermore, intakes of many nutrients are highly correlated, which renders the 
identification of specific associations difficult. Another complicating issue in dietary 
research is the lack of knowledge about the critical time period or window of exposure 
during which patients are at risk to develop PD. It is therefore unclear whether it is 
early, late, or rather cumulative or average lifetime intake that is of importance when 
studying the risk of PD. 
Prospective cohort studies, with exposure assessment before onset of PD, may 
overcome at least part of the problems that pertain to retrospective case-control 
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designs. However, cohort studies have their own limitations in that they are costly 
and less time-efficient, in particular those that apply in-person screening methods. 
Register-based studies, even when prospective, might still lead to biased results as 
PD patients outside medical care –most likely the ones with early or mild disease- 
are not included. Besides, the issue of reverse causality may play a role even in 
prospectively designed studies. Since the exact duration of the preclinical period 
in PD is unknown, some of the participants who seem disease-free at the start of 
the study may already suffer from changes due to presymptomatic dopaminergic 
degeneration, which might theoretically influence study results. 
Exposure to pesticides and herbicides
The discovery in 1983 that several persons developed typical signs of PD after 
intravenous injection of drugs contaminated with 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) and the subsequent finding that MPTP selectively damages 
dopaminergic cells in the substantia nigra39, 40 led to the hypothesis that exposure to 
environmental toxins such as pesticides, herbicides and metals might be related to 
the risk of PD. Since then, many epidemiological studies have been conducted to 
examine the association between exposure to pesticides and herbicides, as well as 
hypothesized surrogate measures for exposure like farming, living in rural areas 
and well water drinking, and the risk of PD. The majority of these studies were 
retrospective case-control studies, and thus subject to most of the methodological 
limitations that were mentioned above. Evidence fairly consistently points towards 
a positive association between pesticide exposure and PD risk, although results 
were statistically significant in only half of the studies.41 In a meta-analysis of 19 
peer-reviewed studies on pesticide exposure and the risk of PD performed between 
1989 and 1999, Priyadarshi et al found significant heterogeneity among studies and 
calculated a pooled odds ratio of 1.94 (95% CI 1.49 to 2.53),42 which fits the results 
of more recently performed case-control studies.43, 44 Findings on farming, rural 
living and well water drinking have been less consistent than those for occupational 
pesticide exposure and both strength and direction of observed associations show 
a wide variation across studies.41 The relationship between (self-reported) pesticide 
exposure and plantation work and PD has only been examined prospectively in one 
large study among men. A significantly increased risk of PD was found among men 
who worked more than 10 years on a plantation, and a non-significant association 
for men exposed to pesticides.45
It is believed that pesticides cause parkinsonian features through inhibition of 
mitochondrial complex I, as MPTP as well as the herbicide paraquat and the plant-
derived pesticide rotenone are selective complex-I inhibitors46 and evidence for 
mitochondrial dysfunction has been obtained from post-mortem material.2 Paraquat, 
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which has a chemical structure very similar to MPTP, has been shown to deplete 
dopamine in frogs47 and rotenone was found to induce selective dopaminergic 
degeneration in the substantia nigra as well as clinical features of parkinsonism in 
rats.48 
Smoking, coffee and alcohol consumption
Smoking is among the most studied risk factors for PD, and one of the few for which 
very consistent results were obtained. Numerous epidemiological studies have shown 
a reduced risk of PD among cigarette smokers. The vast majority of these were case-
control studies, but some large prospective cohort studies have been carried out 
that confirmed their results.49-51 In a large meta-analysis based on 44 case control 
studies and 4 cohort studies on the relationship between smoking and the risk of 
PD conducted in 20 countries between 1968 and 2001, a pooled relative risk of 0.59 
was calculated for ever smokers, and a relative risk of 0.39 for current smokers. In 
pursuit of completeness, meta-analyses often apply rather broad eligibility criteria, 
and results might in part be driven by included studies of poor methodological 
quality. However, the pooled effect estimate for all case control studies in this meta-
analysis was only modestly different from the association for all cohort studies.52 
Our overview in table 2 is restricted to population-based prospective studies on 
the association between smoking and PD. All of them showed a significant inverse 
association, with more or less similar effect estimates. The biological basis that might 
underlie this association is still poorly understood. Several mechanisms have been 
proposed to explain a potential neuroprotective effect of (components of) cigarette 
smoke. Cigarette smoke may stimulate dopamine release through nicotine, inhibit 
free radical damage through carbon monoxide and protect against neuronal damage 
by inhibition of monoamine oxidase B. It has also been hypothesized that PD patients 
are less prone to develop addictive behaviour such as smoking, given the role of 
dopaminergic pathways in reward mechanisms. 52, 53 An alternative theory states that 
PD patients have a characteristic cautious premorbid personality that would make 
them avoid novelty-seeking behaviours.54, 55
On the other hand, it has been suggested that the association might be due to 
several kinds of bias, including selective mortality of smokers among non-PD cases, 
inaccurate recording of PD diagnoses in smokers, and confounding by unknown 
factors.52 These issues however are most likely to play a role in methodologically 
flawed studies. The consistency of findings across different study designs, including 
carefully conducted large prospective studies, provides evidence against bias as a 
sole explanation. 
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Epidemiology of Parkinson disease
A considerable number of studies also looked at coffee consumption in relation to 
PD risk. Results have been less convincing than those for smoking, but still fairly 
consistent. Again, findings from case-control studies have been confirmed in several 
large follow-up studies (see table 3).50, 56, 57 A meta-analysis based on 8 case control 
studies and 5 cohort studies showed a significantly decreased PD risk for coffee 
drinkers (pooled RR 0.69) that was not attenuated when analyses were adjusted for 
smoking.52 Because caffeine is an inhibitor of the adenosine A2 receptor and has been 
shown to improve motor deficits in a mouse model of PD, it is generally thought to be 
the responsible component.56 Interestingly, in two cohort studies comprising only men 
a strong and significant inverse association was seen,56, 57 while in a cohort of only 
women this association was weaker and only borderline significant.57 Furthermore, 
in postmenopausal women from this latter cohort the effect of caffeine consumption 
on PD risk seemed dependent on the use of estrogen replacement therapy.58 Based 
on the finding that estrogen is a competitive inhibitor of caffeine metabolism,59 an 
interactive effect of caffeine and estrogens on PD risk has been suggested,60 but as 
yet a clear explanation for these observations is lacking. 
The relation between smoking and coffee consumption and PD, and the hypothesis 
that dopamine shortage in PD patients would make addictive behaviour less rewarding 
to them have led some researchers to examine the association between alcohol 
consumption and the risk of PD. Results of a number of case-control studies and 
some prospective cohort studies have not been very straightforward, with inverse 
associations in some studies,50, 61 but no significant association in others (table 3).62-65 
As both caffeine and cigarette smoke, but not ethanol, have shown protective effects 
in animal studies, current thinking is more in favour of a biological mechanism for 
the inverse association with PD than a certain non-causal explanation.53, 62
Dietary factors
A broad range of food groups and specific nutrients has been investigated as 
potential risk factors that are either related to an increased or a decreased risk of PD. 
The majority of epidemiological research on dietary factors comprised case-control 
studies, and only a few prospective studies have been performed. The results that 
are summarized in tables 4-6 are restricted to those obtained from population-based, 
prospective cohort studies, as these are supposedly least affected by bias.
Antioxidants
The focus in nutritional epidemiology has been mainly on antioxidants, as oxidative 
stress is thought to be involved in the pathogenesis of PD2 and antioxidants like 
vitamin E and vitamin C might protect cells against oxidative damage by neutralizing 
free radicals. Although intake of vitamin E or foods rich in vitamin E has been 
28
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associated with a significantly lower risk of PD in some case-control studies,66, 67 this 
was confirmed in only one prospective cohort study,68 whereas a prospective nested 
case-control study showed no significant association.69 Clinical trials of vitamin E 
supplementation have shown no effect on primary end points such as the need to 
start levodopa therapy.70 However, it should be pointed out that these trials were 
performed in clinically manifest PD patients, in whom a substantial proportion of 
the dopaminergic neurons have already degenerated, whereas neuroprotection from 
antioxidants is more likely to occur at very early, presymptomatic stages. Several 
studies examined the relation between vitamin C intake and PD risk, but no association 
was seen in most case-control studies71-73 and one prospective study.68
Dietary iron
Several case-control studies have investigated the role of dietary iron, because iron 
may induce free radical formation and increased iron levels have been found in the 
substantia nigra of PD patients.74 Two of these studies found a positive association 
between iron intake and PD,72, 75 but two other observed no association.71, 76 Results 
of prospective studies on the relation between dietary iron and the risk of PD have 
not been published thus far.
Fat and fatty acids
The relation between dietary fat and PD is as yet unclear. Most epidemiological 
studies focused mainly on intake of total fat and saturated fat, given that diets with 
high lipid content could theoretically increase the level of oxygen radicals through 
lipid peroxidation and thus affect the risk of PD.77 Some case-control studies 
reported higher intakes of total fat and animal fat (a major source of saturated fat) 
in PD patients,71, 72, 76 while one prospectively designed study showed no significant 
association78 and another a significant inverse association between total fat intake 
and PD risk.79 For total calorie intake a positive association was found in some case-
control studies,71, 72, 80 but could not be confirmed in any of the prospective studies.78, 
79, 81 Positive associations for dairy products and recently also for milk consumption 
have been observed in two prospective studies, although it remains unclear which is 
the responsible component.82, 83
Recently more attention has been given to unsaturated fatty acids, as these 
components of cell membranes are shown to have neuroprotective and anti-
inflammatory properties and are precursors of endogenous cannabinoids, which 
modulate dopaminergic activity in the basal ganglia.84 Within the Honolulu –Asia 
Aging study, a significantly reduced risk of PD was observed with higher intake of 
polyunsaturated fatty acids,81 a finding that was recently confirmed in the Rotterdam 
Study.79 In contrast, in the Health Professionals Follow-up Study and Nurses’ Health 
Study only intake of arachidonic acid was associated with a lower risk of PD.78 
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Dietary factors related to homocysteine metabolism
Given the potential neurotoxic effects of homocysteine, intakes of nutrients that 
influence homocysteine levels (vitamin B6, vitamin B12 and folate) have been 
investigated in relation with PD. In one large prospective study no significant 
associations were observed,85 whereas as yet unpublished results from the Rotterdam 
Study show a significantly decreased risk of PD with higher intake of vitamin B6 in 
the absence of an association for vitamin B12 and folate. This possibly indicates a 
neuroprotective effect of vitamin B6 that is unrelated to homocysteine metabolism, 
most likely through antioxidant capacities.86
Inflammation
The role of inflammation in the pathogenesis of PD is as yet unclear. Upregulation 
of cytokines was found in the brain and cerebrospinal fluid of PD patients and 
activated glial cells and reactive astrocytes have been observed in post-mortem 
material.87, 88 However, it is uncertain whether this immune response is the cause 
or rather a consequence of neurodegeneration, as so far no prospective studies 
have been performed that investigated inflammatory markers in relation to PD. In 
one epidemiological study however, the use of non-steroid anti-inflammatory drugs 
(NSAIDs) was associated with a significantly decreased risk of PD, which may indicate 
a potential neuroprotective role of these drugs.89
Estrogens
The role of estrogen in PD is as yet unclear and still disputed. The higher prevalence 
and incidence figures for PD in various epidemiological studies have prompted the 
hypothesis that female sex hormones would somehow protect against neuronal cell 
death. Animal studies have provided evidence for beneficial effects of estrogens on 
PD. Estradiol was shown to increase dopamine synthesis and release in rats,90, 91 and 
pretreatment with estradiol protected against MPTP-induced loss of dopaminergic 
neurons in mice.92 Several studies suggest that estrogen may protect neurons via 
antioxidant effects, as estradiol was found to attenuate free radical formation.93 In 
a small trial in postmenopausal women with PD, significant improvement of motor 
function was seen in women who received estrogens.94 Case-control studies on the 
relationship between use of estrogens and PD risk show conflicting results,95-97 as 
well as those regarding length of the reproductive period.96, 98 Large observational 
studies that prospectively study the effect of estrogen levels or hormone therapy on 
the risk of PD therefore are needed, but no such study has been conducted so far.
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Epidemiology of Parkinson disease
PD and cancer
Epidemiological evidence suggests a reduced incidence of many common types of 
cancers in individuals with PD.99-103 The initial hypothesis that this finding might have 
resulted from the inverse association between smoking and PD did not hold, since a 
reduced incidence has been described for both smoking-related and non-smoking-
related cancers.101, 104 An alternative hypothesis that was brought up recently states 
that a specific genetic background that can protect from cancer might also predispose 
an individual to neurodegeneration in PD, or vice versa.104 Several of the genes that 
have been identified in familial PD were studied in cancer research before their link 
with PD was recognized. Some of the genes that cause familial PD (PINK1, UCHL-
1, LRRK-2 and DJ-1) seem to have a peripheral role in the cell cycle and mutations 
in these genes might theoretically influence cancer risk. Although this theory is 
attractive as a potential explanation for the possible link between cancer and PD, it 
is still very preliminary. More research is needed to confirm the existence of such an 
association and to clarify much of the remaining questions.104 
Genetic risk factors
Methodological considerations
Monogenetic causes do not appear to play a primary role in the majority of PD 
patients. Although in several studies a positive family history has been associated 
with an increased risk of PD,105-107 in most cases a clear mode of inheritance could not 
be established. PD has therefore long been thought to be a purely sporadic disease, 
given that familial clustering might simply reflect the effect of shared environmental 
factors and does not necessarily imply a causal genetic pattern. A significant effect 
of genetic factors however was found in a study among almost 20,000 male twins, 
but predominantly in PD with onset before the age of 50 years.108 Since 1997, several 
families have been identified with parkinsonism that displays a clear Mendelian 
mode of inheritance, and familial PD is now estimated to make up about 10% of all 
cases. Although methodological issues at first sight may not be a major concern in 
monogenetic disease, the discovery of genetic variants of PD has brought up some 
definition problems. First, one might wonder whether diseases with such a well-
described cause as a single gene mutation are still to be classified as ‘Parkinson 
disease’, as according to current criteria this requires the parkinsonian syndrome 
to be idiopathic. While they are usually referred to as ‘familial PD’, it might also be 
argued that these diseases make up a distinct category of parkinsonian syndromes, 
especially because many of the familial forms display some atypical features like 
early onset, dystonia or occurrence of dementia. Second, a considerable variability of 
clinical manifestations has been found within families with the same gene mutation, 
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whereas persons with different genetic defects and different neuropathology may 
clinically be indistinguishable from each other.109 These findings have led to the 
notion of a spectrum of neurodegenerative diseases that partially overlap, where 
current classification systems do not longer suffice.110
Sporadic cases of PD are generally thought to be the result of complex interactions 
between different genetic and environmental factors. Many epidemiological studies 
have tried to identify susceptibility genes that might contribute to PD risk, usually 
through a candidate gene approach in which polymorphisms of a gene potentially 
involved in PD are compared between patients and controls. A major issue is that of 
insufficient statistical power. Given the supposed multifactorial etiology underlying 
PD, the impact of each individual susceptibility gene is expected to be only modest 
and large numbers of case-control pairs are required to detect these small effects. 
Many of the epidemiological studies on susceptibility genes have found no effects, or 
weak associations that could not be reproduced in a different setting. Apart from the 
fact that many studies were underpowered, interpretation of results and comparison 
across studies is also complicated by methodological differences. Genetic association 
studies may differ with respect to methods and accuracy of PD diagnosis, the selection 
of control subjects, or choice of a specific polymorphism of the candidate gene under 
study. Besides, certain polymorphisms, especially those involved in toxin metabolism, 
might only increase PD risk in combination with particular environmental exposures 
or lifestyle factors, which are often not assessed.111
Causative genes
So far, six genes have been identified that cause monogenetically inherited PD, 
three with an autosomal dominant inheritance pattern (alpha-synuclein, UCHL-1 and 
LRRK-2) and three associated with autosomal recessive disease (parkin, DJ-1 and 
PINK1). In addition, one potential causative gene (NR4A2) and another four loci 
with as yet unknown genes are identified which are associated to familial forms of 
parkinsonism (PARK3, PARK4, PARK9, PARK10). As these genetic advances have been 
extensively reviewed previously110, 112 we only summarize current genetic knowledge 
on monogenetic PD in an updated113-115 table (table 7). 
Susceptibility genes
A great number of potential susceptibility genes and their polymorphisms have been 
investigated in population-based association studies. Most of these were hypothesized 
to contribute to the risk of sporadic PD based on a biologically argued role in PD 
pathogenesis. The most frequently studied candidate genes are summarized in 
table 8 (grouped by supposed underlying pathogenetic mechanism) and include 
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Table 8. Most frequently studied candidate genes for PD, grouped by supposed 
underlying pathogenetic mechanism
    
Candidate gene  Abbreviation Meta-analysis (ref.)
Dopaminergic metabolism
Monoamine oxidase A / B 111 (MAO-A) NS111
(MAO-B) Sign111
Catechol-O-Methyltransferase 111 (COMT) NS111
Tyrosine hydroxylase 111 (TH) NA
Dopamine transporter 111 (DAT) NS111
Dopamine receptor 2, 4 111 (DRD2) NS111
(DRD4) NS111
Xenobiotic metabolism
Debrisoquine-4-hydroxylase 116,117 (CYP2D6) NS116
N-acetyltransferase 2 111,117 (NAT2) Sign111
Glutathione transferases 111 (GSTT1) Sign111
(GSTM1) NS111
(GSTP1) NS111
(GSTZ1) NS111
Multidrug resistance 118 (MDR-1) NA
Mitochondrial metabolism
tRNA-glu 111 Sign111
ND2 111 NS111
Homocysteine metabolism
Methylenetetrahydrofolate reductase 123,124 (MTHFR) NA
Lipoprotein-related
Apolipoprotein E 117,119 (APOE) Sign119
Genes involved in other 
neurodegenerative diseases
Tau-gene, H1 haplotype 121 Sign121
Hormonal factors
Estrogen receptor gene 122 (ER) NA
    
NS: not significant, NA: not applicable (not evaluated in meta-analysis)
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genes involved in dopamine metabolism, mitochondrial metabolism, activation or 
detoxification of xenobiotics and exogenous toxins, other neurodegenerative diseases, 
familial PD and other putative relations, such as those to lipoproteins, hormonal 
factors and homocysteine metabolism.111, 116-124 Unfortunately, many studies were 
methodologically flawed in terms of number of included subjects and inappropriate 
selection of controls. Most have shown either no or only small effects of these 
candidate genes, and often results have been contradicted or could not be replicated. 
Meta-analyses have been performed to allow pooling or aggregation of study results 
in order to increase statistical power. A meta-analysis of 84 association studies of 14 
genes showed that polymorphisms in four genes (NAT2, MAOB, GST-T1, and tRNAGlu) 
were significantly associated with PD.111 Another meta-analysis recently showed that 
the ε2 allele of the APOE gene was associated with an increased risk of PD119 and 
a meta-analysis of seven case-control studies showed a significantly increased risk 
of PD in persons homozygous for the tau H1 haplotype.121 The pathophysiologic 
significance of these polymorphisms is however not yet clear.
Prognosis
Methodological considerations
Several studies investigated the prognosis of PD patients with respect to life expectancy 
and the risk of developing dementia. Most of these studies have been performed on 
patient groups from specialized centers or have used medical records for case finding. 
Because patients with relatively mild symptoms probably are under-represented in 
these studies, results may be biased and not representative for the general population. 
Few prognostic studies on PD have used community- or population-based cohorts 
that most likely reflect a broader spectrum of disease severity and are expected to 
yield more accurate results. Besides, estimates of prognostic outcomes may be biased 
as in most studies a cohort of prevalent PD patients was followed, which means 
that these studies actually estimate prognosis after enrolment instead of prognosis 
after PD diagnosis. In several prospective epidemiological studies mortality rates 
of PD patients and controls were found to diverge more with increasing time since 
diagnosis.125, 126 In case of a long delay between diagnosis and inclusion in the study 
this may therefore have led to overestimation of mortality risks and probably other 
aspects of prognosis. 
Mortality 
PD has been associated with a reduced life expectancy in most epidemiologic studies, 
only few of which were conducted before levodopa therapy became available. 
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In 1967, Hoehn and Yahr reported a standardized mortality ratio of 2.9, but their 
result was based on a clinical population.127 The introduction of levodopa in 1969 
initially seemed to return life expectancy to approximately normal.128-130 However, the 
observed decline in mortality rates for PD patients was followed by a rise in the late 
1970s and early 1980s, presumably because levodopa delayed the death of a cohort 
of elderly patients with on average 5 years, leading to a catch-up in mortality several 
years later.131, 132 Although levodopa improved the quality of life in the majority of 
PD patients and probably prolonged life expectancy to some extent, most of the 
studies dating from after the introduction of levodopa still report a reduced survival 
in PD patients compared to persons without the disease, with mortality hazard ratios 
varying between 1.5 and 2.7 (see table 9).36, 125, 126, 133-140 
Dementia, falls and institutionalization
One of the late non-motor manifestations of PD is the development of dementia, 
which affects about 25 to 40 % of patients with PD.141 The main feature of this PD 
dementia, thought to be caused by spread of degeneration and Lewy Body formation 
to the cerebral cortex and limbic structures,141 is impairment of executive functions. 
Besides, co-existing pathology of the Alzheimer type might also cause dementia in 
PD.142 Epidemiological studies have reported relative risks of becoming demented 
for PD patients compared to those without the disease ranging between 1.7 and 
5.9.141, 143-146 Factors that seemed to influence the risk of dementia, although not 
consistently across studies, are age at onset of PD, disease duration or severity and 
APOE genotype.120, 144, 146 Dementia seems in great part responsible for the reduced 
life expectancy of PD patients, as mortality risk was found to be only modestly 
increased in those who do not become demented.146 Among other complications 
that were found to occur more often in PD patients were visits to a physician or the 
emergency-department, falling and nursing home residency.138, 147
Conclusions 
In spite of the recent major advances in the genetics of PD, the vast majority of cases 
still are thought to be sporadic, resulting from interplay between several environmental 
factors and susceptibility genes. The role of environmental factors is best evaluated 
through large observational studies, preferably prospective cohort studies with a 
long period of follow-up, as these provide the opportunity to study long-term and 
potentially interactive effects. However, given the supposed multifactorial etiology 
of PD, each potential risk factor may be expected to contribute only modestly to PD 
risk and effects of risk factors may thus be difficult to demonstrate, especially when 
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studies are small and underpowered or prone to bias due to their study design. 
Although many epidemiological studies on PD have been performed, remarkably 
few of them were of sufficient methodological quality. It is therefore not surprising 
that for many of the studied risk factors conflicting results have been obtained or 
observations could not be replicated in well-designed studies. As yet, only few 
factors have been identified that have been consistently related to the risk of PD, 
the most convincing of which are older age and smoking habits. More evidence on 
environmental factors involved in PD must come from the larger prospective cohort 
studies that are now starting to reach sufficient amounts of follow-up time and PD 
patients to confirm earlier results and to detect potentially new risk factors for this 
devastating disease.  
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Abstract
Background 
Parkinson disease is the second most common neurodegenerative disease and the 
proportion of people suffering from parkinsonism and Parkinson disease is expected 
to increase as populations age.  Few studies investigated the incidence of parkinsonism 
and Parkinson disease in the general population, and most of these were based on 
clinical data only.
Objective
To estimate the incidence of parkinsonism and Parkinson disease in a general 
population.
Methods
In the Rotterdam study, a prospective population-based cohort study in people aged 
55 years and older, we assessed age- and sex-specific incidence rates of parkinsonism 
and Parkinson disease among 6,839 participants who were free of parkinsonism at 
baseline. Case-finding involved in-person screening at both baseline and two follow-
up visits, and additional information was obtained through continuous monitoring 
of the cohort by computer linkage to general practitioners’ and pharmacy records.
Results 
After a mean follow-up period of 5.8 years, 132 subjects with incident parkinsonism 
were identified, of whom 67 (51%) had Parkinson disease. The incidence of both 
parkinsonism and Parkinson disease increased with age, with incidence rates for 
Parkinson disease rising from 0.3 per 1000 person years in subjects aged 55-65 years, 
to 4.4 per 1000 person years for those aged 85 years and older. The overall age-
adjusted incidence rate of any parkinsonism was not different in men and women, 
but men seem to have a higher risk for Parkinson disease (male-to-female ratio 1.54; 
95% CI 0.95 – 2.51). 
Conclusion
Incidence rates for both parkinsonism and Parkinson disease were higher than those 
reported by most previous studies. This may be due to our intensive case-finding 
methods involving in-person screening. 
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Introduction
The proportion of people with Parkinson disease (PD) is expected to increase with 
the aging of worldwide populations and to cause substantial economic and social 
burdens on society.1,2 Despite the increasing importance of PD, the exact incidence 
of the disease in the general population is still unknown. In contrast to prevalence 
figures, data on the incidence of parkinsonism and PD are scarce.3 In all but three 
previous studies,4-6 case finding was based on medical records. One of the limitations 
of these register-based studies is their failure to include patients who have not come 
to medical attention.3,7 In several thorough population-based prevalence surveys on 
parkinsonism and PD, it was shown that underestimation of the prevalence by medical 
records may increase up to 52%, and increases with age.8-10 We determined age- and 
sex-specific incidence rates of parkinsonism and PD within the Rotterdam Study, 
a prospective population-based cohort study of subjects aged �≥55 years. Search 
methods involved in-person screening and physical examination of participants at 
baseline and follow-up visits, and additional information was obtained by computer 
linkage to general practitioners’ and pharmacy records.
Methods
The Rotterdam Study
The Rotterdam Study is a prospective population-based cohort study on determinants 
of diseases in the elderly population.11 All inhabitants of a suburb of Rotterdam, the 
Netherlands, aged ≥55 years were eligible. Of these, 7,983 subjects (response rate, 
78%) agreed to participate. Baseline examinations took place between 1990 and 
1993. All participants were interviewed at their homes and subsequently underwent 
extensive physical examination, which included a neurological screening, at the 
research center. Follow-up examinations took place in 1993 to 1994 and 1997 to 
1999. The cohort also was continuously monitored for major disease outcomes and 
mortality through linkage of the study database to general practitioners' medical 
files. Informed consent was obtained from each participant, and the Medical Ethics 
Committee of the Erasmus Medical Center in Rotterdam approved the study.
Study population
At baseline, 6,969 participants underwent neurologic screening. Parkinsonism was 
diagnosed in 130 participants, 99 of whom had PD.7 This resulted in a cohort of 6,839 
subjects at risk to develop any kind of parkinsonism during the follow-up period. For 
the cohort at risk for PD, we further excluded 273 persons with dementia at baseline 
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because a diagnosis of dementia before the onset of parkinsonism precludes the 
diagnosis of PD.7 Thus, the cohort at risk for PD consisted of 6,566 subjects free of 
parkinsonism and dementia at baseline.
Case-finding and diagnostic procedure
At baseline and follow-up evaluation, we used a two–phase design to identify subjects 
with parkinsonism or PD. In the first phase, all participants were screened at the 
research center for signs of parkinsonism (e.g., resting tremor, rigidity, bradykinesia, 
or impaired postural reflexes) in a standardized way. Those who screened positive 
received a structured clinical work-up, comprising the motor examination of the 
Unified PD Rating Scale (UPDRS)12 and neurologic examination and history taking by 
a research physician specialized in neurologic disorders, to establish parkinsonism 
and to classify subtypes. Subjects who were suspected of having PD were invited 
for a further evaluation by a neurologist. In addition to the in-person follow-up 
evaluation, the cohort was continuously monitored for detection of new cases of 
parkinsonism through a surveillance system by computer linkage with the general 
practitioners’ automated medical record systems.
Table 1. Baseline characteristics of the study population
    
Cohort at risk for Cohort at risk for PD,
any parkinsonism, no (%)  no (%)
    
N 6,839 6,566
Women 4,070 (59.5) 3,876 (59.0)
Age at baseline
55 - 65 y 2,537 (37.1) 2,53 (38.5)
65 - 75 y 2,456 (35.9) 2,425 (36.9)
75 - 85 y 1,406 (20.6) 1,294 (19.7)
85 y and older 440 (6.4) 317 (4.8)
mean (SD) 69.4 (9.1) 68.8 (8.7)
Living in nursing home 518 (7.6) 336 (5.1)
Dementia 273 (4.0)
History of stroke 194 (2.8) 155 (2.4)
    
PD : Parkinson disease, SD : standard deviation
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Through this system, we were notified of incident cases of parkinsonism and had 
access to those subjects’ medical records. If possible, a neurologist also examined 
these participants to confirm the diagnosis. We also used the information obtained 
from this surveillance system for subjects who could not be re-examined in person at 
follow-up evaluation (because of death, migration, disease, logistic reasons, or refusal). 
Furthermore, information on all participants who were prescribed antiparkinsonian 
drugs, identified by means of a computerized pharmacy database, was reviewed to 
check whether no cases had been missed.
Parkinsonism was diagnosed if two or more cardinal signs (e.g., resting tremor, 
rigidity, bradykinesia, or impaired postural reflexes) were present in a subject not 
taking antiparkinsonian drugs, or if in a person treated with antiparkinsonian 
medication, one or more signs, documented by medical history, had improved. PD 
was diagnosed if all causes of secondary parkinsonism, as well as dementia before 
the onset of parkinsonism, had been excluded. 
The diagnostic criteria for the several subtypes of parkinsonism have been 
reported previously.7 In short, parkinsonism resulting from other causes included 
1) parkinsonism associated with dementia (with dementia onset clearly preceding 
the onset of parkinsonism); 2) drug-induced parkinsonism (use of neuroleptics or 
other antidopaminergic drugs in the 6 months preceding the onset of symptoms 
and without history of parkinsonism); 3) parkinsonism related to cerebrovascular 
disease (with a clear time relationship between cerebrovascular event and onset 
of atypical parkinsonism, preferably supported by neuroimaging, usually without 
tremor); 4) parkinsonism in multiple system atrophy or progressive supranuclear 
palsy; and 5) parkinsonism unspecified. Included in this latter category were subjects 
with more than one possible cause or with no clear time relationship between the 
possible cause and the onset of parkinsonism, as well as subjects in whom all other 
possible causes of parkinsonism could be excluded but who did not respond to 
antiparkinsonian drugs.
For the age of onset of PD, we took the age at midpoint between the examination in 
which parkinsonism first was identified and the preceding examination. An objective 
indication of the time when the first symptom actually appeared is hard to achieve 
for all patients in an equally adequate way because PD has an insidious onset. Given 
the relatively short screening intervals, we considered age between two subsequent 
examinations a good approximation of the actual age at onset.
Data analysis
We obtained age-specific incidence rates per 10-year age group by dividing the 
number of incident cases by the number of person-years at risk (calculated by adding 
each participant’s contribution of follow-up time per age group). The 95% CIs were 
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based on the Poisson distribution. For participants who did not develop parkinsonism, 
the follow-up period ended at the second follow-up examination, at the date of 
invitation for the second follow-up examination (for nonresponders), or death. In 
case of incident parkinsonism, follow-up time ended at onset of parkinsonism or PD. 
Because subjects who developed dementia were considered no longer to be at risk 
for PD, follow-up time for incident PD, but not for parkinsonism, ended at onset of 
dementia. 
Incidence rates of parkinsonism and PD per 10-year age group were calculated overall 
and for men and women separately. We transformed the age-specific incidence rates 
into cumulative incidences to estimate the risk of developing parkinsonism or PD 
between the age of 55 and 85 years, assuming no competing causes of death, for men 
and women. Age-adjusted male-to-female ratios for the incidence rates were calculated 
for each age category using Cox proportional hazards regression analysis. 
Results
Table 1 shows the baseline characteristics of the cohort at risk for any parkinsonism 
and the cohort at risk for PD. Of the total cohort (n = 6,839), 1,364 subjects (19.9%) 
died during the follow-up period. Follow-up evaluation was virtually complete (99%) 
until December 31, 1999, with complete information during the first follow-up period 
and 67 persons lost to follow-up evaluation during the second follow-up period.
After 39,879 person-years of follow-up evaluation (mean follow-up period, 5.8 years), 
132 new cases of parkinsonism were identified. Of these, 67 subjects (51%) had PD, 
which makes PD the most common type of parkinsonism. 
Figure 1. 
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Fifty cases of PD were detected through the structured workup at the research center. 
Among participants who refused the follow-up visit or died during the interval, 17 
cases of PD were identified through the continuous surveillance system by linkage to 
medical files. Of the incident PD cases, 26 had not been diagnosed with PD before 
(52% of those screened in person, 39% of all incident PD cases). Two cases that were 
diagnosed as PD during the first follow-up round were later revised when at the second 
follow-up evaluation no parkinsonian signs were observed while the participants 
were not using any antiparkinsonian medication. Besides PD, the other diagnoses 
were parkinsonism associated with dementia (18%), drug-induced parkinsonism 
(12%), cerebrovascular disease (5%), multiple system atrophy or progressive nuclear 
palsy (2%), and parkinsonism unspecified (12%).
In table 2, age- and sex-specific incidence rates and cumulative incidence, as well 
as age-adjusted male-to-female ratios, are shown for the cohort at risk for any 
parkinsonism. For the subjects at risk for PD, similar information is presented in 
table 3.The overall incidence rate was 3.3 per 1000 person-years (95% CI, 2.8 to 3.9) 
for any parkinsonism and 1.7 per 1000 person-years (95% CI, 1.4 to 2.2) for PD. The 
risk of developing any parkinsonism between the age of 55 and 85 years, assuming 
no competing causes of death, was 7.7% for women and 8.5% for men, and the risk of 
PD was 4.2% for women and 6.1% for men. As also shown in figure 1, incidence rates 
of parkinsonism and PD show a strong and consistent increase with age for men and 
women. Overall, men and women had identical risks for parkinsonism (age-adjusted 
male-to-female ratio 0.99; 95% CI, 0.68 to 1.44). However, the risk for PD was higher 
for men in all age categories except one (65 to 75 years), with the male-to-female 
ratio increasing with age (also shown in figure 2). The overall age-adjusted male-to-
female ratio was 1.54, which was borderline significant (95% CI, 0.95 to 2.51).
Figure 2. 
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CIs) of Parkinson disease 
per 1000 person years  per 
age category, in men and 
women
0
2
4
6
8
10
12
14
16
18
20
22
55-65          65-75           75-85            85+
age category
in
ci
de
nc
e 
ra
te men
women
60
Chapter 3.1
Ta
b
le
 2
. I
n
ci
d
en
ce
 r
a
te
s 
pe
r 
10
0
0
 p
er
so
n
 y
ea
rs
 (
95
 %
 C
I)
 f
or
 a
n
y 
pa
rk
in
so
n
is
m
 p
er
 1
0
-y
ea
r 
a
ge
 c
a
te
go
ry
M
en
W
o
m
en
O
ve
ra
ll
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
ge
  
P
er
so
n
In
ci
d
en
ce
 
P
er
so
n
In
ci
d
en
ce
 
P
er
so
n
In
ci
d
en
ce
 
M
al
e-
to
-f
em
al
e 
g
ro
u
p
C
as
es
ye
ar
s
ra
te
 (
95
%
 C
I)
C
as
es
ye
ar
s
ra
te
 (
95
%
 C
I)
C
as
es
ye
ar
s
ra
te
 (
95
%
 C
I)
ra
ti
o
 (
95
%
 C
I)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55
-6
5 
y
3
4,
35
6
0.
7
(0
.2
-2
.1
)
2
6,
01
7
0.
3 
(0
.1
-1
.3
)
5
10
,3
74
0.
5
(0
.2
-1
.2
)
2.
0
8 
(0
.3
5
-1
2.
47
)
65
-7
5 
y
10
7,
10
4
1.
4
(0
.8
-2
.6
)
29
9,
10
1
3.
2 
(2
.2
-4
.6
)
39
16
,2
0
6
2.
4
(1
.8
-3
.3
)
0.
38
 
(0
.1
8
-0
.8
0)
75
-8
5 
y
25
3,
66
0
6.
8(
4.
6
-1
0.
1)
29
6,
4
45
4.
5 
(3
.1
-6
.5
)
54
10
,1
0
6
5.
3
(4
.1
-7
.0
)
1.
33
 
(0
.7
7-
2.
31
)
��
 8
5
+
9
74
4
12
.1
(9
.3
-2
3.
3)
25
2,
4
48
10
.2
 (6
.9
-1
5.
1)
34
3,
19
3
10
.6
(7
.6
-1
4.
9)
1.
19
 
(0
.5
0
-2
.8
5)
To
ta
l
47
15
,8
65
8.
5
%
*
85
24
,0
11
7.
7
%
*
13
2
39
,8
78
7.
9
%
*
0.
99
†  
 
(0
.6
8
-1
.4
4)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
C
u
m
u
la
ti
ve
 i
n
ci
d
en
ce
 (
ri
sk
 o
f 
pa
rk
in
so
n
is
m
 b
et
w
ee
n
 a
ge
 5
5
 a
n
d
 8
5)
, 
a
ss
u
m
in
g 
n
o 
co
m
pe
ti
n
g 
ca
u
se
s 
of
 d
ea
th
.
† 
A
ge
-a
d
ju
st
ed
 r
a
ti
o.
61
Incidence of parkinsonism and Parkinson disease in a general population
Discussion
We assessed age- and sex-specific incidence rates of parkinsonism and PD in a large, 
prospective population-based cohort study. In men and women, we found that the 
incidence of parkinsonism and PD increased with age. The overall age-adjusted 
incidence rate of parkinsonism did not differ between men and women, but men 
seem to have a higher risk for PD.
Our study had several strengths. We followed a large cohort over a period of nearly 
six years, resulting in a large number of person-years of follow-up. At baseline and at 
follow-up evaluation, participants were screened in person and in a similar way, and 
if screened positive, received a similar diagnostic workup. Only a small proportion 
of the subjects who were suspected of parkinsonism during the screening did not 
undergo the second, diagnostic phase. For those, as well as for the persons who 
were screened at baseline but could not be screened at follow-up, we were able 
to achieve a complete follow-up evaluation during the first follow-up period and 
a virtually complete follow-up evaluation during the second follow-up period by 
using a population surveillance system. Our follow-up periods were relatively short. 
This reduced the proportion of subjects who could not be screened in person due 
to death, disease, or migration, and ensured a more complete case-ascertainment. It 
also allowed us in case of incident parkinsonism to take the midpoint between two 
subsequent examinations as a fairly accurate approximation of age at onset, which is 
usually hard to indicate exactly in a disease with an insidious onset like PD. 
Furthermore, because of the continuous surveillance system, we had access to medical 
information concerning the period after symptom onset, providing data on response 
to medication and development of additional symptoms and thereby ensuring a more 
accurate diagnosis and subtyping of parkinsonism. 
We found overall and age-specific incidence rates of parkinsonism and PD that are 
higher than most of the figures previously reported. Currently, there is no evidence 
suggesting that this can be explained by differences in environmental exposure 
or genetic makeup of the population of the Rotterdam Study, although we cannot 
completely exclude this possibility. We think that the high rates in our study are mainly 
the result of more intensive case finding methods. Most of the previously published 
studies were based on existing medical records.13-17 Prevalence surveys have shown 
that a large proportion of patients with parkinsonism remain undiagnosed if search 
strategies only rely on medical records and no population screening is done.3,7,9,10 As 
was reported by the Europarkinson group, this underestimation may vary from 11 
to 52% and increases with age.8 Only three previous studies on the incidence of PD 
involved in-person screening.4-6  Two prospective population based studies in Italy 
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(ILSA) and Spain (NEDICES), both using a two-phase design, found incidence rates 
more or less similar to ours.5,6 The third study, the Honolulu Heart Study (restricted to 
Hawaiian men of Japanese and Okinawan ancestry), showed lower figures.4 However, 
this study had no in-person screening at baseline, and >20 years had elapsed between 
baseline and the follow up screening for PD. Therefore, subjects with early or mild 
parkinsonism who did not come to medical attention or were lost during the interval 
will not have been included in the incidence estimates. 
Thirty-nine percent of the PD cases identified in our study had not been diagnosed 
with PD before and would thus not have been included as a PD case in a register-
based study. In the NEDICES study, 53% of the cases with PD were newly identified 
through the screening process. This confirms the observation from the Europarkinson 
prevalence survey that the proportion of newly diagnosed patients in the Netherlands 
was relatively low compared with other European countries,8 probably reflecting the 
low-threshold accessibility of Dutch medical services. Together with the increased 
awareness of parkinsonism and PD among general practitioners through participation 
in the Rotterdam Study, this could in part contribute to the relatively high number of 
cases observed in our study. 
From pathology studies, it is known that there is always a certain amount of misdiagnosis 
of parkinsonism and PD.18,19 Still, we do not find it likely that overdiagnosis of 
parkinsonism and PD has played a role in the high incidence figures because every 
participant was screened in person, and if possible, the diagnosis was confirmed by 
a neurologist applying strict diagnostic criteria. Moreover, we continued following 
participants after a diagnosis of parkinsonism or PD had been made. This enabled us 
to revise cases when additional symptoms appeared or participants did not respond 
to medication, thereby reducing the possibility of incorrectly diagnosing subjects 
with multiple system atrophy or dementia with Lewy bodies (DLB) as having PD.
We found that the incidence rates of parkinsonism and PD increased with age. No 
decrease in the incidence in the highest age groups was observed, as was previously 
reported.4,16 A possible explanation is that the decrease in some of the earlier studies 
was an artificial one caused by selective nonresponse or loss to follow-up in the 
highest age groups. Furthermore, older people may not consult their physician for 
parkinsonian signs because these signs are often considered to be part of the normal 
aging process.20 Therefore, parkinsonism in the oldest patients may be missed when 
case finding is based on medical records only. 
We identified 26 subjects who developed parkinsonism after onset of dementia 
(20% of all incident parkinsonism). These participants might have DLB. DLB is 
suggested to be the second most common type of degenerative dementia in the 
elderly population and is clinically characterized by fluctuating cognitive impairment, 
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attentional deficits, psychiatric symptoms (especially visual hallucinations), and mild 
extrapyramidal features that usually develop after impairment of cognitive function.21 
Thus far, few population-based studies have been performed on the prevalence 
of DLB,22 and incidence was studied only in the clinical setting of a memory and 
dementia assessment unit in Spain.23 Although DLB was not specifically assessed in 
our study, our data might give some clues about the incidence of DLB in a general 
population. Assuming that subjects with parkinsonism associated with dementia all 
had DLB, the overall incidence rate in this cohort aged ≥55 years would be 0.7 per 
1000 person-years (95% CI, 0.4 to 1.0).
Although only borderline significant, we found evidence for a higher incidence of PD 
in men. Previous studies show conflicting results on differences of the incidence of 
PD in men and women.3 Several studies found a significant higher risk in men,5,6,13,16 
but a minority reported a female preponderance.24,25 The exact cause of the possibly 
higher incidence of PD in men is still unknown, but it has been suggested that 
hormonal factors play a role in the etiology of PD and that estrogens may provide 
neuroprotective effects.26-28
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Abstract
Background
Neuronal degeneration and dopamine loss in the preclinical phase of Parkinson 
disease may produce subtle complaints before clinically recognizable symptoms 
emerge.
Objective
To examine whether subjective complaints of stiffness, slowness, tremors, or postural 
imbalance in persons without clinical signs of parkinsonism are related to an increased 
risk of future Parkinson disease.
Methods
We recorded subjective complaints of stiffness, slowness of movement, tremors, and 
postural instability (falling or a feeling of imbalance) in a standardized interview 
in 6,038 non-demented participants in whom no parkinsonian signs were found on 
physical examination at baseline, and studied them prospectively for the occurrence 
of incident Parkinson disease. Participants were examined in-person both at baseline 
(1990-1993) and two follow-up visits (1993-1994 and 1997-1999) and the cohort 
was continuously monitored through computerized linkage of the study database to 
general practitioners’ medical records.
Results 
Participants who reported stiffness, tremors, or imbalance at baseline had a 
significantly increased risk to develop Parkinson disease during follow-up (hazard 
ratios (95% confidence intervals) for stiffness 2.11 (1.25 to 3.55), for tremor 2.09 (1.12 
to 3.90) and for imbalance 3.47 (1.69 to 7.00)). 
Conclusion
Subjective complaints of stiffness, tremors and imbalance are associated with an 
increased risk of future Parkinson disease and may reflect early effects of dopamine 
shortage, even when standard neurological testing cannot yet demonstrate any motor 
symptoms. 
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Introduction
Parkinson disease (PD) is caused by a selective degeneration of the dopaminergic 
neurons in the substantia nigra of the brain.1 The typical clinical signs of PD (tremor, 
rigidity, bradykinesia, and postural instability) start to appear when degeneration 
and associated dopamine loss exceed 50%.2,3 Manifest PD is thus preceded by a 
preclinical phase of several years, during which neuronal degeneration develops 
without motor symptoms being present yet.4 Evidence suggests however that non-
motor abnormalities may occur during this phase, such as olfactory dysfunction, 
personality disturbances, and depression.3,5-8 More general non-specific symptoms 
have also been reported to predate the typical PD signs for several years.9 
We hypothesized that moderate dopamine deficiency in preclinical PD might result in 
subtle subjective complaints specifically related to motor function, and we examined 
in a prospective population-based cohort study whether these complaints were 
associated with an increased risk of PD in the future.
Methods
The Rotterdam study
The Rotterdam study is a prospective, population-based cohort study on determinants 
of diseases in the elderly.10 Of all inhabitants aged 55 years and older of a district of 
Rotterdam, 7,983 subjects (response rate 78%) agreed to participate. Both at baseline 
(1990-1993) and two follow-up rounds (1993-1994 and 1997-1999), all participants 
were interviewed and underwent extensive physical examination, including 
cognitive screening and screening for parkinsonian signs.11-13 In addition, the cohort 
was continuously monitored for major disease outcomes and mortality through 
computerized linkage to general practitioners’ medical files. Informed consent was 
obtained from each participant and the Medical Ethics Committee of the Erasmus 
Medical Center Rotterdam approved the study.
Subjective complaints assessed during the baseline interview
At baseline, all participants were interviewed at their homes by means of a standardized 
questionnaire. This questionnaire included a set of five symptom-specific questions 
that concern the four cardinal signs characteristic of PD. Participants were asked to 
indicate whether they ever experienced stiffness (rigidity), tremors of head, arms or 
legs (resting tremor), slowness of movement (bradykinesia), falling, or a feeling of 
imbalance (both related to postural imbalance). We assessed imbalance in a stepwise 
fashion by first asking participants whether they ever experienced dizziness, and if so, 
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to specify whether this concerned a near-fainting sensation (presyncope), spinning 
sensation (vertigo), a feeling of imbalance (disequilibrium), or the perception of 
lacking control over leg movement. 
Assessment of Parkinson disease
Both at baseline and at follow-up, we used a two–phase design to identify subjects with 
PD.12,13 All participants were screened for parkinsonian signs (rigidity, resting tremor, 
bradykinesia, and impaired postural reflexes) in a standardized way. Individuals 
who screened positive received a structural diagnostic workup comprising the 
Unified Parkinson’s Disease Rating Scale14 and neurological examination. Additional 
information obtained from the computerized surveillance system was reviewed by a 
panel of neurologists and research physicians. A neurologist examined persons who 
were suspected of having PD to confirm the diagnosis. Parkinsonism was diagnosed if 
at least two parkinsonian signs were present in a subject not taking antiparkinsonian 
drugs, or if at least one sign had improved after medication was started. PD was 
diagnosed when all causes of secondary parkinsonism (parkinsonism due to 
dementia, use of neuroleptics, cerebrovascular disease, multiple system atrophy, or 
progressive supranuclear palsy) could be excluded.
Table 1. Baseline characteristics of the study population
No. 6,038
Age, yr (SD) 68.5  (8.5)
Women 3,569 (59.1)
Subjective complaints:
Stiffness 1,938 (32.1)
Tremor of arms, legs or head 636 (10.5)
Slowness of movement 1,262 (20.9)
Feeling of imbalance* 524 (10.7)
Falling 905 (15.0)
At least one complaint 3,146 (52.1)
At least two complaints 1,359 (22.5)
  
Values denote numbers (percentages), unless stated otherwise
* Assessed in 4,897 participants 
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Study population
At baseline, 6,818 participants underwent neurological screening and provided 
information on subjective complaints. Of those, 116 subjects were diagnosed with 
any parkinsonism, including 89 PD cases.12 To examine the relationship between 
baseline subjective complaints and the risk of incident PD, we excluded all 
participants diagnosed with any parkinsonism or dementia at baseline, as they could 
no longer fulfill the criteria for incident PD.12 Because absence of parkinsonism does 
not preclude the presence of one cardinal sign, and to be maximally sure to evaluate 
subjects free of any parkinsonism, we only studied participants in whom none of 
the parkinsonian signs was found during the baseline neurological screening. This 
resulted in a study population at risk for PD of 6,038 persons free of parkinsonian 
signs and dementia at baseline. 
Data analysis
Because the complaints that we studied specifically concerned the cardinal signs of 
PD, we first evaluated whether they were cross-sectionally related to the presence of 
PD at baseline. Odds ratios (ORs) for PD according to the presence of each complaint 
were calculated through binary logistic regression, adjusted for age and sex. To 
examine the association between baseline complaints in non-demented participants 
free of parkinsonian signs and the risk of future PD, we used Cox proportional 
hazards regression analysis to calculate Hazard ratios (HRs), adjusted for age and 
sex. 
Results
Baseline characteristics of the study population are shown in table 1. The prevalence 
of self-reported complaints suggestive for parkinsonism appears considerably high in 
the elderly population, even in persons without any parkinsonian sign on physical 
examination. Over half of the participants (52.1%) reported at least one of the five 
complaints related to the typical features of PD. Stiffness was reported by almost one 
third of the study population, slowness by one fifth and tremors, imbalance, and 
falling each by over 10%. 
Results of the cross-sectional analysis are shown in table 2. The vast majority (92.1%) 
of individuals diagnosed with PD at baseline had at least one complaint, and 75% 
reported at least two. As expected, reported stiffness, falling, and especially slowness 
of movement and tremors were strongly related to the presence of PD at baseline. 
Table 3 shows the relation between reported complaints at baseline and the risk to 
develop PD during follow-up in non-demented participants who screened negative 
for any parkinsonian sign on routine examination. Follow-up information was 
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available for 99% of the participants, either through in-person re-examination or the 
continuous surveillance system. Complete in-person re-examination was performed 
in 80.6 % of the participants (84.6% of those still alive) in the first follow-up round 
and in 62 % (74.4 % of those still alive) in the second follow-up round. During a 
total of 35,429 person-years of follow-up (mean follow-up time, 5.8 years), 56 new 
cases of PD were identified. Of those, 43 cases were detected through the structured 
workup at the research center and 13 through the computerized surveillance system. 
Mean follow-up after disease onset of the incident cases was 4.3 (SD, 1.8) years.11 
Of the participants who developed PD during follow-up, 71.8% had reported at least 
one and 41.0% at least two of the complaints related to motor function at baseline. 
Complaints of stiffness at baseline were significantly associated with a more than 
two-fold increased risk of future PD (HR, 2.11; 95% confidence interval (CI), 1.25-
3.55), as were reported tremors of arms, legs, or head (HR, 2.09; 95% CI, 1.12-3.90).
Table 2. Association between reported complaints and the presence of PD at 
baseline, cross-sectionally. Odds ratios (95% CIs), adjusted for age and sex
OR  (95% CI)
   
Stiffness
No 1.00 (ref.)
Yes 2.43 (1.58-3.73)
Tremor of arms, legs or head
No 1.00 (ref.)
Yes 13.61 (8.45-21.92)
Slowness of movement
No 1.00 (ref.)
Yes 5.97 (3.74-9.52)
Feeling of imbalance
No 1.00 (ref.)
Yes 1.27 (0.62-2.61)
Falling
No 1.00 (ref.)
Yes 2.60 (1.66-4.08)
   
OR : odds ratio, CI : confidence interval
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Interestingly, self-reported falling and slowness of movement, that were both 
significantly cross-sectionally related to the presence of PD at baseline, were not 
prospectively associated with an increased risk of future PD. A feeling of imbalance, 
on the other hand, showed a strong association with a future diagnosis of PD (HR, 
3.47; 95% CI, 1.69-7.00), and no significant association with the presence of PD at 
baseline.
Comment
In this population-based study, a considerable proportion of the elderly experienced 
stiffness, slowness, tremors, falling, or a feeling of imbalance. Even among persons 
without any parkinsonian signs on clinical examination, over half of participants 
reported at least one of these complaints. Furthermore, persons who reported stiffness, 
tremors, or a feeling of imbalance at baseline had an increased risk to develop 
PD during follow-up. One of the major strengths of this study is its prospective 
design; complaints were assessed while future disease status was unknown and 
therefore recall bias is not an issue. Moreover, we used in-person screening of 
participants instead of register-based methods to assess parkinsonism. This limits 
the possibility that at baseline relatively early or mild cases of PD who had not 
sought medical attention yet were incorrectly diagnosed as not having PD. Besides, 
we restricted our study population to those participants in whom no abnormalities 
were found on physical examination specifically aimed at detecting parkinsonian 
signs. We also consider incorrect diagnoses during follow-up unlikely. Follow-up was 
almost complete, we applied strict diagnostic criteria for PD, and continued to follow 
participants after a diagnosis had been made, which enabled us to revise diagnoses 
on the basis of additional information if necessary.12 Unfortunately, we could not 
perform in-person re-examinations in all of the participants due to death, refusal, 
or inability to visit the research center because of disease or handicaps. One might 
thus argue that incident PD cases may have been missed, probably especially those 
with the postural instability / gait disorder-dominant form of PD, which is more 
difficult to diagnose without standardized screening. However, since the majority of 
participants underwent direct examination and the computerized surveillance system 
provided virtually complete coverage for those who could not be seen, we think this 
possibility is limited and will not have affected our results substantially. Limitations of 
the baseline questionnaire include absence of questions on the duration of reported 
complaints, which precludes potentially interesting subanalyses, and the fact that 
both limb and head tremor were assessed in one question. Because head tremor 
usually is not considered typical for PD, a question about limb tremor only would 
probably have yielded more PD-specific results.
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Our findings support the notion that clinically manifest PD is preceded by a 
preclinical phase that is not entirely asymptomatic. Subjective complaints related to 
motor function might indicate a very early phase of not yet diagnosable PD, during 
which dopamine loss is not sufficient to produce overt typical PD symptoms, but may 
result in subtle signs that are very mild or only intermittently present and therefore 
not likely to be detected in routine screening or examination. In our study, falling 
was related cross-sectionally, but not prospectively to the risk of PD, while for a 
subjective feeling of imbalance the opposite held true. Perceived imbalance may be 
a very early symptom that progresses to overt postural instability and an increased 
risk of falling later in the course of the disease. In the same way, a subjective feeling 
of stiffness may precede clinically detectable rigidity and patients may experience 
occasional tremors long before clinical examination confirms their perception.
Table 3. Subjective complaints related to motor function and the risk of incident PD. 
Hazard ratios (95% CIs), adjusted for age and sex
HR  (95% CI)
   
Stiffness
No 1.00 (ref.)
Yes 2.11 (1.25-3.55)
Tremor of arms, legs or head
No 1.00 (ref.)
Yes 2.09 (1.12-3.90)
Slowness of movement
No 1.00 (ref.)
Yes 1.49 (0.84-2.65)
Feeling of imbalance
No 1.00 (ref.)
Yes 3.47 (1.69-7.00)
Falling
No 1.00 (ref.)
Yes 0.61 (0.27-1.36)
   
HR : hazard ratio, CI : confidence interval 
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It has been observed that prior to developing clinically manifest PD, many patients 
experience a range of non-specific symptoms, such as depression, fatigue, anxiety, 
or pain.8,9 Similar findings have been observed in prospective studies of Alzheimer 
disease (AD) or cerebral small vessel disease, which showed that subjective memory 
complaints in persons without objective cognitive impairment were associated 
with an increased risk of developing dementia or more white matter lesions.15-18 
Both PD and AD are characterized by a phase of neuronal degeneration and loss 
of function before the appearance of typical symptoms,4 and apparently such a 
preclinical phase also exists in slowly progressive vascular disease. Researchers have 
shown particular interest in possible markers of preclinical disease, since putative 
neuroprotective agents would ideally be administered as early in the degenerative 
process as possible and preferably before clinical symptoms appear.19,20 Several 
potential biomarkers for presymptomatic PD are now being investigated, such as 
loss of the dopamine transporter detected by PET imaging, subtle abnormalities on 
psychological testing, olfactory dysfunction, and biochemical markers in serum or 
CSF.5,20,21 A questionnaire on complaints related to motor function is in itself probably 
of limited use as a preclinical marker. In spite of the strong associations between self-
reported complaints and the risk of future PD, the specificity will be low, given the 
high proportion of elderly reporting these complaints. Combined with the relatively 
low prevalence and incidence of PD in the general population12,22 this will result in 
a low positive predictive value (defined as the proportion of persons with a positive 
test that will actually develop the disease). As a matter of fact, in our data each of 
the subjective complaints had a positive predictive value of no higher than 1 to 2.5%, 
which is clearly insufficient for a questionnaire to be used alone as a marker for 
preclinical disease. It is, however, generally believed that a single test will unlikely 
fulfil all criteria for the ideal biomarker and that presumably a stepwise approach 
with a simple and inexpensive initial screening test is required.4,20 A questionnaire on 
subjective complaints might qualify for being part of such a first step. 
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Abstract
Background
Unsaturated fatty acids are important constituents of neuronal cell membranes and 
have neuroprotective, antioxidant, and anti-inflammatory properties. 
Objective
To examine whether a high intake of unsaturated fatty acids is associated with a 
lower risk of Parkinson disease. 
Methods
In the Rotterdam Study, a prospective population-based cohort study of people aged 
�≥ 55 years, we evaluated the association between intake of unsaturated fatty acids 
and the risk of incident Parkinson disease among 5,289 subjects who were free of 
dementia and parkinsonism and underwent complete dietary assessment at baseline. 
Parkinson disease was assessed through repeated in-person examination and the 
cohort was continuously monitored by computer linkage to medical records. We 
analyzed the data using Cox proportional hazards regression models. 
Results
After a mean follow up of 6.0 years, we identified 51 participants with incident 
Parkinson disease. Intakes of total fat, monounsaturated fatty acids (MUFAs) and 
polyunsaturated fatty acids (PUFAs) were significantly associated with a lower risk 
of Parkinson disease (adjusted Hazard Ratios per standard deviation increase of 
energy-adjusted intake of total fat, 0.69 (95% confidence interval (CI) 0.52 to 0.91), 
of MUFAs, 0.68 (0.50 to 0.94), and of PUFAs, 0.66 (0.46 to 0.96)). No associations 
were found for dietary saturated fat, cholesterol, or trans fat. 
Conclusion
These findings suggest that high intake of unsaturated fatty acids might protect against 
Parkinson disease.
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Introduction
Parkinson disease (PD) is the second most common neurodegenerative disorder, 
caused by a selective degeneration of dopaminergic cells in the substantia nigra. 
The exact mechanism underlying this process is still unclear, but oxidative stress, 
mitochondrial dysfunction, and inflammation are thought to play a major role.1-3 There 
are several reasons why dietary intake of unsaturated fatty acids might influence 
the risk of neurodegenerative diseases and in particular PD. First, polyunsaturated 
fatty acids (PUFAs) have anti-inflammatory and neuroprotective properties,4-7 and 
monounsaturated fatty acids (MUFAs) are thought to reduce oxidative stress.8,9 
Second, the fatty acid composition of cell membranes is affected by diet. In infants 
and young animals, dietary deficiencies in MUFAs and PUFAs reportedly lead to 
poorer brain function.5,6,10 Third, PUFAs are precursors for endogenous cannabinoids, 
which play a role in the control of movement by modulating dopaminergic activity 
in the basal ganglia.11,12 Finally, evidence is increasing that genes involved in lipid 
metabolism may also regulate toxicity of alpha-synuclein, the major component of 
the inclusion bodies found in the brains of patients with PD.13 
Previous epidemiologic studies on the association between dietary fat intake and 
the risk of PD have shown inconsistent results.14-21 Most of these studies were case-
control studies or investigated only total fat intake. We hypothesized that higher 
dietary intake of unsaturated fatty acids might lower the risk of PD and examined this 
association prospectively within the population-based Rotterdam Study.
Methods
The Rotterdam Study
The Rotterdam Study is a large prospective cohort study on determinants of 
diseases in the elderly.22 All inhabitants aged ≥�55 years of a district of Rotterdam 
were eligible. Of these, 7,983 subjects (response rate 78%) agreed to participate. 
Baseline examinations took place between 1990 and 1993. All participants were 
interviewed and subsequently underwent extensive physical examination, which 
included a neurologic screening, at the research center. Follow-up examinations took 
place in 1993 to 1994 and 1997 to 1999. In addition, the cohort was continuously 
monitored for major disease outcomes and mortality through linkage of the study 
database to general practitioners’ medical files. Informed consent was obtained 
from each participant, and the Medical Ethics Committee of the Erasmus Medical 
CenterRotterdam approved the study.
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Assessment of PD
A two-stage protocol was used at baseline and both follow-up examinations to 
identify subjects with PD.23 At the research center, all participants were screened for 
symptoms of parkinsonism by study physicians. Individuals who screened positive 
received a structural diagnostic work-up using the Unified Parkinson’s Disease Rating 
Scale to establish and further classify parkinsonism. A neurologist examined persons 
who were suspected of having PD to confirm the diagnosis. PD was diagnosed 
if two or more cardinal signs (resting tremor, rigidity, bradykinesia, or impaired 
postural reflexes) were present in a subject not taking antiparkinsonian drugs or 
if at least one sign had improved after starting antiparkinsonian medication and 
all causes of secondary parkinsonism had been excluded. In addition, the cohort 
was continuously monitored for new cases of parkinsonism by linkage to general 
practitioners’ and other medical records. Information obtained from this surveillance 
system was reviewed by a panel of neurologists and research physicians to establish 
parkinsonism or PD. Because of the relatively short screening intervals, the midpoint 
between age at last screening and age at time of diagnosis was considered a good 
approximation of age at onset.
 
Dietary assessment
Dietary intake was assessed in two stages at baseline. During the home interview, 
participants received a checklist to indicate all foods and drinks they had consumed at 
least twice a month during the preceding year. The checklist also contained questions 
on use of supplements and prescribed diets. Subsequently, at the research center, a 
trained dietician interviewed the participants on the basis of the completed checklist. 
An extensive, validated semiquantitative food-frequency questionnaire was used to 
quantify the amounts of food and drink intake, and these data were converted to 
energy intake and nutrient intake using the computerized Dutch Food Composition 
Table.24 For this study, we used data on intake of total energy (in kilocalories per 
day, including energy from alcohol), total fat, saturated fatty acids, trans fatty acids, 
cholesterol, MUFAs, PUFAs (subdivided into the omega-3 PUFAs alpha-linolenic acid, 
docosahexaenoic acid and eicosapentaenoic acid (together denoted as n3- PUFAs) 
and the omega-6 PUFAs linoleic acid and arachidonic acid (together denoted as n6-
PUFAs)), carbohydrates, dairy products, alcohol (all calculated in grams per day), 
vitamin E (in milligrams per day), and coffee (expressed in number of cups per 
day).
Total fat intake consists of intake of saturated and unsaturated fatty acids and 
cholesterol. Over 99% of the energy from dietary fat is provided by fatty acids. Dietary 
cholesterol is found only in food from animal sources, including meat, eggs, milk, 
and butter. Main sources of saturated fat are dairy products and meat. MUFAs are 
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present in sunflower oil, peanut oil, and olive oil and hence relatively abundant in the 
so-called Mediterranean diet. PUFAs are found in vegetable oils (n6-PUFAs) and fish 
and marine animals (n3-PUFAs). MUFAs and PUFAs together make up the category 
of cis-unsaturated fatty acids. Trans-fat is industrially produced by adding hydrogen 
to unsaturated fatty acids and can be found in margarine and snack foods.
Other variables
The baseline interview contained questions about smoking habits (categorized as 
never, former, and current smoking) and medication use. Drugs were classified 
according to their Anatomic-Therapeutical-Chemical code.25 APOE genotyping was 
performed as described previously on coded genomic DNA samples drawn at the 
baseline visit.26 In case of discrepancies, APOE genotyping was repeated. 
Study sample
At baseline, 6,969 participants underwent screening for PD. Parkinsonism was 
identified in 130 participants, of whom 99 had PD.27 This resulted in 6,839 subjects 
free of parkinsonism at baseline. The food frequency questionnaire was not 
administered to participants with dementia at baseline because they might give 
unreliable information on dietary habits. Nursing home residents did not receive a 
food frequency questionnaire either because their current diet may not reflect dietary 
habits in the past. Persons with incomplete data or inconsistencies in their reported 
daily intake were excluded. The study sample thus consisted of 5,289 independently 
living participants with normal cognition and free of parkinsonism at baseline.
Data analysis
Because of the high correlation between fat intake and total energy intake, energy-
adjusted intake of fat and fatty acids was calculated by means of the residual method.28 
We used Cox proportional hazards regression analyses to evaluate the associations 
between energy-adjusted intake of various types of fat and the risk of PD. Subjects 
who became demented were censored at age at onset of dementia, because subjects 
with dementia were considered to be no longer at risk for PD.27 Persons with incident 
parkinsonism but not PD were also censored at age at onset of parkinsonism for the 
same reason. 
First, we performed analyses with intake of fat expressed in tertiles to check whether 
the relation between dietary fat and the risk of PD showed gross deviations from 
linearity. As this appeared not to be the case, analyses were then performed using 
a linear term for fat intake, with regression coefficients expressed per standard 
deviation (SD) of energy-adjusted intake. 
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Table 1. Baseline characteristics of the study population
Characteristic
     
Age (yr), mean (SD) 67.6   (7.7)
Women, no (%) 3,122  (59.0)
Cigarette smoking:
Current, no (%) 1,225  (23.2)
Former, no (%) 2,252  (42.6)
Never, no (%) 1,781  (33.7)
Use of lipid lowering medication 
at baseline, no (%) 137    (2.6)
APOE genotype:
ε3ε3, no(%) 2,962  (56.0)
At least one ε2 allele, no (%)† 700  (13.2)
At least one ε4 allele, no (%)† 1,268  (24.0)
Intake, median per tertile (grams/day) Tertile 1 Tertile 2 Tertile 3
     
Total energy, kcal/day 1507,3 1922,9 2426,6
Total carbohydrates 155,9 205,6 268,8
Total fat 55,1 77,4 105,1
Saturated fatty acids 23,4 32,6 44,6
Cholesterol 0,15 0,22 0,32
Unsaturated trans fatty acids 1,6 2,4 3,7
Unsaturated cis fatty acids 27,5 39,7 55,3
MUFA 16,4 23 31,4
PUFA 9,5 16,4 24,9
n-3 PUFA 0,8 1,2 1,9
Alpha-linolenic acid 0,6 1,0 1,7
Docosahexaenoic acid 0,01 0,05 0,15
Eicosapentaenoic acid 0,01 0,03 0,11
n-6 PUFA 8,3 15,0 23,3
Linoleic acid 8,2 14,8 23,1
Arachidonic acid 0,06 0,10 0,14
Dairy products 166,9 361,10 602,1
Vitamin E 8,1 12,90 19,3
Coffee, cups/day 1,0 4,0 6,0
     
SD : standard deviation, APOE : Apolipoprotein E, 
MUFA : monounsaturated fatty acids, PUFA : polyunsaturated fatty acids
† Exclusion of participants with �ε2ε4 genotype
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Models were initially adjusted for age and sex. Additional adjustments were made for 
cigarette smoking, as smoking is reportedly associated with a lower risk of PD29 and 
might be related to dietary habits as well. Because previous studies have indicated 
a possible inverse relationship between dietary intake of vitamin E, a fat-soluble 
vitamin, and the risk of PD,30 models were also adjusted for daily vitamin E intake. We 
also considered consumption of dairy products, alcohol, and coffee to be potential 
confounders and therefore repeated analyses with these variables included in the 
models.29,31,32 APOE genotype is known to influence lipid metabolism and thus might 
modify the relation between fat intake and PD risk.33,34 Therefore, we additionally 
adjusted for APOE genotype (ε3ε3, ε4+ and ε2+ [ε2ε4 excluded]). Because of low 
numbers, it was not possible to perform separate analyses in these three strata of 
APOE genotype. Because the association between fat intake and risk of PD might be 
disturbed by the use of lipid-lowering medication, all analyses were repeated after 
exclusion of subjects who used lipid-lowering medication at baseline (n=137). 
It has been suggested that the dopamine deficiency in early PD may cause a change 
in food preferences, leading to a shift toward higher carbohydrate intake at the 
expense of dietary fat.35 Therefore, to check whether the associations that we found 
could be attributed to the consequence of preclinical PD at baseline, we adjusted all 
models for total energy-adjusted carbohydrate intake. Furthermore, we performed 
separate analyses using only incident cases identified at the first follow-up round 
(mean follow-up 2.1 years; short follow-up) and those identified at the second follow-
up round (mean follow-up since baseline 6.0 years; long follow-up). For this latter 
analysis, we excluded all person-time until first follow-up and all persons who had 
developed PD or dementia within the first follow-up interval.  
Results
Baseline characteristics of the study sample are shown in table 1. Follow-up 
information was available on 6,778 individuals (99%), through either complete re-
examination at the research center or the continuous surveillance system. After a 
mean follow-up of 6.0 years, 77 subjects with incident parkinsonism were identified, 
of whom 51 had incident PD. 
Hazard ratios (HRs) with 95 % confidence intervals (CIs) for the association between 
energy-adjusted intake of various types of dietary fat and the risk of PD are presented 
in table 2. Total energy intake itself was not associated with risk of PD in our study 
(adjusted HR 1.24, 95% CI 0.87 to 1.77). Intakes of total fat, MUFAs, and n3-PUFAs 
were significantly associated with a lower risk of PD (age- and sex-adjusted HR per 
SD of energy-adjusted intake for total fat 0.67 [95% CI 0.51 to 0.89], for MUFAs 0.67 
[95% CI 0.49 to 0.91], and for n3-PUFAs 0.66 [95% CI 0.46 to 0.94]). After additional 
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adjustments for smoking and vitamin E intake, a significantly decreased risk of PD 
was also observed for intake of n6-PUFAs (HR 0.69, 95% CI 0.47 to 1.00). Of the n3-
PUFA subtypes, only alpha-linolenic acid was significantly associated with a lower 
risk of PD (HR 0.65, 95% CI 0.45 to 0.95), whereas of the n6-PUFAs, only linoleic acid 
seemed protective (HR 0.79, 95% CI 0.59 to 1.06). No significant association was found 
between intake of saturated fatty acids, cholesterol, or trans-fatty acids and the risk 
of PD. None of the results changed when we adjusted the analyses for intake of total 
carbohydrates, coffee, dairy products, or alcohol or when we excluded participants 
who used lipid-lowering medication at baseline. Additional adjustment for APOE 
genotype did not change any of these associations. Results were not different for 
men and women.
Table 2. Dietary fat and the risk of Parkinson disease. Hazard ratios  (95% CIs) per 
standard deviation of energy-adjusted intake (grams/day) 
    
Additionally adjusted
Adjusted for for smoking and
age and sex intake of vitamin E
SD HR (95% CI) HR (95% CI)
    
Total fat 13.2 0.67 (0.51 - 0.89) 0.69 (0.52 - 0.91)
Saturated fatty acids 7.2 0.82 (0.61 - 1.10) 0.82 (0.61 - 1.10)
Cholesterol 0.06 0.81 (0.61 - 1.08) 0.81 (0.59 - 1.10)
Unsaturated trans fatty acids 1.0 0.87 (0.64 - 1.18) 0.84 (0.61 - 1.17)
Unsaturated cis fatty acids 9.7 0.67 (0.51 - 0.90) 0.64 (0.47 - 0.87)
MUFA 5.4 0.67 (0.49 - 0.91) 0.68 (0.50 - 0.94)
PUFA 6.7 0.77 (0.58 - 1.03) 0.66 (0.46 - 0.96)
n-3 PUFA 0.6 0.66 (0.46 - 0.94) 0.68 (0.48 - 0.97)
Alpha-linolenic acid 0.6 0.65 (0.45 - 0.95) 0.64 (0.44 - 0.92)
Docosahexaenoic acid 0.1 1.02 (0.79 - 1.31) 1.03 (0.45 - 2.38)
Eicosapentaenoic acid 0.09 1.02 (0.81 - 1.29) 1.03 (0.81 - 1.31)
n-6 PUFA 6.6 0.79 (0.59 - 1.06) 0.69 (0.47 - 1.00)
Linoleic acid 6.6 0.79 (0.59 - 1.06) 0.68 (0.47 – 1.00)
Arachidonic acid 0.04 0.96 (0.72 - 1.28) 0.96 (0.72 - 1.27)
SD : standard deviation, HR : hazard ratio, CI : confidence interval,
MUFA : monounsaturated fatty acids, PUFA : polyunsaturated fatty acids
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Table 3 shows the results of the analyses stratified on duration of follow-up. HRs 
for fat intake derived after short follow-up (mean 2.1 years) did not differ from 
those derived after longer follow-up (mean 6.0 years). Results were similar after 
adjusting for smoking, coffee consumption, and intake of dairy products, vitamin E, 
and total carbohydrates. In contrast, we found a positive association between total 
carbohydrate intake and risk of PD for participants who developed PD within a few 
years since baseline, but no association for those who developed PD after a longer 
period.
Discussion
In this large, prospective population-based study, we found that a higher dietary 
intake of unsaturated fatty acids was associated with a decreased risk of PD. 
An important feature of our study is the fact that dietary habits were assessed before 
onset of PD. Most previous studies on the relationship between dietary fat and 
PD used a retrospective case-control design, which makes it difficult to determine 
whether differences in fat intake play a causal role in PD or rather are a consequence 
of the disease. Dopamine shortage in PD patients might influence food preferences 
and eating behavior and thereby change dietary habits.35 We considered that in the 
current study, bias might have occurred owing to the presence of preclinical disease 
at the time of baseline assessments. The length of the preclinical period in PD is 
unknown. Yet we considered that if persons changed their dietary habits because 
of preclinical PD, these changes would be more outspoken the shorter the interval 
between dietary assessment and diagnosis of PD. We therefore separately analyzed 
the data of the first and those of the second follow up round. Total carbohydrate 
intake tended to be positively associated with the risk of PD but, indeed, only when 
follow-up was short, probably reflecting a changed food preference in presymptomatic 
disease. In contrast, the point estimates for the associations for fatty acid intake with 
risk of PD were very similar for short and longer follow up, although owing to the 
smaller number of PD cases in each substrata, the confidence intervals became wider 
and included 1. Furthermore, adjusting for total carbohydrate intake did not change 
the results. Together, these findings make it unlikely that the observed associations 
actually resulted from a shift toward more carbohydrate consumption at the expense 
of fat intake in early PD. 
Single dietary assessment by means of a food frequency questionnaire may lead 
to misclassification of nutrient intake. However, because future disease status was 
unknown at baseline, this misclassification, if any, will most likely have occurred to 
the same extent in participants with and without PD, causing dilution of the results 
and thus underestimation of the association.
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Our extensive case finding procedures, almost complete follow-up, and strict 
diagnostic criteria ensure an optimal case ascertainment and limit the possibility 
of misclassification of PD. Moreover, we continued following participants after a 
diagnosis of PD had been made, which enabled us to revise cases on the basis of 
additional information. Although we cannot completely rule out the possibility of 
residual confounding, it is unlikely that our results can be entirely explained by 
confounding by other factors, since adjusting for several potential confounders did 
not essentially change any of the results. 
Table 3. Hazard ratios (95% CIs) of Parkinson disease per standard deviation of 
energy-adjusted intake of fat and carbohydrates (grams/day), adjusted for age and sex
Overall Short follow-up Longer follow-up
(n=51) (n=25) (n=26)
HR (95% CI) HR (95% CI) HR (95% CI)
    
Total fat 0.67 (0.51 - 0.89) 0.70 (0.48 - 1.04) 0.74 (0.50 - 1.09)
Saturated fatty acids 0.82 (0.61 - 1.10) 0.83 (0.54 - 1.26) 0.85 (0.57 - 1.27)
Cholesterol 0.81 (0.61 - 1.08) 0.81 (0.53 - 1.23) 0.86 (0.58 - 1.28)
Unsaturated trans fatty acids 0.87 (0.64 - 1.18) 0.85 (0.54 - 1.35) 0.87 (0.57 - 1.33)
Unsaturated cis fatty acids 0.67 (0.51 - 0.90) 0.73 (0.48 - 1.10) 0.73 (0.49 - 1.09)
MUFA 0.67 (0.49 - 0.91) 0.71 (0.45 - 1.09) 0.72 (0.47 - 1.10)
PUFA 0.77 (0.58 - 1.03) 0.82 (0.54 - 1.25) 0.82 (0.55 - 1.23)
n-3 PUFA 0.66 (0.46 - 0.94) 0.79 (0.50 - 1.25) 0.60 (0.36 - 1.01)
Alpha linolenic acid 0.64 (0.44 - 0.92) 0.69 (0.41 - 1.14) 0.65 (0.39 - 1.09)
Docosahexaenoic acid 1.03 (0.45 - 2.38) 1.13 (0.94 - 1.36) 0.74 (0.41 - 1.33)
Eicosapentaenoic acid 1.02 (0.81 - 1.29) 1.13 (0.94 - 1.35) 0.72 (0.40 - 1.30)
n-6 PUFA 0.79 (0.59 - 1.06) 0.83 (0.55 - 1.27) 0.85 (0.57 - 1.27)
Linoleic acid 0.79 (0.59 - 1.06) 0.83 (0.55 - 1.27) 0.85 (0.57 - 1.27)
Arachidonic acid 0.96 (0.72 - 1.27) 1.07 (0.73 - 1.57) 0.88 (0.58 - 1.33)
Carbohydrates 1.29 (0.98 - 1.70) 1.41 (0.97 - 2.06) 0.98 (0.67 - 1.45)
SD = standard deviation, HR = hazard ratio, CI = confidence interval, 
MUFA = monounsaturated fatty acids, PUFA = polyunsaturated fatty acids
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Evidence from several research areas underlines the importance of unsaturated fatty 
acids for neuronal cell function. Dietary intake affects fatty acid composition of the 
cell membrane, which determines membrane fluidity and function of membrane 
transporters and enzymes.5,6 Unsaturated fatty acids may be protective against the 
pathogenetic processes of oxidative damage and inflammation supposedly involved 
in PD.1-3 Both MUFAs and PUFAs are shown to have anti-inflammatory and immune-
modulating properties6,7,36 and might protect against oxidative stress.5,6,8 PUFAs 
are shown to inhibit neuronal apoptosis,4 which is thought to play a role in the 
pathogenesis of PD.37 Furthermore, PUFAs (mainly the n6 type) are precursors for 
endocannabinoids, endogenous ligands that bind to a specific receptor (CB1) that is 
particularly abundant in the basal ganglia.38 The endocannabinoid system modulates 
dopaminergic activity in the basal ganglia, thereby playing an important role in the 
control of movement.11,12 Animal studies have shown that endocannabinoid levels can 
be modified by the amount PUFAs in the diet.39 Interestingly, several recent findings 
suggest a role of lipid metabolism in the pathogenesis of PD. A genomic screen in 
yeast recently showed that genes that enhanced toxicity of alpha-synuclein, the major 
component of the pathologic inclusions found in PD, clustered in the processes 
of lipid metabolism.13 Besides, in vitro studies showed that the formation of the 
potentially cytotoxic alpha-synuclein oligomers is regulated by fatty acids.40 
Epidemiologic studies indicate that high dietary intake of both PUFAs and MUFAs 
might protect against cognitive decline and Alzheimer disease,41-46 although the results 
from the Rotterdam Study could not be confirmed at longer follow-up.47 Previous 
epidemiologic studies on the relation between dietary fat and PD show inconsistent 
results. Most of these were retrospective case-control studies focusing mainly on intake 
of total fat and saturated fat. Three case-control studies reported higher intakes of 
total fat and animal fat (a major source of saturated fat) in PD patients,15,16,18  whereas 
results from two other case-control studies and the prospectively designed Health 
Professionals Follow-up Study and the Nurses’ Health Study showed no significant 
associations between dietary total fat or animal fat and the risk of PD.14,17,19 Few 
studies focused on unsaturated fat in relation to PD. Within the Honolulu –Asia Aging 
study, a prospective cohort study among men of Japanese ancestry, a significantly 
reduced risk of PD was observed with higher intake of PUFAs, which is in line 
with our observations.21 In the Health Professionals Follow-up Study and the Nurses’ 
Health Study, no significant association between intake of unsaturated fat and the 
risk of PD was found, although the effect estimates suggested a slightly lower risk of 
PD with higher intake of PUFAs. Of the several PUFA subtypes, only arachidonic acid 
was significantly associated with a lower PD risk.14 However, isocaloric replacement 
of polyunsaturated fat with saturated fat was associated with a significantly increased 
risk of PD in the men in the Health Professionals Follow-up Study, which may again 
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fit our observation of a possible protective effect of polyunsaturated fat. Both the 
Health Professionals Follow-up Study and the Nurses’ Health Study had longer 
follow-up and repeated instead of single dietary assessments and therefore probably 
less misclassification with regard to life-time cumulative dietary exposure than the 
Rotterdam Study. On the other hand, case ascertainment was based on self-reported 
medical diagnoses of PD and did not involve in-person screening, which makes it 
likely that a larger proportion of PD patients was missed or misdiagnosed in those 
studies. Possible explanations for the discrepant findings are that the larger diagnostic 
misclassification in the US studies may have limited the power to find a significant 
effect or that it is later-life dietary exposure rather than average life-time intake that 
is related to the occurrence of PD. 
The association we observed for n3-PUFA intake seemed to be driven by the subtype 
of alpha-linolenic acid, which makes up 88% of all n3-PUFA intake. Linoleic acid 
accounts for 99% of all n6-PUFA intake and drove the association for total n6-PUFA. 
Intakes of other subtypes were very low and not related to the risk of PD. We found 
an inverse association of total fat intake with PD risk, which was very similar to 
the one for cis-unsaturated fatty acids (MUFA and PUFA together). This association 
may have been partly driven by the association between cis-unsaturated fatty acids 
and PD, as more than half of total fat intake consists of cis-unsaturated fatty acids. 
However, we also saw a trend for an inverse association between saturated fatty acids 
and cholesterol and the risk of PD. It is unclear whether these latter associations 
were due to chance or resulted from some as yet unexplained mechanism. Additional 
prospective studies and a longer follow-up period are needed to confirm our 
results.
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Abstract
Background
Alterations in lipid and cholesterol metabolism are likely involved in the pathogenesis 
of neurodegenerative diseases, including Parkinson disease. Moreover, serum 
cholesterol is closely correlated with serum concentration of coenzyme Q10, a powerful 
antioxidant and mitochondrial electron acceptor that has shown beneficial effects in 
animal studies and trials on Parkinson disease.
Objective
To examine whether serum levels of total and HDL-cholesterol are related to the risk 
of Parkinson disease.
Methods
In the population-based Rotterdam study, we prospectively examined the association 
between serum levels of total and HDL cholesterol and the risk of Parkinson disease 
among 6,465 subjects aged  ≥55 years. Parkinson disease was assessed through 
repeated in-person examination and continuous monitoring by computer linkage to 
medical records. We analyzed the data using Cox’ proportional hazards regression 
models. 
Results
After a mean follow up of 9.4 years, we identified 87 participants with incident 
Parkinson disease. Higher baseline levels of total cholesterol were associated with a 
significantly decreased risk of Parkinson disease (age and sex adjusted hazard ratio 
per mmol increase in serum cholesterol 0.77 (95% confidence interval 0.64-0.94)), 
with clear evidence for a dose-effect relationship. Further analyses showed that the 
association was restricted to women and remained unchanged after adjusting for 
multiple potential confounders. No association was observed between HDL cholesterol 
and risk of Parkinson disease.
Conclusion
Total cholesterol levels are inversely associated with the risk of Parkinson disease 
in women. The strong correlation -especially in women- between serum levels of 
cholesterol and the antioxidant coenzyme Q10 might provide a clue to explain these 
findings. 
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Introduction
Parkinson disease (PD), the second most common neurodegenerative disorder, is 
pathologically characterized by degeneration of dopamine-producing cells in the 
substantia nigra of the brain and the presence of intracellular inclusions called Lewy 
Bodies.1 The exact mechanism that underlies the selective dopaminergic cell death 
in PD is as yet unknown, but mitochondrial dysfunction, oxidative stress and protein 
mishandling are thought to play a major role.2-4 
Cholesterol is a major component of neuronal cell membranes and synapses and 
essential for maintaining their structure and function.5 Evidence is increasing 
that changes in metabolism of cholesterol and other lipids are involved in 
neurodegeneration. Although most evidence originates from research in Alzheimer 
disease (AD),5-13 several recent findings also suggest a role of lipid metabolism in PD 
pathogenesis. Results of in vitro studies suggest an association between lipids and 
the localization and structure of the alpha-synuclein protein, the major component 
of the pathological Lewy Bodies found in PD brains. Alpha-synuclein specifically 
binds to cholesterol-enriched domains of the neuronal cell membrane14 and alpha-
synuclein toxicity seems to be mediated by fatty acids and by genes involved in 
lipid metabolism.15-18 Lower serum levels of total cholesterol have been described in 
patients with PD compared with controls.6,19 Moreover, serum cholesterol is the most 
important determinant of serum levels of coenzyme Q10, a powerful antioxidant 
and electron acceptor for mitochondrial complex I and II.20 Because mitochondrial 
complex I dysfunction is thought to play a key role in PD pathogenesis, the effects of 
oral supplementation of coenzyme Q10 have been examined in animal models and 
an initial trial in PD patients, with promising results.20-22 
To evaluate a potential role of cholesterol in PD, we examined the relationship 
between serum levels of total and HDL cholesterol and the risk of PD prospectively 
among 6,465 participants of the population-based Rotterdam Study.
Methods
The Rotterdam Study
The Rotterdam Study is a prospective population-based cohort study on determinants 
of diseases in the elderly.23 Of all inhabitants aged ≥55 years of a district of Rotterdam, 
7,983 subjects (response rate 78%) agreed to participate and gave their informed 
consent. At baseline (1990-1993) and three follow-up rounds (1993-1994, 1997-1999 
and 2002-2004), participants were interviewed at their homes and subsequently 
underwent extensive physical examination and venipuncture at the research center. 
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In addition, the cohort was continuously monitored for major disease outcomes and 
mortality through computerized linkage of the study database to general practitioners’ 
medical files. The Medical Ethics Committee of the Erasmus Medical Center Rotterdam 
approved the study.
Assessment of Parkinson disease
Both at baseline and at follow-up, we used a two–phase design to identify subjects 
with PD.24,25 All participants were screened at the research center for cardinal signs 
of parkinsonism (resting tremor, rigidity, bradykinesia, or impaired postural reflexes) 
in a standardized way. Individuals who screened positive received a structural 
diagnostic workup comprising the Unified Parkinson’s Disease Rating Scale26 and 
neurological examination to establish and further classify parkinsonism. Information 
obtained from the computerized surveillance system was reviewed by a panel of 
neurologists and research physicians. A neurologist examined persons who were 
suspected of having PD to confirm the diagnosis. PD was diagnosed if two or more 
cardinal signs were present in a subject not taking antiparkinsonian drugs, or if at 
least one sign had improved after starting antiparkinsonian medication and all causes 
of secondary parkinsonism (parkinsonism associated with dementia, drug-induced 
parkinsonism, parkinsonism related to cerebrovascular disease, and parkinsonism in 
multiple system atrophy or progressive supranuclear palsy) had been excluded. 
Assessment of serum levels of total and HDL cholesterol 
Serum concentrations of total cholesterol and high-density lipoprotein were 
determined within 2 weeks after venipuncture by an automated enzymatic procedure 
in non-fasting blood samples drawn at the baseline visit to the research center.27 Non-
HDL cholesterol was computed by subtracting HDL cholesterol from total cholesterol 
and was used to calculate the ratio of non-HDL to HDL cholesterol. 
Assessment of covariates
Smoking habits and use of medication, including lipid-lowering agents, were assessed 
during the baseline interview, which also contained a semiquantitative food frequency 
questionnaire (SFFQ). Ever use of lipid-lowering agents during the study period was 
recorded by computerized linkage to the automated pharmacies serving the study 
area. Drugs were classified according to their Anatomic-Therapeutical-Chemical 
(ATC) code.28 Dietary intakes of vitamin E and coffee were assessed by means of 
the SFFQ as described in detail elsewhere.29,30  Height and weight were measured to 
calculate body mass index (BMI, kg/m2) and Apolipoprotein E (APOE) genotyping 
was performed on coded genomic DNA samples as described previously.31 
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Study population
At baseline, 6,969 participants underwent complete neurological screening. We 
excluded participants diagnosed with parkinsonism (n=130) or dementia (n=273) 
at baseline, resulting in a cohort at risk to develop PD during follow-up of 6,566 
persons. In 6,465 of those, serum total and HDL cholesterol measurements were 
available
Table 1. Baseline characteristics of the study population
Mean (SD) Overall Men Women
     
N (%) 6,465 2,654 (41.1) 3,811 (58.9)
Age (years) 69.0 (8.6) 67.8 (8.0) 69.3 (9.0)
Total cholesterol (mmol/l) 6.64 (1.23) 6.33 (1.18) 6.85 (1.22)
HDL-cholesterol (mmol/l) 1.35 (0.37) 1.21 (0.33) 1.44 (0.37)
Non-HDL/HDL ratio (unit) 5.25 (1.63) 5.50 (1.62) 5.07 (1.61)
Smoking 
Current, no (%) 1,500 (23.2) 783 (29.5) 712 (18.7)
Former, no (%) 2,728 (42.2) 1,651(62.2) 1,075 (28.2)
Never, no (%) 2,237 (34.6) 220 (8.3) 2,024 (53.1)
Coffee consumption, cups/day 3.3 (2.2) 3.6 (2.4) 3.1 (2.0)
Vitamin E intake, g/day 13.8 (6.2) 15.4 (6.7) 12.8 (5.6)
APOE genotype*
�ε3ε3, no(%) 3,639 (60.3) 1,537 (61.4) 2,102 (59.5)
At least one �ε2 allele, no (%) 841 (13.9) 311 (12.4) 530 (15.0)
At least one �ε4 allele, no (%) 1,555 (25.8) 657 (26.2) 898 (25.4)
BMI, kg/m2 26.3 (3.7) 25.7 (3.0) 26.8 (4.1)
Use of lipid-lowering medication
At baseline, no(%) 160 (2.5) 73 (2.8) 87 (2.3)
Ever use, no (%) 1,008 (15.6) 431 (16.2) 577 (15.1)
     
SD : standard deviation, BMI : body mass index
* Genotyping performed in 6,035 participants
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Data analysis
We used Cox proportional hazards regression analysis to evaluate the association 
of baseline serum total cholesterol, HDL cholesterol, and the ratio of non-HDL to 
HDL cholesterol with the risk of incident PD. Cholesterol levels were analyzed both 
as continuous variables and in quartiles of the distribution. Analyses were initially 
adjusted for age and sex. Additional adjustments were made for smoking habits 
(classified as former, current, or never smoking), vitamin E intake (in milligrams/
day), and coffee consumption (expressed in number of cups/day), because all these 
factors have been related to a decreased risk of PD32-34 and probably are associated 
with concentrations of total and HDL cholesterol.35 Analyses were further adjusted 
for BMI, baseline and ever use of cholesterol-lowering medication, and APOE 
genotype (categorized into ε3ε3,ε4+ and�ε2+ [ε2ε4 excluded]), as APOE genotype is 
an important determinant of plasma cholesterol5 and the ε2 allele is associated with 
an increased risk of PD.36,37 
All analyses were repeated after exclusion of participants who reported use of lipid-
lowering medication at baseline. We performed separate analyses for men and women, 
as mean baseline serum levels for men and women were significantly different. 
Analyses were furthermore stratified by smoking status, coffee consumption, APOE 
genotype, high or low vitamin E intake, and use of lipid-lowering medication.
Results
Follow-up information was available on 99% of the participants, either through 
complete in-person re-examination or the continuous monitoring system. During a 
total of 60,709 person-years of follow-up (mean follow-up time, 9.4 years), 87 new 
cases of PD were detected. 
Baseline characteristics of the study population are shown in table 1. Table 2 shows 
hazard ratios (HRs) with 95% confidence intervals (CIs) for PD according to serum 
total cholesterol, overall and for men and women separately. Overall, higher levels 
of serum total cholesterol were associated with a significantly decreased risk of 
PD, with analyses in quartiles showing a clear linear relationship. Stratified analyses 
showed a strong association in women, but no association in men. None of the other 
stratified analyses showed different results across strata. Results for HDL levels are 
shown in table 3. No obvious association was seen in men. In women there was a 
slight positive association, but without clear evidence for linearity. Results for the 
non-HDL to HDL ratio were very similar to those for total cholesterol (table 4). 
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Additional adjustments for smoking, dietary vitamin E, coffee consumption, BMI, 
APOE genotype, and baseline or ever use of lipid-lowering drugs did not change 
any of the results; neither did exclusion of participants who used lipid-lowering 
medication at baseline. 
Discussion
In this prospective, population-based cohort study with a large number of person-
years of follow-up, we found that serum total cholesterol and the ratio of non-
HDL to HDL cholesterol were inversely related to the risk of PD. This association 
appeared restricted to women. As serum cholesterol levels were measured before 
the clinical onset of PD, the observed associations are unlikely to have resulted from 
consequences of the disease itself. We furthermore consider it improbable that the 
associations may be explained by the effect of smoking habits, coffee consumption, 
APOE genotype, BMI, use of lipid-lowering drugs, or vitamin E intake on PD risk, 
since results remained virtually unchanged after adjusting for all these potential 
confounders. Potential misdiagnosis is limited because of the extensive case finding 
procedures, strict diagnostic criteria, and almost complete follow-up. 
Evidence is accumulating that alterations in metabolism of cholesterol and other 
lipids are involved in the pathogenesis of neurodegenerative diseases.5-8 A positive 
association between serum cholesterol and the risk of AD has been observed in 
some epidemiological studies,9,10,38 and a decreased risk of AD was found in users of 
cholesterol-lowering statins,11 although cholesterol-independent effects of statins on 
cerebral circulation and inflammation might in part be responsible for this finding.7 
Abnormalities in cholesterol metabolism have been described in brains of AD patients 
compared with control subjects12 and evidence suggests that cholesterol influences 
production and probably clearance and aggregation of the amyloid-beta peptide, the 
principal component of the extracellular plaques that are considered a pathological 
hallmark of AD.7,8,13,39 
Several lines of evidence also indicate a role of lipid metabolism in the pathogenesis 
of PD, which offers one possible explanation for our findings. Decreased cholesterol 
synthesis was observed in skin fibroblasts from patients with PD40 and lower levels 
of total cholesterol have been described in PD patients compared with controls.6,19 
Localization and structure of the alpha-synuclein protein, which in aggregated form 
is a major component of the pathological inclusion bodies found in the brains of PD 
patients,16 have been linked to lipids and cholesterol. In vitro studies have shown that 
alpha-synuclein is closely associated to lipid rafts, cholesterol-enriched domains in 
the cell membrane that are involved in protein activity and cell signaling.14
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Oligomerization of alpha-synuclein, which might be the first step in the formation 
of the insoluble aggregates, is regulated by fatty acids,16-18 and genes that modified 
alpha-synuclein toxicity in yeast were found to be mostly involved in processes of 
lipid metabolism.15 
We previously found a significant inverse association between dietary intake of total 
fat and unsaturated fatty acids and the risk of PD in the prospective Rotterdam Study. 
Our results also suggested an inverse association between dietary cholesterol and PD 
risk, although they did not reach statistical significance.30 A decreased risk of PD with 
higher intake of polyunsaturated fatty acids was observed in another prospective 
cohort study as well.41 Furthermore, results from a recent meta-analysis showed 
that carriers of the APOE ε2 allele, which is associated with lower plasma levels of 
total cholesterol,5 have an increased risk of PD.36,37 The latter finding is particularly 
interesting because for AD, the�ε2 allele is considered protective, whereas the APOE 
ε4 allele (associated with higher total cholesterol levels) is an important genetic risk 
factor.42 This parallels the contrast between our finding of an inverse association 
between total cholesterol and PD risk and the previously reported positive association 
between total cholesterol and AD risk. 
The intact blood–brain barrier, however, is impermeable to cholesterol-transporting 
lipoproteins and most brain cholesterol is synthesized in situ.7 It is therefore unclear 
to what extent serum cholesterol levels correspond with brain levels and whether 
they accurately reflect changes in cholesterol metabolism in the central nervous 
system. An alternative hypothesis to explain our findings is provided by the strong 
correlation between serum cholesterol and serum concentration of coenzyme Q10, a 
molecule present in all body cells that acts as both an essential electron acceptor for 
complex I and II in the mitochondrial respiratory chain and as a powerful endogenous 
antioxidant.20 Serum cholesterol is the most important determinant of coenzyme Q10 
levels, as both substances derive from the same biosynthetic pathway and virtually all 
coenzyme Q10 in plasma is incorporated in lipoproteins, primarily LDL.43-45 Because 
oxidative stress and mitochondrial complex I dysfunction are thought to play a key 
role in PD pathogenesis2-4 and reduced coenzyme Q10 levels have been found in 
mitochondria from PD patients,46 there is growing interest in the use of coenzyme 
Q
10
 as a potential treatment for PD.20,47 In animal models, oral administration of 
coenzyme Q10 increased brain concentrations and attenuated 3-NP-induced lesions20 
and MPTP-induced striatal dopamine depletion.21 In a multicenter placebo-controlled 
randomized phase II trial, treatment with coenzyme Q10 significantly reduced the 
worsening of PD.22 
Unfortunately, we were not able to directly test the hypothesis that our results might 
reflect an inverse association between coenzyme Q10 concentration and PD risk, 
because we can no longer measure levels of coenzyme Q10 in baseline serum 
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from the Rotterdam Study, due to instability of the samples after a long storage 
period.48 Another issue is why the observed association was restricted to women. In 
a study conducted to investigate determinants of coenzyme Q10 levels, it was found 
that 18.4% of the variation in coenzyme Q10 levels in men is explained by total 
cholesterol, against 30.7% in women.44 Mean levels of coenzyme Q10 were found to 
be significantly higher in men, even after adjusting for several covariates, including 
serum cholesterol.44 The lack of an association between cholesterol levels and PD risk 
in men might thus be due to a weaker correlation between cholesterol and coenzyme 
Q10 levels. 
We think our results are potentially relevant and call for further research on the 
relationship between cholesterol, coenzyme Q10 and the risk of PD.
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Abstract
Background
Elevated plasma levels of homocysteine might accelerate the selective dopaminergic 
cell death underlying Parkinson disease, through direct neurotoxic effects. The TT 
genotype of the C677T polymorphism of the methylenetetrahydrofolate reductase 
(MTHFR) gene is associated with reduced enzymatic activity, resulting in mild 
hyperhomocysteinemia. 
Objective
To investigate whether the MTHFR TT genotype is associated with an increased risk of 
Parkinson disease.
Methods
In the Rotterdam Study, a prospective population-based cohort study of people aged ≥� 
55 years, we evaluated the association between MTHFR C677T genotype and the risk 
of Parkinson disease in 5,920 subjects who were free of dementia and parkinsonism 
at baseline. MTHFR genotyping was performed on baseline blood samples and 
incident Parkinson disease was assessed through repeated in-person examination 
and continuous monitoring of the cohort by computer linkage to medical records. We 
analyzed the data using Cox proportional hazards regression models. 
Results
After a mean follow up of 5.8 years, we identified 65 participants with incident 
Parkinson disease. TT genotype, compared to CC and CT genotypes, was associated 
with an increased risk of Parkinson disease, which was borderline significant (relative 
risk (RR) 1.74, 95% confidence interval (CI), 0.91 to 3.32, p=0.09). Analyses stratified 
on smoking status showed a strong and significant increase in risk of Parkinson 
disease associated with the TT genotype in smokers (RR, 3.74; 95% CI, 1.78 to 7.85), 
and no association in non-smokers (RR, 0.28; 95% CI, 0.04 to 2.07). 
Conclusion
Our findings support the hypothesis that homocysteine plays a role in the pathogenesis 
of Parkinson disease.  
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Introduction
Oxidative stress and mitochondrial dysfunction are thought to be involved in the 
selective dopaminergic cell death in Parkinson disease (PD).1,2 Increasing evidence 
suggests that high plasma levels of homocysteine might contribute to these processes 
through direct neurotoxic effects. In animal models of PD, brain injections of 
homocysteine exacerbated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced 
motor dysfunction and loss of dopaminergic neurons. Homocysteine has also been 
observed to cause DNA strand breaks and to enhance oxidative stress, mitochondrial 
dysfunction, and apoptosis induced by rotenone and iron in cultured human 
dopaminergic cells.2,3 
Increased plasma levels of homocysteine have been found in patients with PD, 
although mainly in those receiving L-dopa therapy.4-6 Therefore, it is unclear whether 
this increase precedes PD or is caused by the L-dopa itself. 
Methylenetetrahydrofolate reductase (MTHFR) is a folate-dependent enzyme that 
catalyzes remethylation of homocysteine. Individuals homozygous for the C677T 
polymorphism of the MTHFR gene (the TT genotype) display reduced enzymatic 
activity, resulting in mild hyperhomocysteinemia.7-9 We hypothesized that through 
increasing plasma homocysteine, the TT genotype might be associated with a greater 
risk for PD, and studied this association within the population-based Rotterdam 
Study.
Materials and methods
The Rotterdam Study is a prospective, population-based cohort study among 7,983 
individuals aged 55 years or older in a district of Rotterdam, the Netherlands.10 Both 
at baseline (1990 to 1993) and two follow-up rounds (1993 to 1994 and 1997 to 
1999), all participants underwent interviewing, extensive physical examination, and 
venipuncture. We used a two-phase design to identify subjects with PD.11 Participants 
were screened for parkinsonian signs (resting tremor, rigidity, bradykinesia, or 
impaired postural reflexes) in a standardized way. Individuals who screened positive 
received a structural diagnostic workup comprising the Unified Parkinson’s Disease 
Rating Scale12 and neurological examination. In addition, the cohort was continuously 
monitored through linkage to general practitioners’ medical files. All available 
information was reviewed by a multidisciplinary panel to make a final diagnosis. PD 
was diagnosed if two or more cardinal signs were present in a participant not taking 
antiparkinsonian drugs, or if at least one sign had improved after medication was 
started, and when all causes of secondary parkinsonism (dementia, use of neuroleptics, 
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cerebrovascular disease, multiple system atrophy, or progressive supranuclear palsy) 
could be excluded.
The C677T polymorphism was genotyped on baseline DNA samples, using the Taqman 
allelic discrimination assay (Applied Biosystems, CA, USA). Forward and reverse primer 
were 5’-CCTCAAAGAAAAGCTGCGTGATG and 5”-GCACTTGAAGGAGAAGGTGTCT, 
respectively, and the probes were VIC-ATGAAATCGACTCCCGC and FAM-
ATGAAATCGGCTCCCGC. Reactions were performed on the Taqman Prism 7900HT 
in 384 wells format. At baseline, we assessed smoking status (classified as ever 
[current or former] or never smoking) and measured intima-media thickness of 
the carotid arteries by ultrasonography according to a protocol that was described 
previously.13 Homocysteine was measured only in a small random subset of the study 
population (n=652). 
Baseline neurological screening was performed in 6,969 participants. We excluded 
participants diagnosed with any parkinsonism (n=130) or dementia (n=273) at 
baseline, resulting in a cohort at risk for development of PD during follow-up of 
6,566 individuals. Of those, MTHFR genotyping was performed in 5,920 individuals. 
Because hyperhomocysteinemic effects have only been described for the TT genotype 
without any allele dosage effect,7,9 we used a recessive model with the CC and CT 
genotype together as a reference group to analyze the effect of the TT genotype on 
the risk for incident PD. 
Table 1. Baseline characteristics of the study population
Characteristic Entire cohort Incident PD cases Subjects without PD
No. of subjects 5,920 65 5,855
Women, no (%) 3,452 (58.3) 35 (53.8) 3,417 (58.4)
Age, yr (SD) 68.7 (8.6) 74.9 (7.2) 68.7 (8.6)
Smokers, no (%) 3,872 (65.4) 34 (52.3) 3,841 (65.6)
Nonsmokers, no (%) 2,048 (34.6) 31 (47.7) 2,014 (34.4)
Genotype
CC, no (%) 2,680 (45.3) 27 (41.5) 2,653 (45.3)
CT, no (%) 2,635 (44.5) 27 (41.5) 2,608 (44.5)
TT, no (%) 605 (10.2) 11 (16.9) 594 (10.1)
PD : Parkinson disease, SD : Standard deviation
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Analyses were preformed with Cox’ proportional hazards regression analysis, 
adjusted for age and sex. We also adjusted for intima-media thickness as a measure 
of atherosclerosis to evaluate whether vascular mechanisms could explain the results. 
Because smoking influences homocysteine levels14 and is associated with a decreased 
risk of PD,15 analyses were both adjusted for and stratified on smoking status. We 
tested for statistical interaction between TT genotype and smoking by adding a 
multiplicative interaction term to the model.
Results
Follow-up information was available on 99% of the participants, either through in-
person examination or the computerized monitoring system. During a total of 34,512 
person-years of follow-up (mean, 5.8 years), 65 new cases of PD were detected. 
MTHFR genotype distribution of the study population was in Hardy-Weinberg 
equilibrium and similar across age categories. Of participants who remained free 
of PD, 10.1 % appeared homozygous for the T allele compared with 16.9% of the 
incident PD cases (table 1). 
Table 2 shows the relative risk (RR) estimates with 95 % confidence interval (CI) of 
development of PD according to MTHFR genotype. The TT genotype, compared 
with CC and CT genotypes, was associated with an increased risk of PD, which was 
borderline significant (RR, 1.74; 95% CI, 0.91 to 3.32; p=0.09). Adjusting for intima-
media thickness and smoking did not change the results substantially. However, 
stratified analyses showed a strong and significant increase in risk for PD associated 
with the TT genotype in smokers (RR, 3.74; 95 % CI, 1.78 to 7.85), but no association 
was found in nonsmokers (RR, 0.28; 95 % CI, 0.04 to 2.07). The multiplicative 
interaction term was highly significant (p=0.021).  
Unfortunately, the low number of incident PD cases with available homocysteine 
measurements (n=4) did not allow us to examine the association between plasma 
homocysteine and the risk for PD directly. Levels of homocysteine, however, appeared 
to be greater in individuals homozygous for the T allele compared with those with 
the CC or CT genotype (mean level in TT group = 16.9 µmol/L, mean level in CC/CT 
group = 15.0 µmol/L, p=0.07).
Discussion
In this prospective, population-based cohort study, we found that the 
hyperhomocysteinemic MTHFR 677 TT genotype was associated with an increased 
risk for PD, particularly in smokers. Methodological strengths of our study are its 
population-based and prospective nature, extensive case-finding procedures, and 
122
Chapter 5.1
virtually complete follow-up with a large number of person-years. Unfortunately, 
the number of incident PD cases was limited, which resulted in rather wide CIs and 
precluded potentially interesting subanalyses, for example, in strata of number of 
pack-years smoked.
Homocysteine is increasingly discussed to be involved in the pathogenesis of 
neurodegenerative diseases through direct neurotoxic effects. It may promote 
cell death through stimulation of N-methyl-D-aspartate receptors or by inducing 
DNA strand breaks.3,16 In a mouse model of PD, brain injections of homocysteine 
exacerbated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced motor dysfunction, 
dopamine depletion, and loss of dopaminergic neurons. Furthermore, in cultured 
human dopaminergic cells, homocysteine enhanced oxidative stress, mitochondrial 
dysfunction, and apoptosis induced by rotenone and iron.2 Several studies have 
reported increased plasma homocysteine levels in PD patients; however, this 
occurred mainly in patients receiving L-dopa therapy. Because the relation between 
homocysteine levels and PD has not been examined prospectively thus far, it is still 
unclear whether hyperhomocysteinemia precedes the onset of PD or rather is a result 
of treatment.5,6 The MTHFR 677 TT polymorphism codes for a MTHFR variant with 
reduced enzymatic activity, resulting in increased plasma homocysteine levels, and 
might therefore increase the risk for PD.
Table 2. Risk of Parkinson disease according to MTHFR genotype, stratified by 
smoking status (relative risks with 95 % confidence intervals)
      
Genotype Overall Smokers Nonsmokers
  
CC / CT 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) p-interaction
TTa 1.74 (0.91 - 3.32) 3.74 (1.78 - 7.85) 0.28 (0.04 - 2.07) 0.021
TTb  1.92 (0.93 – 3.97) 3.92 (1.69 – 9.09) 0.39 (0.05 – 2.86) 0.044
aAdjusted for age and sex
bAdditionally adjusted for IMT and (only the overall analysis) for smoking status 
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Smoking is also reported to increase homocysteine levels, and previous studies showed 
an effect of TT genotype on plasma homocysteine that was especially pronounced 
in smokers, probably because both factors affect remethylation of homocysteine to 
methionine.8,14 This might explain our observation that the association between the 
MTHFR 677 TT genotype and PD was restricted to smokers. Our findings support the 
hypothesis that homocysteine metabolism is involved in the pathogenesis of PD. 
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Abstract
Background
Elevated homocysteine levels might accelerate the selective dopaminergic cell death 
underlying Parkinson disease, through direct neurotoxic effects. Higher dietary 
intakes of folate, vitamin B12, and vitamin B6 (essential co-factors in homocysteine 
metabolism) might decrease the risk of Parkinson disease through lowering of plasma 
homocysteine. Besides, evidence suggests neuroprotective effects of vitamin B6 
independent from its role in homocysteine metabolism, most likely through antioxidant 
activities. 
Objective
To determine whether high dietary intakes of folate, vitamin B12, and vitamin B6 are 
related to the risk of Parkinson disease.
Methods
In the Rotterdam Study, a prospective, population-based cohort study of people aged 
≥55 years, we evaluated the association between intake of folate, vitamin B12, and 
vitamin B6 and the risk of incident Parkinson disease among 5,289 participants who 
were free of dementia and parkinsonism and underwent complete dietary assessment 
at baseline. Parkinson disease was assessed through repeated in-person examination 
and continuous monitoring by computer linkage to medical records. Data were 
analyzed using Cox proportional hazards regression analysis.
Results
After a mean follow-up of 9.7 years, we identified 72 participants with incident 
Parkinson disease. Higher dietary intake of vitamin B6 was associated with a 
significantly decreased risk of Parkinson disease (Hazard Ratio per standard deviation, 
0.69 (95% confidence interval, 0.50-0.96), for highest versus lowest tertile, 0.46 (0.22-
0.96)), while no association was observed for dietary folate and vitamin B12.
Conclusion
These findings suggest that vitamin B6 may decrease the risk of Parkinson disease, 
either through lowering homocysteine levels, or through anti-oxidative effects.  
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Introduction
Parkinson disease (PD), a progressive neurodegenerative disorder which is clinically 
characterized by resting tremor, rigidity, bradykinesia, and postural imbalance, is 
caused by selective degeneration of dopaminergic neurons in the substantia nigra of 
the brain stem. The exact mechanism that underlies this process is as yet unclear, but 
oxidative stress is generally thought to play a prominent role.1,2 
High homocysteine levels might enhance dopaminergic degeneration through direct 
neurotoxic effects. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal 
models of PD, brain injections of homocysteine exacerbated dopaminergic cell loss 
and motor dysfunction.3 Homocysteine was furthermore found to cause DNA strand 
breaks and increase rotenone-induced oxidative stress and apoptosis in cultured 
human dopaminergic neurons.3,4 Some studies have reported elevated homocysteine 
levels in PD patients, but due to their retrospective design it is unclear whether this 
increase preceded the disease or rather was a result of treatment with levodopa.5-7 
Prospective studies on homocysteine levels and PD risk have not been published 
thus far, but our group previously found an increased risk of PD in carriers of the 
hyperhomocysteinemic MTHFR 677 TT genotype.8
Homocysteine levels are kept low by remethylation to methionine, which requires 
folate and vitamin B12, and by conversion to cysteine, for which vitamin B6 is an 
essential co-factor.9 Plasma homocysteine reportedly is inversely related to both 
plasma levels and dietary intakes of folate, vitamin B12, and vitamin B6.10-13 Vitamin 
B6 (pyridoxine) might furthermore influence PD risk through antioxidant effects and 
through its role in dopamine synthesis.14-19 
We hypothesized that higher intakes of folate, vitamin B12, and vitamin B6 might be 
associated with a decreased risk of PD, and studied this association prospectively in 
5,289 participants of the population-based Rotterdam Study. 
Subjects and methods
The Rotterdam Study
The Rotterdam Study is a prospective, population-based cohort study among 7,983 
persons aged ≥55 years in a district of Rotterdam, the Netherlands.20 At baseline 
(1990-1993), all participants were interviewed and subsequently underwent extensive 
physical examination, which included a neurologic screening. Follow-up examinations 
according to the same protocol took place in 1993-1994, 1997-1999, and 2002-2004. 
In addition, the cohort was continuously monitored for major disease outcomes and 
mortality through computerized linkage of the study database to general practitioners’ 
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medical files. Informed consent was obtained from each participant, and the Medical 
Ethics Committee of the Erasmus Medical Center Rotterdam approved the study.
Assessment of PD
In all four examination rounds, we used a similar two–phase design to identify 
subjects with PD.21 Participants were screened for cardinal signs of parkinsonism 
(resting tremor, rigidity, bradykinesia, or impaired postural reflexes) in a standardized 
way. Persons in whom at least one of these signs was observed were considered 
screen-positive and received a structural diagnostic workup, comprising the Unified 
Parkinson’s Disease Rating Scale22 and neurologic examination. Besides, a panel of 
neurologists and research physicians reviewed the information that was obtained 
from the computerized surveillance system to detect possible new cases of PD. PD 
was diagnosed if two or more cardinal signs were present in a participant not taking 
antiparkinsonian drugs, or if at least one sign had improved through medication, 
and when all causes of secondary parkinsonism (dementia, use of neuroleptics, 
cerebrovascular disease, multiple system atrophy, or progressive supranuclear palsy) 
could be excluded.
Assessment of dietary variables and covariates
At baseline, dietary intake was assessed through an interview by a trained dietician, 
using an extensive, validated semiquantitative food-frequency questionnaire (SFFQ).23 
The amounts of food and drink intake indicated on the SFFQ were converted 
to energy intake and nutrient intake by means of the computerized Dutch Food 
Composition Table. For the present study, we used data on dietary intake of folate (in 
µg/d), vitamin B12 (in µg/d), vitamin B6 (in mg/d), alcohol (in g/d), coffee (number 
of cups/d), and total energy (in kcal/d), as well as data on use of B-vitamin and folate 
supplements.
At baseline, we assessed smoking status during the interview (classified as ever 
[current or former] or never smoking) and measured intima-media thickness (IMT) of 
the carotid arteries by ultrasonography as described elsewhere.24
Study population
Baseline neurologic screening was performed in 6,969 participants, of whom 130 
were diagnosed with any parkinsonism, resulting in a cohort at risk to develop PD 
during follow-up of 6,839 persons. The SFFQ was not administered to participants 
with dementia at baseline (because they might give unreliable dietary information), 
and nursing home residents (as their current diet may not reflect dietary habits in the 
past). Participants with incomplete or inconsistent dietary data were also excluded 
from the analyses. The study sample for the present study thus comprised 5,289 
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independently living participants free of dementia and parkinsonism at baseline, for 
whom complete dietary data were available.
Data analysis
The relation between dietary folate, vitamin B12, and vitamin B6 and the risk of 
incident PD was analyzed with Cox proportional hazards regression analysis, adjusted 
for age, sex, and total energy intake, per standard deviation and expressed in tertiles 
of intake. 
Because smoking reportedly influences both homocysteine levels25 and PD risk,26 
analyses were both adjusted for and stratified by smoking status. Additional 
adjustments were made for intake of alcohol and coffee, being determinants of 
plasma homocysteine,25 and for IMT as a measure of atherosclerosis, to evaluate 
whether vascular mechanisms could explain the results. We re-analyzed the data 
after exclusion of users of B-vitamin and folate supplements (n=675), and after 
adding supplement users to the highest tertile of intake, and examined the effect of 
supplement use itself on PD risk. We tested for statistical interaction between dietary 
intake and smoking status by adding multiplicative interaction terms to the model. 
All analyses were performed using SPSS software, version 12.0.
Table 1. Baseline characteristics of the study population
Characteristic Mean (SD)
   
 
N 5,289
Age, yrs 67.7 (7.7)
Intake:
Total energy, kcal/day 1,975.2 (504.2)
Vitamin B12, micrograms/day 5.3 (4.5)
Vitamin B6, milligrams/day 1.63 (0.4)
Folate, micrograms/day 218.7 (77.8)
Alcohol, g/day 10.4 (15.2)
Coffee, no. of cups/day 3.3 (2.2)
Use of vitamin B/folate supplements, no (%) 675 (12.7)
Ever smokers, no (%) 3,495 (66.1)
Intima-media thickness, mm 0.79 (0.15)
   
SD: standard deviation
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Results
Follow-up information was available on 99% of the participants, either through in-
person examination or the computerized monitoring system. During a total of 53,262 
person-years of follow-up (mean, 9.7 years), 72 new cases of PD were identified. Of 
those, 44 cases were detected through the structured workup at the research center 
and 28 through the computerized surveillance system.
In table 1, baseline characteristics of the study population are presented. Table 2 
shows the hazard ratios (HRs) with 95% confidence intervals (CIs) for the association 
between dietary folate, vitamin B12, and vitamin B6 and the risk of PD, per standard 
deviation and in tertiles of intake. Higher intake of vitamin B6 was associated with 
a significantly decreased risk of PD (HR per SD, 0.69 (95%CI, 0.50-0.96), for highest 
versus lowest tertile 0.46 (0.22-0.96)), with evidence for a dose-effect relationship (p-
value for trend over tertiles, 0.048). No association with PD risk was seen for dietary 
vitamin B12 and folate. 
Results were not substantially different after adjusting for smoking, alcohol intake, 
coffee consumption, and IMT, or when supplement users were excluded or added to 
the highest tertile. Supplement use itself was not associated with the risk of PD (data 
not shown). Adding dietary folate, vitamin B12, and vitamin B6 simultaneously to the 
model for mutual adjustments did not change the effect estimates for vitamin B6 and 
B12, but attenuated the HR for folate intake to 1.04 (95%CI, 0.64-1.70). 
Stratified analyses (see table 3) showed a significant inverse association between 
vitamin B6 intake and PD risk in smokers (HR per SD, 0.53; 95%CI, 0.35-0.81), but no 
association in non-smokers (HR, 0.99; 95%CI 0.58-1.68). The multiplicative interaction 
term containing vitamin B6 intake and smoking was significant (p=0.036). Results for 
vitamin B12 and folate intake were not different for smokers and non-smokers. 
Discussion
In this prospective, population-based cohort study we found that higher intake of 
vitamin B6, but not vitamin B12 or folate, was associated with a significantly decreased 
risk of PD, particularly in smokers. Methodological strengths of this study include 
the extensive case-finding procedures and virtually complete follow-up with a large 
number of person-years. Moreover, the prospective design with dietary assessments 
before onset of PD limits the possibility that changes in intake as a consequence of 
the disease influenced the results. Among the constraints of our study are the limited 
statistical power to perform stratified analyses, and the possibility of misclassification 
of nutrient intake inherent to a food frequency questionnaire.
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Future disease status though was unknown at baseline, and dietary misclassification 
–if any- therefore most likely did not differ between participants with and without 
incident PD, causing at most an underestimation of the association. A certain degree 
of uncertainty regarding disease status is unavoidable in epidemiologic studies on 
PD, as in the absence of an unambiguous test for the disease the diagnosis is still 
based on clinical criteria. However, by applying extensive case-finding methods and 
strict diagnostic criteria, and through the availability of additional and long-term data 
from the computerized follow-up system, we think that diagnostic inaccuracy was 
reduced as much as possible.
Considering the potential neurotoxicity of homocysteine,3,4,8 we hypothesized that 
higher intakes of folate and vitamins B12 and B6 might decrease the risk of PD by 
lowering homocysteine levels. We found, indeed, a significant inverse association for 
vitamin B6, but no significant association for folate and vitamin B12. This may point 
towards an additional mechanism underlying the association for vitamin B6 intake. 
Several lines of evidence suggest neuroprotective properties of vitamin B6 through 
antioxidant capacities, in addition to lowering plasma homocysteine.14-19 As oxidative 
stress is thought to play a prominent role in PD pathogenesis,2 higher vitamin B6 
intake may thus reduce PD risk through antioxidant effects. In rats, oxidative stress 
was induced by vitamin B6 deficiency18 and prevented by vitamin B6 supplementatio
n.14Antioxidant activities of vitamin B6 were also observed in yeast cells, monocytes 
and blood plasma.15,16,19 Furthermore, vitamin B6 is a cofactor in dopamine synthesis 
and is required to convert homocysteine to cysteine, which in turn is the rate-limiting 
forerunner in the synthesis of glutathione.19 Reduced levels of glutathione, a major 
antioxidant, have been found in dopaminergic neurons of PD patients.2
The relation between dietary folate, vitamin B12, and vitamin B6 and the risk of PD 
has only been examined in one study previously, in which no significant associations 
were observed for either of these vitamins.27 In this US-based prospective study 
among health professionals, with repeated dietary assessments and case ascertainment 
based on self-reported diagnoses, median intakes of folate (men 388 µg/d, women 
277 µg/d), vitamin B12 (men 10.4 µg/d, women 6.8 µg/d), and vitamin B6 (men 5.6 
mg/d, women 2.3 mg/d) were considerably higher than the corresponding median 
intakes in the Rotterdam Study (folate: men 223 µg/d, women 197 µg/d; vitamin 
B12: men 4.7 µg/d, women 3.9 µg/d; vitamin B6: men 1.8 mg/d, women 1.5 mg/d), 
probably due to a raised health-consciousness among the US health professionals, 
together with the 1998 FDA requirement to fortify grain products with folate in the 
US.28 These differences in intake may explain the discrepant findings for vitamin B6 
intake, as adequate intake in the US-based study probably precluded demonstrating 
associations with the risk of PD.
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The inverse relation between vitamin B6 intake and PD risk in our study appeared 
only present in smokers. A potential explanation for this finding is the increased free 
radical load and associated oxidative stress in smokers29 and thus a stronger expected 
antioxidant effect of vitamin B6. Alternatively, putative neuroprotective effects of 
cigarette smoke components26 might reinforce the beneficial effects of vitamin B6 
intake on PD risk.
In conclusion, our findings suggest that higher dietary intake of vitamin B6 may 
decrease the risk of PD, either through lowering homocysteine levels, or through its 
antioxidant properties.
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Abstract
Background
Oxidative stress is thought to play a key role in the pathogenesis of Parkinson disease. 
Uric acid might protect against Parkinson disease through anti-oxidant and iron-
chelating properties. 
Objective
To examine whether higher serum levels of uric acid are associated with a lower risk 
of Parkinson disease. 
Methods
In the Rotterdam Study, a prospective population-based cohort study of people aged 
�≥55 years, we evaluated the association between serum levels of uric acid and the 
risk of incident Parkinson disease among 4,695 participants. Parkinson disease was 
assessed through repeated in-person examination and the cohort was continuously 
monitored by computer linkage to medical records. We analyzed the data using Cox 
proportional hazards regression models. 
Results
After a mean follow up of 9.4 years, we identified 68 participants with incident 
Parkinson disease. Higher serum levels of uric acid were associated with a significantly 
decreased risk of Parkinson disease (adjusted hazard ratio per standard deviation 
increase, 0.70; 95% confidence interval, 0.50-0.98), with strong evidence for a dose-
effect relationship (p-value for trend over quartiles 0.035). 
Conclusion
Our findings support the hypothesis that oxidative stress contributes to the risk of 
Parkinson disease and suggest a potential protective effect of the natural antioxidant 
and free radical scavenger uric acid.
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Introduction
The exact cause of the selective dopaminergic cell death that underlies Parkinson 
disease (PD) is still unknown, but oxidative stress and mitochondrial dysfunction 
are generally thought to play a prominent role.1 Uric acid is an important natural 
antioxidant that may reduce oxidative stress through its actions as a scavenger of 
free radicals and iron-chelator.2-5 Uric acid was found to suppress oxidative stress 
and prevent dopaminergic cell death in animal models of PD,6 and reduced levels 
of uric acid have been observed in the substantia nigra of PD patients compared 
with controls.7,8  In the only prospective study to our knowledge that evaluated 
the relationship between uric acid concentrations and the risk of PD thus far, a 
significantly lower PD risk was found for men with uric acid concentrations above 
the median.9 
We hypothesized that through antioxidant effects, higher concentrations of uric acid 
might protect against PD and studied this association prospectively in the population-
based Rotterdam Study.
Subjects and methods
The Rotterdam Study is a prospective population-based cohort study among 7,983 
persons aged 55 years or older in a district of Rotterdam, the Netherlands.10 Both 
at baseline (1990-1993) and three follow-up rounds (1993-1994, 1997-1999, and 
2002-2004), all participants were interviewed and underwent extensive physical 
examination and venipuncture. We used a two–phase design to identify subjects 
with PD.11 Participants were screened for parkinsonian signs (resting tremor, rigidity, 
bradykinesia, or impaired postural reflexes) in a standardized way. Individuals who 
screened positive received a structural diagnostic workup comprising the Unified 
Parkinson’s Disease Rating Scale (UPDRS)12 and neurological examination. In 
addition, the cohort was continuously monitored through computerized linkage to 
general practitioners’ medical files. PD was diagnosed if two or more parkinsonian 
signs were present in a person not taking antiparkinsonian drugs, or if at least one 
sign had improved after medication was started, and when all causes of secondary 
parkinsonism (dementia, use of neuroleptics, cerebrovascular disease, multiple 
system atrophy, or progressive supranuclear palsy) could be excluded.
Uric acid activity was determined in serum obtained from nonfasting blood within 1 
week after baseline venipuncture by an enzymatic method using a Kone Diagnostica 
reagent kit and a Kone autoanalyzer.13 At baseline, smoking status (classified as 
current, former, or never smoking), medication use, consumption of dairy products, 
and alcohol intake (g/day) were assessed during the interview, and height and weight 
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were measured to calculate body mass index (BMI, kg/m2).
Baseline neurological screening was performed in 6,969 participants. We excluded 
participants diagnosed with any parkinsonism (n=130) or dementia (n=273) 
at baseline, and participants who visited the research center after December 31, 
1992 (n=1871), because by that time uric acid measurements were stopped due to 
financial constraints. The study population thus consisted of 4,695 participants free 
of parkinsonism and dementia at baseline with serum uric acid levels available.
The relation between serum uric acid levels and the risk of incident PD was analyzed 
by means of Cox proportional hazards regression analysis, with serum uric acid as a 
continuous variable (expressed per standard deviation increase) as well as in quartiles 
of its distribution. Analyses were initially adjusted for age and sex. We additionally 
adjusted for smoking habits, alcohol intake, consumption of dairy products, and 
BMI, because these variables reportedly affect serum uric acid levels and might 
be associated with PD risk, and therefore were considered potential confounders.14-
19 Analyses were repeated after stratification on sex and smoking status and after 
exclusion of participants who used uric acid-lowering (anti-gout) medication at 
baseline. 
Results
Follow-up was virtually complete (> 98%), through either in-person examination or 
the computerized monitoring system. During a total of 44,121 person-years of follow-
up (mean, 9.4 years), 68 new cases of PD were detected. Baseline characteristics of 
the study population, as well as regression coefficients with 95% confidence intervals 
(CIs) for the relation between potential confounders and serum uric acid levels, are 
presented in Table 1. 
Table 2 shows the hazard ratios (HRs) with 95% CIs of developing PD according to 
serum uric acid concentration. Higher serum uric acid levels seemed associated with 
a lower risk of PD in the age- and sex-adjusted analyses (HR per standard deviation 
increase 0.82; 95% CI, 0.63-1.08). This association was significant after additional 
adjustments for smoking, BMI, consumption of dairy products, and alcohol intake 
(adjusted HR per standard deviation increase 0.71; 95% CI, 0.51-0.98), with evidence 
for a dose-effect relationship (adjusted HR for highest compared with lowest quartile 
0.42 (95% CI, 0.18-0.96), p-value for trend over quartiles 0.040). The strengthening 
of the association was almost exclusively caused by the adjustment for BMI, being 
the potential confounder that appeared most strongly associated with uric acid levels 
(see Table 1). 
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Results were not significantly different for men and women, or for smokers and 
nonsmokers. Exclusion of participants who used anti-gout preparations at baseline 
(n=25) did not change the results either (data not shown).
Discussion
In this large, population-based cohort study we found that higher serum levels of 
uric acid were associated with a significantly decreased risk of PD. Bias is unlikely 
to explain our findings, given the prospective nature of our study, extensive case 
ascertainment, and nearly complete follow-up. Besides, the results show evidence for 
a dose-effect relationship and were not attenuated after adjusting for several potential 
confounders. Uric acid measurements were stopped before all patients had visited 
the research center. However, as participants were invited in random order, we do 
not think this affected our results.
Uric acid is an important antioxidant and scavenger of free radicals.2,4,5 Because 
oxidative stress is thought to play a key role in the pathogenesis of PD,1 uric acid might 
exert protective effects against PD through its antioxidant capacities. Furthermore, 
uric acid has a strong ability to bind iron,3 which may contribute to oxidative damage 
in PD by enhancing generation of reactive oxygen species.20
Table 2. Serum uric acid and the risk of Parkinson disease. Hazard Ratios (HRs) 
with 95 % confidence intervals (CIs), per standard deviation (SD) and in quartiles
Model 1 a Model 2 b
HR (95% CI) HR (95% CI)
       
Per SD 0.82 (0.63 - 1.08) 0.71 (0.51 - 0.98)
Quartiles:
1 1.00 (ref.) 1.00 (ref.)
2 0.75 (0.39 - 1.45) 0.68 (0.34 - 1.39)
3 0.70 (0.36 - 1.35) 0.59 (0.28 - 1.25)
4 0.50 (0.24 - 1.03) 0.42 (0.18 - 0.96)
p-trend 0.065 p-trend 0.040
      
aAdjusted for age and sex
bAdditionally adjusted for smoking, alcohol intake, consumption of dairy products, and BMI
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Two studies on postmortem material have shown reduced levels of uric acid in 
the substantia nigra of PD patients compared with controls.7,8 In a mouse model 
of PD, treatment with uric acid suppressed oxidative stress and prevented death of 
dopaminergic cells caused by administration of homocysteine or iron.6 
As yet, the relationship between serum uric acid and PD has been examined 
prospectively in only one study, which was restricted to men. Serum uric acid levels 
in the Honolulu Heart Study were measured in 1965 in 7,968 middle-aged men, 
who were followed up until 1994 for incident PD. Participants with baseline uric 
acid concentrations above the median had a significantly lower risk to develop PD 
during follow-up, which is in line with our findings.9 Although the possibility that 
our findings are due to residual confounding or confounding by unmeasured factors 
cannot be completely ruled out, we think these results support the hypothesis that 
oxidative stress is involved in the pathogenesis of PD and that uric acid might reduce 
the risk of PD via antioxidant and iron-chelating properties. 
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Abstract
Background
Most prognostic studies on Parkinson disease have been hospital-based or applied 
register-based case-finding methods. Potential underrepresentation of mild cases may 
have given biased results.
Objective
To evaluate whether Parkinson disease is associated with an increased risk of dementia 
and death.
Methods
In the Rotterdam Study, a prospective population-based cohort study of people aged 
�≥55 years, we compared the risk of incident dementia and death of patients with 
Parkinson disease and participants without Parkinson disease. The study sample 
comprised 6,969 persons, including 99 prevalent and 67 incident cases of Parkinson 
disease. Parkinson disease and dementia were assessed through repeated in-person 
examination at baseline (1990-1993) and two follow-up visits (1993-1994 and 1997-
1999). Computerized linkage to medical and municipality records provided additional 
information on disease outcomes and mortality. We analyzed the data using Cox 
proportional hazards regression models. 
Results 
Patients with Parkinson disease had an increased risk of dementia (hazard ratio 
(HR), 2.8; 95% confidence interval (CI), 1.8-4.4), which was especially pronounced 
in participants carrying at least one APOE ε2 allele (HR, 13.5; 95% CI, 4.5-40.6). 
Parkinson disease was associated with an increased mortality risk (HR, 1.8; 95% CI, 
1.5-2.3). The association consistently diminished when analyses were sequentially 
restricted to patients with shorter disease duration and after adjustment for the 
occurrence of dementia. 
Conclusion
Especially PD patients who carry an APOE ε2 allele have an increased risk of 
developing dementia. Increased mortality risk in Parkinson disease is dependent on 
disease duration and only modest in the absence of dementia. 
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Introduction
The prevalence of Parkinson disease (PD), the second most common neurodegenerative 
disorder, is expected to increase as populations worldwide age. Insight into the 
prognosis is therefore desirable. PD has been associated with an increased risk 
of developing dementia and a reduced life expectancy. However, most prognostic 
studies have been hospital-based, yielding results that are not representative of the 
general population. Our group previously showed that, even in population-based 
studies, a considerable proportion of cases of PD remain undiagnosed when case 
finding relies on medical records only and no population screening is done.1 The 
potential under-representation of relatively mild cases in register-based studies might 
result in overestimating the risk of dementia or mortality. Another issue is whether 
the prognosis of patients with PD varies with apolipoprotein E (APOE) genotype, 
because previous studies have shown conflicting results.2-6 
In a prospective population-based cohort study involving in-person examination 
of all participants, we evaluated the prognosis of PD with respect to dementia and 
mortality, studying both prevalent cases identified at baseline and incident cases 
diagnosed during follow-up. We furthermore investigated to what extent reduced 
survival in patients with PD is due to their higher risk of dementia, and whether 
APOE genotype influences prognosis.
Methods
The Rotterdam Study
The Rotterdam Study is a prospective population-based cohort study among 7,983 
subjects aged 55 years and older. At baseline (1990-1993) and two follow-up visits 
(1993-1994 and 1997-1999), participants were interviewed and underwent extensive 
physical examination. In addition, the cohort was continuously monitored for major 
disease outcomes and mortality through computerized linkage to general practitioners’ 
medical files. All participants gave their informed consent, and the Medical Ethics 
Committee of the Erasmus Medical Center, Rotterdam, the Netherlands approved the 
study.
Assessment of Parkinson disease and dementia
At baseline and follow-up, we used a two-stage protocol to identify subjects with PD 
and a three-stage protocol to assess dementia, both of which have been described 
extensively elsewhere.1,7-9 Briefly, all participants were screened for symptoms of 
parkinsonism, and those who screened positive received a structural diagnostic workup 
using the Unified Parkinson’s Disease Rating Scale. Persons suspected of having PD 
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were examined by a neurologist. PD was diagnosed if at least two parkinsonian signs 
were present or if at least one sign had improved through medication and all causes 
of secondary parkinsonism had been excluded. Age at diagnosis of PD and Hoehn 
and Yahr scale score for disease severity were assessed in the diagnostic workup and 
verified from medical records if possible. 
Cognitive screening of all participants was performed with the Mini-Mental State 
Examination and Geriatric Mental State schedule. Subjects in whom screening was 
positive were examined with the Cambridge Examination of Mental Disorders in 
the Elderly. If the result of this examination was inconclusive, a neuropsychologist 
performed further examination and, if possible, magnetic resonance imaging was 
done. Final diagnosis was made according to Diagnostic and Statistical Manual of 
Mental Disorders, Revised Third Edition criteria.10 The computerized surveillance 
system continuously provided additional information on both PD and dementia.
Assessment of mortality and covariates
Mortality until January 1, 2000, was assessed through continuous monitoring of the 
municipal address files and computerized reports from general practitioners on the 
deaths of participants. Information on highest attained educational level, smoking 
habits, medication use, and living situation was obtained during the baseline 
interview. APOE genotyping was performed on baseline samples.2  
Study population
At baseline, 6,969 participants underwent neurologic screening. PD was diagnosed in 
99 participants (prevalent PD). During follow-up, another 67 patients were identified 
(incident PD). All 6,969 participants were followed up to study mortality risk. 
To examine the risk of incident dementia, we excluded participants with incomplete 
baseline cognitive screening (n=6) and those diagnosed as having dementia at 
baseline (n=312). The resulting study sample of 6,651 nondemented participants 
comprised 72 prevalent and 67 incident PD cases.
Data analysis
Hazard ratios (HRs) for incident dementia and mortality were computed by means of 
Cox proportional hazards regression analysis allowing for delayed entry, with age as 
the time scale and PD as a time-dependent covariate. Models were initially adjusted 
for age and sex. Potential confounders we additionally adjusted for were smoking 
(ever versus never), nursing home residency, antiparkinsonian medication use, and 
educational level (primary education only versus more than primary education). 
Because of the wide range of disease duration of prevalent PD cases at the time 
of inclusion in the study, we performed separate analyses for cases with disease 
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duration of 5 years or more and less than 5 years. Within the latter group, we 
further looked separately into those with less than 2 years duration (hence including 
incident PD cases) and incident PD cases only. To evaluate whether and to what 
extent reduced survival in patients with PD is explained by an increased risk of 
dementia, we adjusted  for occurrence of dementia in a time-dependent fashion. All 
analyses were stratified on APOE genotype (�ε3ε3, ε4+, and ε2+; ε2ε4 excluded) to 
examine potential modifying effects on prognosis. 
Table 1. Baseline characteristics of the study population
Free of PD Prevalent PD Incident PD
at baseline* at baseline during
follow-up
Characteristic (n = 6,870) (n = 99) (n = 67)
       
Age at baseline, mean (SD), y 69.4 (9.1) 78.3 (8.2) 74.6 (7.2)
Women, no (%) 4,092 (59.6) 64 (64.6) 36 (53.7)
Ever smoking, no (%) 4,373 (63.7) 50 (50.5) 34 (50.7)
APOE genotype, no (%)± 
�ε2+ 833 (13.8) 16 (21.1) 10 (14.9)
�ε3�ε3 3,813 (59.9) 45 (59.2) 35 (59.7)
�ε4+ 1,673 (26.3) 15 (19.7) 19 (25.4)
Primary education only, no (%) 2,624 (38.2) 44 (44.4) 25 (37.3)
Nursing home residency, no (%) 533 (7.8) 43 (43.4) 8 (11.9)
Antiparkinsonian medication use, no (%) 9 (0.1) 52 (52.5) 0 (0.0)
Dementia at baseline, no (%) 290 (4.2) 22 (22.2) NA
No cognitive testing at baseline, no (%) 1 (0.01) 5 (5.1) NA
Age at onset of PD, mean (SD), y NA 71.2 (9.9) 77.5 (7.1)
Duration of disease, mean (SD), y NA 5.7 (5.4) NA
Hoehn and Yahr scale score, mean (SD) NA 2.3 (1.2) 1.8 (1.0)
       
PD: Parkinson disease, SD: standard deviation, APOE: Apolipoprotein E gene, NA: not applicable 
*Includes people who developed PD during follow-up (incident PD)
±Available for 6,445 participants
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Median survival from diagnosis was calculated with the Kaplan-Meier method. All 
analyses were performed with SAS software (version 8.2; SAS Institute Inc, Cary, 
NC).
Results
Table 1 displays baseline characteristics of the study population. Follow-up was 
virtually complete (99%) until January 1, 2000. The total follow-up time was 48,606 
person-years (overall mean, 6.9 years; mean of incident PD cases after disease onset, 
4.3 years). The mean Hoehn and Yahr scale score of patients with prevalent PD (2.3) 
and especially of patients with incident PD (1.8) was relatively low compared with 
previous studies.
Risk of dementia
At baseline, 22% of the participants with PD and 4% of those without PD were 
diagnosed as having dementia. Demented patients with PD were significantly older 
than those without dementia. Of the cohort free of dementia at baseline, 21 (15.1%) 
of the 139 patients with PD and 318 (4.9%) of the 6,512 participants without PD 
developed dementia during follow-up. The presence of PD was associated with a 
significantly increased risk of dementia (HR, 2.80; 95% CI, 1.79 - 4.38; table 2). Results 
were similar after additional adjustments and for subgroups of disease duration at 
baseline. 
Table 2. PD and the risk of incident dementia, in strata of APOE genotype; Hazard 
ratios (HRs) with 95% confidence intervals (CIs)
      
Model Overall APOE �ε2+ APOE �ε3ε3 APOE �ε4+ P -value
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) interaction
      
1 2.80 (1.79-4.38) 13.46 (4.46-40.64) 1.74 (0.77-3.97) 6.27 (3.07-12.82) 0.000
2 2.82 (1.80-4.42) 14.26 (4.68-43.50) 1.82 (0.80-4.16) 6.49 (3.17-13.31) 0.024
      
Model 1: adjusted for age and sex
Model 2 : adjusted for age, sex, and educational level 
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However, restricting analyses to only incident PD cases resulted in a higher estimate 
(HR, 4.74; 95% CI, 2.49 - 9.02). Disease duration did not seem to affect dementia risk 
within PD cases (HR increase per year, 0.96; 95% CI, 0.84-1.09). The association of PD 
with incident dementia was more pronounced in participants with at least one APOE 
ε4 allele (HR, 6.27; 95% CI, 3.07 - 12.82), and especially in those carrying at least one 
APOE ε2 allele (HR, 13.46; 95% CI, 4.46-40.64), compared with ε3ε3 carriers. 
Mortality risk
During follow-up, 90 (54.2%) of the 166 patients with PD and 1,623 (23.9%) of the 6,803 
participants without PD died. Median survival since diagnosis of PD was 9.1 years 
(95% CI, 7.4 - 10.9 years). Overall, PD was associated with a significantly increased 
mortality risk (HR, 1.83; 95% CI, 1.47 - 2.26; table 3). However, HRs consistently 
decreased when the analyses were sequentially restricted to patients in whom PD 
was diagnosed more recently. Additional adjustments did not substantially change 
the results, but adjusting for occurrence of dementia yielded lower mortality HRs. 
The effect of PD on survival was not different for men and women, or by strata of 
APOE genotype (data not shown). Within PD cases, mortality risk was influenced by 
disease duration (HR increase per year, 1.03; 95% CI, 0.99 - 1.07) and by occurrence 
of dementia (HR, 2.85; 95% CI, 1.77 - 4.62).
Comment
The strengths of this study are its population-based nature, size, and almost complete 
follow-up. In addition, thorough case ascertainment for PD and dementia was 
ensured through in-person instead of record-based screening methods. The use of 
strict diagnostic criteria enhanced diagnostic accuracy, and continuous monitoring of 
participants after diagnosis enabled us to revise diagnoses on the basis of additional 
information. Furthermore, because we followed up prevalent as well as incident PD 
cases, we could evaluate the effect of disease duration on prognosis and potential 
bias in prevalent cohorts.
An increased risk of dementia associated with PD has repeatedly been reported, with 
relative risks varying from 1.7-5.9.11-14 Our estimate of a 2.8-times increased risk is 
relatively low. A possible explanation is the low average disease severity in our study, 
which resulted from our screening methods, through which we identified a large 
number of previously unrecognized patients with mild PD.1,7 Moreover, we consider 
it likely that PD patients who agreed to participate at baseline had fewer cognitive 
complaints and thus a lower risk of future dementia than nonresponders, which may 
have led us to underestimate the risk for prevalent cases. The HR for incident cases 
was notably higher (4.7), despite lower disease severity, and presumably reflects the 
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actual situation more accurately. 
We found that the effect of PD on dementia risk was more pronounced in participants 
carrying at least one APOE ε4 allele and remarkably strong in those carrying at least 
one APOE ε2 allele. Apolipoprotein E, coded for by the APOE gene, is a polymorphic 
protein abundant in the brain that is involved in lipid transport, immunoregulation, 
and modulation of cell growth.15 For Alzheimer disease, the APOE ε4 allele is an 
established risk factor, whereas the ε2 allele is considered protective.15 In contrast, a 
recent meta-analysis3 confirmed the repeatedly observed association of the ε2 allele 
with an increased risk of PD, while results for the ε4 allele were inconsistent.2-5 A 
significant positive association with occurrence of dementia in patients with PD has 
been observed for both the ε4 allele and the ε2 allele,2,6 which suggests that the 
APOE gene might modify the risk of dementia associated with PD. However, the 
exact mechanism by which APOE genotype or apolipoprotein E isoforms influence 
the risk and course of PD is still unclear.
The overall mortality HR of 1.8 we observed is in line with figures from other studies, 
ranging from 1.5-2.7.16-24 We found that the mortality HR was higher for patients with 
longer disease duration and relatively low for newly diagnosed incident cases. This fits 
previous observations20,25 that mortality rates in patients with PD were not increased 
compared with those in controls in the first years of follow-up and differed more as 
time since diagnosis increased. Apart from the effect of aging, disease duration thus 
seems to influence mortality risk in PD, and differences in the composition of study 
populations with respect to mean and range of duration of PD may lead to different 
estimates of mortality risk. From studies in prevalent cohorts, in fact, only prognosis 
after enrollment can be derived, which is different from prognosis after diagnosis of 
PD, especially in case of a long delay between diagnosis and inclusion in the study. 
Since we observed that mean Hoehn and Yahr scale scores were consistently higher 
in categories of longer disease duration, the effect of disease duration on mortality 
risk might reflect the effect of disease severity. Independent effects of disease severity 
on mortality have been described previously.14 To correctly evaluate prognosis after 
PD diagnosis, prospective studies of incident cases are required. These are difficult, 
given the low incidence rate of PD, and were only conducted twice previously.21,25 
Both studies found a mortality HR somewhat higher than our figure for incident 
cases. This may be accounted for by the relatively high proportion of patients with 
mild PD and the fact that follow-up of incident PD cases was relatively short in our 
study. 
Although both PD and dementia have separately been associated with increased 
mortality, few studies have investigated to what extent dementia contributes to 
the observed shorter survival in patients with PD.14,19,24 We tried to evaluate this by 
adjusting in a time-dependent fashion for the occurrence of dementia, which led to 
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lower estimates of the mortality HRs in all strata of disease duration. This suggests 
that part of the reduced life expectancy of patients with PD can be ascribed to their 
increased risk of becoming demented. In fact, mortality risk is only slightly increased 
in the absence of dementia.
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The aim of this thesis was to assess the impact of Parkinson disease (PD) in the 
general population in terms of frequency and prognosis, and to identify potential risk 
factors for the disease. The studies we conducted were all embedded in the Rotterdam 
Study, a large prospective population-based cohort study in participants aged 55 
years and older. In this chapter, I will briefly summarize the main findings and try to 
place them in a broader perspective. First, I will consider some methodological issues 
relevant for epidemiological research on PD in general and the Rotterdam Study in 
particular. I will furthermore discuss how our findings fit into current knowledge 
and models for PD pathogenesis. Finally, I will reflect on the relevance and potential 
implications of our observations and discuss directions for future research. 
Main findings
Incidence of PD
In the Rotterdam Study the incidence of PD consistently increased with age, and 
seemed to be higher in men (chapter 3.1). The incidence rates in our study were 
higher than those reported by most previous studies, most likely due to our intensive 
case-finding methods. A considerable proportion of the PD cases identified in our 
study had not been diagnosed with PD before, and hence would not have been 
included in a register-based study. 
Subjective complaints precede onset of clinically manifest PD
At baseline, more than half of the non-demented participants in whom no 
parkinsonian signs were observed on physical examination nevertheless reported 
at least one complaint suggestive for parkinsonism (i.e. stiffness, occasional tremors, 
slowness of movement, falling or a feeling of imbalance). In these participants we 
found that subjective complaints about stiffness, tremors or imbalance at baseline 
were associated with an increased risk to develop PD during follow-up (chapter 3.2). 
Given the high proportion of elderly reporting these complaints and the relatively 
low frequency of PD in the general population, the specificity and positive predictive 
value of such complaints will be insufficient to use them as a sole screening 
instrument for preclinical disease. However, in a stepwise approach to detect early 
PD a questionnaire on subjective complaints might be an inexpensive initial test.
Risk factors: role of cholesterol and other lipids
We prospectively studied the association between dietary intake of various types 
of fat, as well as serum levels of total and HDL cholesterol and the risk of PD. 
People with higher intake of unsaturated fatty acids, main elements of neuronal 
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cell membranes with neuroprotective and antioxidant properties, had a significantly 
decreased risk of incident PD (chapter 4.1). This association remained unchanged 
after adjustments for several potential confounders and after exclusion of PD cases 
that were diagnosed relatively shortly after baseline dietary assessments. The results 
presented in chapter 4.1 were based on follow-up until January 1, 2000 and although 
they also suggested an inverse association between dietary cholesterol intake and 
PD risk, this did not reach statistical significance. Further analyses after we had 
completed an additional number of on average 3.4 years of follow-up indeed showed 
that higher dietary intake of cholesterol was related to a significantly lower risk of 
PD, in particular in women. This fitted the observation that higher baseline levels of 
total cholesterol were associated with a significantly lower risk of PD in a dose-effect 
manner (chapter 4.2), although only in women. Again, adjusting for several potential 
confounders did not change the results.
Risk factors: homocysteine and oxidative stress
Homocysteine may contribute to neuronal cell death in PD through neurotoxic effects, 
probably by increasing oxidative stress. We therefore investigated the effect on PD 
risk of the TT variant of the methylenetetrahydrofolate reductase (MTHFR) C677T 
polymorphism, which is associated with mild hyperhomocysteinemia, and of dietary 
intake of folate, vitamin B12 and vitamin B6, essential co-factors that are required 
to keep plasma homocysteine levels low. The TT genotype was associated with an 
increased risk of PD, particularly in smokers (chapter 5.1). This is in accordance with 
reported synergistic effects of smoking and TT genotype on plasma homocysteine 
levels. Higher dietary intake of vitamin B6, but not of folate or vitamin B12, was 
associated with a significantly decreased risk of PD (chapter 5.2). This observation 
might be explained by the antioxidant properties of vitamin B6, in addition to its 
homocysteine-lowering effects, although its function as a co-factor for dopamine 
synthesis might also play a role. We also prospectively examined the relationship 
between serum levels of the antioxidant uric acid and PD risk. Higher levels of uric 
acid were associated with a significantly lower risk of PD (chapter 5.3). A dose-
effect relationship was found and the association did not change after adjusting for 
potential confounders.
Prognosis: risk of dementia and mortality 
We observed that patients with PD had a significantly increased risk of developing 
dementia and a reduced life expectancy compared with participants without PD 
(chapter 6). The risk of dementia was more pronounced in participants carrying 
at least one APOE ε4 allele, and especially in those carrying at least one APOE �ε2 
allele, compared with ε3ε3 carriers. Increased mortality risk was more prominent in 
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PD patients with longer disease duration and was attenuated after adjustment for the 
occurrence of dementia, which suggests that an increased risk of dementia is partly 
responsible for the reduced survival in PD.
Methodological considerations
Most of the methodological issues related to case finding, diagnosis and potential 
sources of bias in epidemiological research on PD in general have already been 
extensively discussed in chapter 2. Methodological strengths of the Rotterdam Study 
(the large number of participants, prospective design and in-person examination of 
all subjects) by which many of these problems have at least partly been overcome are 
described in the previous chapters. However, even carefully designed and conducted 
epidemiological studies on PD have methodological limitations that should be borne 
in mind when interpreting the results. 
An almost inevitable limitation is the inaccuracy inherent to PD diagnosis in an 
epidemiological setting. As long as a reliable test or marker for PD suited for large-
scale population-based research (i.e. widely available, inexpensive and minimally 
invasive) is not available, diagnosis will depend on clinical criteria. According to 
current consensus criteria, a definite diagnosis requires confirmation in post-mortem 
material.1 Therefore, unless neuropathological material is routinely collected, at best 
a diagnosis of ‘probable PD’ is obtained, which from clinicopathological studies is 
estimated to be correct in only less than 80% of the cases.2-4 It should, however, be 
noted that post-mortem tissue is usually obtained at the end-stages of the illness, and 
one might dispute whether observed changes really reflect the processes at the time 
of diagnosis.
In the majority of epidemiological studies on PD, including ours, examination 
of post-mortem material is not part of the standard data collection and a certain 
amount of misclassification of disease status is thus unavoidable. We have tried to 
reduce diagnostic inaccuracy as much as possible by applying extensive case-finding 
methods and strict clinical diagnostic criteria for PD. Besides, long-term follow-up 
of participants was assured through a continuous computerized surveillance system. 
This enabled us to evaluate disease course and progression, response to levodopa 
medication and appearance of additional cognitive, autonomic or other non-motor 
symptoms, which are important for PD diagnosis and cannot be appreciated when 
disease is assessed at one point in time only.
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A second issue concerns the preclinical period in PD. As was described in chapter 
3.2, neuronal degeneration is already ongoing for at least several years before PD 
becomes clinically manifest.5,6 As the duration of this preclinical phase is not known, 
early dopamine deficiency might theoretically exert its effects in persons seemingly 
unaffected at baseline. Even in prospective studies like ours, changes resulting from 
early disease processes may thus be mistaken for causally related risk factors. 
However, this form of bias is less likely to be of influence as time between assessment 
of risk factors and diagnosis of PD increases, and will thus be of limited concern 
in studies with longer duration of follow-up like the Rotterdam Study. Moreover, 
the design with multiple follow-up rounds allows for separate analyses of patients 
diagnosed at different intervals from baseline assessments, to evaluate potential 
influence of preclinical disease at baseline (as described in chapter 4.1 on dietary fat 
intake).
How do our findings fit current knowledge on PD 
pathogenesis?
It is as yet unclear which mechanisms underlie the selective dopaminergic cell death 
in PD. Until less than a decade ago, most insights into the pathogenesis of PD 
were derived from post-mortem studies, epidemiological research and experimental 
animal models. The discovery of the first causative gene mutation responsible for 
familial PD in 1997 and subsequent identification of several other causative genes 
gave new impulses to PD research and greatly enhanced knowledge on pathogenetic 
mechanisms that may underlie both familial and sporadic forms of the disease.7 
Current notion is that sporadic PD is a multifactorial disease, resulting from complex 
interactions of several environmental and genetic factors.7-10 Although PD seems to 
have many different causes, including gene mutations for hereditary PD and factors 
involved in sporadic cases, these appear to converge on one or a few common 
molecular mechanisms that ultimately lead to dopaminergic cell death.8 
It is commonly believed that there is sufficient evidence for a role of oxidative stress 
in PD pathogenesis, mainly on the basis of post-mortem observations of increased 
oxidative stress markers in the substantia nigra of PD patients.8,11,12 Oxidative stress 
results from damage by free radicals, also known as reactive oxygen species (ROS), 
which are highly reactive molecules that may damage cell structures, resulting in 
functional alteration of proteins, lipids and DNA. Much research has focused on 
potential sources of oxidative stress, i.e. sources of increased formation of ROS 
or impaired defense against ROS. Dysfunction of complex I of the mitochondrial 
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respiratory chain seems to be one of the major sources of free radical formation that is 
specifically involved in PD pathogenesis.8 Decreased activity of this enzyme complex 
(NADH:ubiquinone oxidoreductase) has been described in the substantia nigra and 
platelets from PD patients.13,14 Furthermore, three selective inhibitors of complex I 
have been found to induce selective dopaminergic cell death as well as clinical 
features resembling PD: the synthetic drug contaminant 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), the herbicide paraquat and the widely used insecticide 
rotenone.15 Impairment of complex I induces oxidative stress, but oxidative stress 
itself may also lead to impaired complex I function, which makes it difficult to 
determine which one is the primary process.11 Recent research on the biological 
function of gene products of DJ-1 and PINK1, both linked to familial PD, has further 
contributed to the notion that mitochondrial dysfunction and increased oxidative 
stress might be central to PD pathogenesis. The DJ-1 protein seems to be involved 
in the cell’s response to oxidative stress,16 and the PINK1 protein, a mitochondrial 
protein kinase, may protect the cell against mitochondrial dysfunction.17 
Several of our findings are in line with the concept of oxidative stress as an important 
molecular mechanism underlying PD. The observation that the incidence of PD 
sharply rises with age is consistent with this idea, as increasing age is known to be 
accompanied by enhanced oxidative stress.11 In animal models, oxidative stress has 
been described as a result of homocysteine administration.18 The observed association 
between the hyperhomocysteinemic MTHFR 677 TT genotype and an increased risk 
of PD is therefore also in agreement with the oxidative stress hypothesis. Other 
findings in favor of this hypothesis are the observations that several substances 
known to have antioxidant (i.e. oxidative stress-lowering) properties were associated 
with a decreased risk of PD in our studies. These include dietary unsaturated fatty 
acids, dietary vitamin B6 and serum levels of uric acid. We also found an inverse 
association between serum levels of cholesterol and PD risk. Although highly 
speculative, a potential hypothesis to explain this finding is provided by the strong 
correlation between cholesterol level and serum concentration of coenzyme Q10, a 
powerful anti-oxidant and mitochondrial complex I acceptor.19,20 Through a link with 
coenzyme Q10, our observation might theoretically support not only the concept of 
oxidative stress in PD pathogenesis, but also more specifically a role of complex I 
dysfunction.
The first mutation that was identified for familial PD (alpha-synuclein, PARK1)21 is 
associated with the formation of an abnormal, aggregated form of the alpha-synuclein 
protein. Alpha-synuclein was subsequently found to be the main component of the 
pathological Lewy Bodies that are seen in familial as well as sporadic PD,22 which 
170
Chapter 7
gave rise to the idea that impaired folding and degradation of proteins may contribute 
to PD pathogenesis.23 This notion is supported by evidence of malfunctioning of the 
pathway responsible for the elimination of abnormal cellular proteins, the ubiquitin 
proteasomal system (UPS), in post-mortem substantia nigra from PD patients.24 
Inhibition of the UPS was furthermore found to induce formation of inclusion bodies 
and selective loss of dopaminergic neurons in cultured neurons and rat brain.25 Two 
of the genetic mutations for familial PD (parkin and UCHL-1) are directly associated 
with the UPS. Parkin is an E3 ubiquitin-protein ligase that ubiquinates target proteins 
before they are degraded,26 and UCHL-1 is an enzyme of the UPS that can hydrolyze 
peptide-ubiquitin bonds and recycle ubiquitin monomers for re-use.27 Mutations 
in these genes are hypothesized to induce accumulation of damaged or misfolded 
proteins through malfunction of the UPS.28 
None of our findings directly relates to misfolded proteins or dysfunction of the 
UPS, but according to preliminary evidence from laboratory studies, aggregation of 
alpha-synuclein is probably linked to fat metabolism. Fatty acids seem to regulate 
alpha-synuclein oligomerization, which might precede the formation of insoluble 
aggregates29,30 and genes that affect alpha-synuclein toxicity in yeast were found to 
be involved in lipid metabolism.31 We found that both dietary intake of unsaturated 
fatty acids and serum cholesterol levels were inversely related to the risk of PD, and 
that APOE genotype seems to modify the risk of dementia associated with PD. These 
observations suggest a role of fat metabolism in PD pathogenesis, which might act 
through processes of protein aggregation.
It is still not completely understood why the systemic processes of mitochondrial 
dysfunction, oxidative stress and impairment of the UPS selectively affect the 
substantia nigra in PD patients. The brain depends mostly on mitochondrial energy 
supply, which is associated with the production of reactive oxygen species and an 
increased sensitivity to mitochondrial dysfunction.32 A possible explanation that 
applies more specifically to the substantia nigra is the suggestion that neuromelanin, 
a dark brown pigment present in the cells of the substantia nigra, is responsible 
for the selective susceptibility of these dopaminergic cells.33 Besides, products of 
dopamine metabolism are thought to increase the vulnerability of dopaminergic cells 
by inducing additional oxidative stress.34 
Another unsolved issue is the inverse association between smoking and the risk of PD, 
which is one of the most robust findings in many epidemiological studies. Because 
of the consistency across different study designs, including several large prospective 
studies, and because the effects of smoking appear to be dose-dependent, these 
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findings are commonly considered to indicate a true association.35 In the Rotterdam 
Study, we observed a hazard ratio for PD of 0.58 for ever compared to never smokers, 
which is in line with the effects sizes obtained in other studies (see chapter 2). 
Our finding that smoking modified the relationship between MTHFR genotype and 
PD as well as the association of vitamin B6 intake and PD also provides evidence 
that smoking somehow affects the pathological processes underlying the disease. 
An explanatory biological mechanism for the effect of smoking is however still 
lacking. Beneficial effects of cigarette smoke that have been hypothesized include 
stimulation of dopamine release, inhibition of monoamine oxidase B, upregulation of 
nicotinic receptors by nicotine and inhibition of free radical damage through carbon 
monoxide,35 but as yet no link with either oxidative stress, mitochondrial dysfunction 
or UPS impairment has been established. On the other hand, the inverse association 
between smoking and PD might also be considered an epiphenomenon and does not 
necessarily indicate a causal relation.
 
Implications of our findings
We observed that the incidence of PD increases with age and that PD patients have 
an increased risk to develop dementia and a reduced life expectancy compared 
to people without the disease. These findings on the impact of PD in the general 
population are of importance for health care planning, notably in the light of the 
worldwide aging of populations. PD may be expected to become more prevalent and 
to impose an increasing socio-economic burden on societies. It may furthermore be 
concluded that an increased level of awareness of PD is needed in clinical practice, 
given that over one third of the patients who fulfilled the clinical criteria for PD 
in our study had never received this diagnosis before. Parkinsonian symptoms 
apparently are often considered normal phenomena of physiological aging instead 
of potential disease manifestations, both by patients and physicians. The presence 
of co-morbidity, in particular in the elderly, may further complicate PD diagnosis. 
Familiarity with PD and its clinical appearance should enhance timely recognition 
of symptoms suggestive for parkinsonism. This could prevent that symptomatic 
treatment, which may give substantial symptom relief, is being withheld. Even in the 
absence of obvious parkinsonian signs on physical examination, subjective complaints 
of stiffness, tremors or imbalance deserve careful attention. Our observation that 
persons reporting such complaints had an increased risk to develop PD during 
follow-up suggests that preclinical dopamine deficiency may induce subtle signs 
before onset of typical motor symptoms. This notion may also be relevant to the 
detection and diagnosis of presymptomatic PD, which will become more urgent once 
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preventive therapies are available. The assessment of subjective complaints might be 
a simple and inexpensive first step of a series of tests meant to identify patients in 
the early stages of neurodegeneration. 
It would be premature to draw conclusions regarding treatment or prevention of PD 
from the results of our studies on potential risk factors for the disease. Before any 
recommendations can be given on dietary intake, measurement of serum levels or 
genetic screening, our data need confirmation in other studies. The implications of our 
findings rather lie in their contribution to current knowledge on the pathofysiological 
processes that underlie the selective dopaminergic cell death in PD. As was discussed 
previously, most of these findings are in line with the idea that oxidative stress is 
implicated in PD pathogenesis. Much of the evidence for a role of oxidative stress 
is derived from animal models, post-mortem studies and genetic research and 
mainly concerns biochemical or neuropathological characteristics in individuals 
or animals already affected by PD. This may complicate the distinction between 
causal mechanisms on the one hand and reactive phenomena secondary to the 
disease process on the other. Prospectively designed epidemiological studies like the 
Rotterdam Study, in which potential risk factors are assessed before onset of disease, 
may help to draw conclusions regarding causal mechanisms. Observational studies 
in large cohorts are well suited to test laboratory findings in the general population. 
Integration of lessons learned form experimental studies, genetics and epidemiology 
will eventually help to identity the common pathways involved in PD. 
Recommendations for future research
Despite all the recent advances that have led to new and crucial pathofysiological 
insights, PD is still an incurable disease. Therapies for PD are as yet only symptomatic 
and especially chronic medication use is accompanied by considerable side effects. 
A major challenge for the next years is therefore to further unravel the mechanisms 
responsible for dopaminergic cell death, in order to stimulate the development of 
treatments that may slow down, stop or preferably prevent the disease. The various 
pathways that have been implicated in PD pathogenesis provide targets for putative 
neuroprotective therapies. Many candidate drugs have been identified and tested in 
small-scale preliminary trials, including the antioxidants vitamin E and coenzyme 
Q10, MAO-B inhibitor deprenyl and several dopamine agonists that have been 
demonstrated to protect dopaminergic neurons and to inhibit apoptosis in laboratory 
studies.36 Although evidence has been found for neuroprotection from coenzyme Q10 
in the form of slowing of disease progression, preventive or curative effects have not 
yet been observed for any of the investigated agents.37 
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Several of our findings deserve further exploration, as they might provide clues to PD 
pathogenesis. This holds in particular for the putative link between fat metabolism 
and PD. The significance of the inverse association between serum total cholesterol 
and the risk of PD is as yet unclear, but could be further elucidated in epidemiological 
studies with long term follow-up and repeated cholesterol measurements, which 
would provide an opportunity to see whether cholesterol levels vary with disease 
progression or severity. More insights could come from evaluating the effect on PD risk 
of polymorphisms of genes involved in transport and metabolism of cholesterol, such 
as the hepatic lipase gene, cholesterol ester transfer protein (CETP) and apolipoprotein 
E (APOE) genes,38,39 or a potential modifying effect of these polymorphisms on the 
effect of other risk factors for PD. At the start of the Rotterdam Study in the early 
1990s, use of lipid lowering drugs was not yet as widespread among elderly people 
as it is nowadays. Therefore, low numbers precluded analyses on the association 
between statin use and PD risk. This will, however, become less of a problem now 
that participants are still followed and both the number of persons with a prescription 
for lipid-lowering medication and the number of incident PD cases are expected to 
increase. The potential link with coenzyme Q10 is of particular interest given its role 
in mitochondrial complex I and antioxidant effects, and merits evaluation in a large 
prospective study with coenzyme Q10 measurements before onset of PD. 
The intriguing observation that smoking seems to protect against PD has been the 
subject of many research projects, but underlying mechanisms have not yet been 
found. Other findings from epidemiological research that need to be clarified include 
the higher incidence of PD in men and the increased risk of PD in carriers of the 
APOE ε2 allele. Thus far, potentially interesting interactions and subgroup effects 
that might provide more insight could not be evaluated in many cohort studies, 
because of low numbers of PD cases. Due to the relatively low incidence of PD (at 
least compared to other major disease outcomes like dementia and cardiovascular 
illness), large cohorts and long follow-up periods are needed to identify a sufficient 
number of patients to allow for more sophisticated analyses. As was mentioned 
before, follow-up is still ongoing and more PD patients are expected to be identified, 
especially since participants are getting older. 
Besides longer follow-up and larger numbers, the implementation of new techniques 
in epidemiological studies may open up new possibilities to evaluate the role of 
earlier hypothesized but not yet proven risk factors in PD. MRI scanning of the brain 
in large population-based studies might for example shed a light on the hypothesis 
that iron metabolism is involved in PD pathogenesis. Iron is thought to contribute 
to neuronal damage in PD through enhanced generation of reactive oxygen species 
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and an increase in oxidative stress.40 Increased iron levels have been found post 
mortem in the substantia nigra of PD patients and a positive association between 
dietary iron intake and PD risk has been observed.40,41 Prospective studies with iron 
measurements on MRI before onset of PD have not been conducted thus far, but 
might be valuable for research on the role of iron in PD pathogenesis.
Not only pathogenetic insight, but also the diagnosis of PD should be improved, as 
inaccuracy inherent to the clinical diagnosis of PD is a problem in both research and 
clinical practice. An easily applicable and reliable test or marker for PD would greatly 
improve diagnostic accuracy. Candidate biomarkers for PD that have been investigated 
so far are characteristics of functional neuroimaging techniques such as PET and 
SPECT scanning42 and markers of oxidative stress and mitochondrial dysfunction 
in brain tissue, cerebrospinal fluid and blood such as malonaldehyde, superoxide 
radicals, the coenzyme Q10 redox ratio, 8-hydroxy-2’-deoxyguanosine from oxidized 
DNA and 8-hydroxyguanosine from RNA oxidation.43 However, functional imaging is 
still expensive and not yet widely available, and none of the biochemical markers was 
proven specific enough to be useful as a diagnostic marker in clinical practice.44 
Biomarkers could also be used to diagnose PD in very early or even preclinical 
stages. It has been shown that typical motor symptoms of PD only appear after 
more than half of the dopaminergic neurons have degenerated,45,46 implying that 
the processes leading to cell death have already been set into motion long before a 
clinical diagnosis can be made. It is of particular interest to identify means to detect 
patients during this preclinical period, because disease-modifying and preventive 
therapies, including neural cell transplantation, likely are most beneficial when 
applied as early in the pathogenetic process as possible.6,47 Prospective population-
based epidemiological studies are particularly well suited to identify markers of 
preclinical disease, as biochemical and clinical characteristics are assessed when 
all participants are still without symptoms, which enables comparison between 
future patients and persons who remain disease-free during follow-up. Proteomics, a 
methodology that studies and compares peptide profiles in various tissues, is likely 
to make an increasingly important contribution to this kind of research, given the 
recent interest in the processes of protein misfolding and degradation supposedly 
involved in PD pathogenesis. It should finally be pointed out that considering the 
complex and multifactorial etiology of PD, it is probably more useful to combine 
potential biomarkers, gene polymorphisms, clinical characteristics and other risk 
factors to construct models that may predict future risk of disease. Again, the study 
design of population-based prospective cohort studies provides an optimal setting to 
accomplish this challenge.
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Summary
Parkinson disease (PD) is the second most common neurodegenerative disorder, 
and is clinically characterized by resting tremor, rigidity, bradykinesia and postural 
imbalance. These typical motor symptoms result from a selective degeneration of 
dopamine-producing neurons in the substantia nigra in the brain stem. Despite 
intensive research in the last decades, the pathogenetic mechanisms responsible 
for this process are still not completely understood and therapies for PD are as 
yet only symptomatic. Current thinking is that in the majority of cases, PD is a 
multifactorial disease that results from interactions between several genetic and non-
genetic risk factors. Since 1997, several gene mutations have been identified that 
cause familial forms of the disease with a clear Mendelian mode of inheritance, but 
monogenetically determined PD is thought to make up only 10% of all cases. Although 
there seem to be many different causes for PD, they converge on several common 
molecular mechanisms that ultimately lead to dopaminergic cell death. These include 
dysfunction of mitochondria, oxidative stress and impaired function of the ubiquitin-
proteasome system, which is responsible for the elimination of misfolded or damaged 
proteins. More insight in these pathogenetic pathways is needed to acquire a better 
understanding of the disease and to develop effective therapeutic interventions.
The aim of this thesis was to assess the impact of PD in the general population 
in terms of frequency and prognosis, and to identify potential risk factors for the 
disease. The studies we conducted were all embedded in the Rotterdam Study, a 
large prospective population-based cohort study in 7,983 participants aged 55 years 
and older, with assessment of many potential risk factors at baseline and repeated 
in-person screening for PD.
Chapter 1 is a brief introduction to the work presented in this thesis. In Chapter 
2, I discuss currently available evidence on diagnosis, frequency, risk factors and 
prognosis of PD from an epidemiological point of view. Numerous epidemiological 
studies on PD have been carried out, but many of them were hampered by inferior 
study designs, low numbers of included subjects or inadequate case ascertainment 
or –definition. We therefore paid special attention to methodological issues and the 
influence of study design on the usefulness of epidemiological data and interpretation 
of findings.
In Chapter 3.1, I describe the results of our study on the incidence of parkinsonism 
and PD. The incidence of both parkinsonism and PD consistently increased with age. 
Incidence rates in our study were higher than those reported by most previous studies, 
most likely due to our intensive case-finding methods. Over one third of the incident 
PD cases that we identified had not been diagnosed with PD before. The incidence 
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of PD seemed higher in men, possibly as a result of neuroprotective effects that have 
been found for estrogens. These findings suggest a substantial underdiagnosis of PD 
in the general population and emphasize the importance of direct examination of all 
participants in epidemiological studies on PD.
In Chapter 3.2, I evaluate the relationship between subjective motor complaints at 
baseline in participants free of dementia and without clinically obvious parkinsonian 
signs, and the risk to develop PD during follow-up. Subjective complaints of tremors, 
stiffness, slowness, a feeling of imbalance or falling were reported by more than half 
of the participants at baseline, although no parkinsonian signs were observed on 
physical examination. We found that subjective complaints about stiffness, tremors or 
imbalance at baseline were associated with an increased risk to develop PD during 
follow-up. Our results suggest that early dopamine deficiency may induce subtle 
signs before onset of typical motor symptoms, and that a questionnaire on subjective 
complaints could add to the earlier recognition of PD.
Chapter 4.1 addresses the relationship between dietary intake of various types of fat 
and the risk of PD. People with higher intake of unsaturated fatty acids at baseline 
had a significantly decreased risk of incident PD. Given the reported antioxidant 
properties of polyunsaturated fatty acids, this is in line with the hypothesis that 
oxidative stress plays a role in dopaminergic cell death in PD. On the other hand, 
recent evidence suggests that alterations in fat metabolism might be involved in PD 
pathogenesis. In Chapter 4.2, I describe the association between serum levels of total 
and HDL cholesterol and PD risk. Higher baseline levels of total cholesterol were 
associated with a significantly lower risk of PD in a dose-effect manner, although 
only in women. Possible explanations for this association include the link with fat 
metabolism or the correlation between cholesterol and the strong antioxidant and 
electron acceptor for mitochondrial complex I, coenzyme Q10.
Evidence from animal studies suggests that high levels of homocysteine may contribute 
to neuronal cell death in PD, probably by increasing oxidative stress. In Chapter 5.1, 
I therefore explore the association between the TT variant of the methylenetetrahy
drofolate reductase (MTHFR) C677T polymorphism, which is associated with mild 
hyperhomocysteinemia, and the risk of PD. The TT genotype was associated with an 
increased risk of PD, particularly in smokers, which fits reported synergistic effects 
of smoking and TT genotype on plasma homocysteine levels. In Chapter 5.2 we 
investigated the effect on PD risk of dietary intake of folate, vitamin B12 and vitamin 
B6, essential co-factors that are required to keep plasma homocysteine levels low. 
Higher dietary intake of vitamin B6, but not of folate or vitamin B12, was associated 
with a significantly decreased risk of PD. These findings may be explained by the 
antioxidant properties that have been reported for vitamin B6 (in addition to its 
homocysteine-lowering effects), or its role in dopamine synthesis. To further explore 
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the role of oxidative stress in PD, we studied the relationship between serum levels 
of the antioxidant uric acid and the risk of PD. In Chapter 5.3 I report our finding that 
higher levels of uric acid were associated with a significantly lower risk of PD, with 
a clear dose-effect relationship.
Chapter 6 describes the prognosis of PD patients in terms of risk of dementia and 
mortality. Patients with PD had a significantly increased risk of developing dementia 
and a reduced life expectancy compared to participants without PD. The risk of 
dementia was especially pronounced in participants carrying at least one APOE ε2 
allele. Although modifying effects of APOE genotype on the prevalence of PD and 
the risk of dementia associated with PD have been described previously, a biological 
explanation is as yet lacking. Increased mortality risk was more prominent in PD 
patients with longer disease duration and was attenuated after adjustment for the 
occurrence of dementia, which suggests that the increased risk of dementia is partly 
responsible for the reduced survival in PD patients. 
In Chapter 7 an attempt is made to place our findings in a broader perspective. I 
discuss how our findings fit into current knowledge and models for PD pathogenesis, 
reflect on the relevance and potential implications of our observations and discuss 
directions for future research. 
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Samenvatting
De ziekte van Parkinson is na de ziekte van Alzheimer de meest voorkomende 
neurodegeneratieve aandoening. Kenmerkende verschijnselen voor de ziekte van 
Parkinson zijn rusttremor, rigiditeit, bradykinesie en gestoorde houdingsreflexen. Deze 
symptomen zijn het gevolg van het afsterven van dopamine-producerende zenuwcellen 
in de substantia nigra in de hersenstam. Ondanks recente wetenschappelijke 
doorbraken zijn de precieze oorzaken en onderliggende pathogenetische mechanismen 
van de ziekte nog grotendeels onbekend en is er tot op heden geen preventieve of 
curatieve therapie voorhanden. 
Sinds 1997 zijn enkele genmutaties ontdekt die verantwoordelijk zijn voor familiaire 
vormen van de ziekte van Parkinson. Het aandeel van deze monogenetisch bepaalde 
varianten wordt echter geschat op slechts 10% van alle ziektegevallen. In de overige 
gevallen wordt de zieke beschouwd als een multifactoriële aandoening die het gevolg 
is van wisselwerking tussen diverse genetische en niet-genetische risicofactoren. 
Hoewel er sprake lijkt van vele en zeer diverse potentiële risicofactoren, zijn deze 
waarschijnlijk terug te voeren op een beperkt aantal moleculaire mechanismen die 
uiteindelijk leiden tot dopaminerge celdood. Als belangrijkste mechanismen worden 
momenteel gezien mitochondriële disfunctie, oxidatieve schade en stoornissen in 
het ubiquitine-proteasoom systeem, een systeem verantwoordelijk voor afbraak en 
eliminatie van afwijkende of beschadigde eiwitten uit lichaamscellen. Meer inzicht 
in deze mechanismen is vereist om de ziekte van Parkinson te doorgronden en 
werkzame therapieën te ontwikkelen.
Het doel van het onderzoek dat is beschreven in dit proefschrift was het vaststellen 
van de frequentie en prognose van de ziekte van Parkinson in de algemene bevolking 
en het identificeren van mogelijke risicofactoren voor de ziekte. Alle studies maakten 
deel uit van het Erasmus Rotterdam Gezondheid en Ouderen (ERGO) onderzoek, een 
groot prospectief bevolkingsonderzoek naar frequentie en oorzaken van chronische 
ziekten bij ouderen. Tussen 1990 en 1993 werden 7983 personen van 55 jaar en 
ouder uitgebreid onderzocht en geïnterviewd, waarbij gegevens werden vastgelegd 
over diverse mogelijke risicofactoren. In de jaren die daarop volgden werd van alle 
deelnemers onder meer bijgehouden of ze de ziekte van Parkinson ontwikkelden. 
Hiertoe werden de deelnemers opnieuw lichamelijk onderzocht (in 1993-1994, 1997-
1999 en 2002-2004) en werden medische dossiers en medicatiegegevens geraadpleegd 
via een continue geautomatiseerde koppeling met bestanden van huisartsen en 
apotheken.
Na een korte inleiding in hoofdstuk 1 geven we in hoofdstuk 2 een uitgebreid overzicht 
van de tot nu toe gepubliceerde resultaten van epidemiologisch onderzoek naar de 
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diagnose, frequentie, risicofactoren en prognose van de ziekte van Parkinson. Hoewel 
er wereldwijd vele epidemiologische studies zijn uitgevoerd, was een aanzienlijk 
deel hiervan wat betreft studie-opzet, uitvoering en omvang niet optimaal. In dit 
hoofdstuk besteden we bij het bespreken van deze studies dan ook vooral aandacht 
aan de methodologische kwaliteit, omdat deze van invloed is op de bruikbaarheid 
en de interpretatie van de verkregen resultaten.
Hoofdstuk 3.1 beschrijft ons onderzoek naar de incidentie van parkinsonisme en 
de ziekte van Parkinson in de algemene bevolking. Voor zowel parkinsonisme als 
de ziekte van Parkinson zagen we een duidelijke stijging van de incidentie met 
toenemende leeftijd. De ziekte van Parkinson leek iets vaker voor te komen bij 
mannen dan bij vrouwen, hoewel het verschil net niet statistisch significant was. De 
incidentie van de ziekte van Parkinson lag in onze studie hoger dan in veel van de 
eerder gepubliceerde onderzoeken. Dit is vermoedelijk het gevolg van de intensieve 
manier waarop in het ERGO onderzoek naar aanwijzingen voor het bestaan van 
de ziekte van Parkinson wordt gezocht. Door niet alleen gebruik te maken van 
informatie in medische dossiers, maar de deelnemers ook zo veel mogelijk persoonlijk 
te onderzoeken werd een aanzienlijk aantal patiënten ontdekt bij wie de diagnose 
ziekte van Parkinson nog niet eerder was gesteld, hetgeen doet vermoeden dat deze 
aandoening lang niet altijd herkend wordt. Daarnaast benadrukt deze observatie het 
belang van direct lichamelijk onderzoek van alle deelnemers in epidemiologische 
onderzoeken naar de ziekte van Parkinson .
In hoofdstuk 3.2 beschrijven we de relatie tussen subjectieve motorische klachten 
en het risico om later de ziekte van Parkinson te ontwikkelen. Van de deelnemers 
die bij het lichamelijk onderzoek aan het begin van de studie geen parkinsonistische 
verschijnselen vertoonden, rapporteerde meer dan de helft desondanks subjectieve 
klachten van stijfheid, trillen, traagheid, een onvast gevoel of vallen. We vonden 
dat subjectieve klachten van stijfheid, trillen of een onvast gevoel bij aanvang van 
de studie geassocieerd waren met een significant verhoogd risico om later in het 
onderzoek te ziekte van Parkinson te ontwikkelen. Dit kan betekenen dat een tekort 
aan dopamine vroeg in het ziekteproces al subtiele verschijnselen kan geven, voordat 
de voor de ziekte zo kenmerkende motorische symptomen optreden. Een vragenlijst 
over dergelijke subjectieve klachten zou dan ook mogelijk een bijdrage kunnen 
leveren aan het opsporen van de ziekte van Parkinson in een vroeger stadium.
In hoofdstuk 4.1 onderzoeken we het verband tussen consumptie van verschillende 
typen vetzuren (gemeten via een voedingsvragenlijst) en het risico op de ziekte van 
Parkinson. Een hogere inname van onverzadigde vetzuren bleek geassocieerd met een 
significant lager risico op de ziekte van Parkinson. Gezien de anti-oxidant werking 
van onverzadigde vetzuren ondersteunt deze bevinding de hypothese dat oxidatieve 
schade een rol speelt bij het afsterven van dopaminerge zenuwcellen. Daarnaast 
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suggereren recente literatuurgegevens dat veranderingen in vetmetabolisme een 
rol kunnen spelen bij de pathogenese van neurodegeneratieve aandoeningen. In 
hoofdstuk 4.2 bekijken we daarom de relatie tussen het cholesterol (totaal cholesterol 
en HDL cholesterol) gehalte in het bloed en het risico op de ziekte van Parkinson. 
Hogere spiegels van totaal cholesterol bleken gerelateerd aan een significant verlaagd 
risico op de ziekte van Parkinson, echter alleen bij vrouwen. Een duidelijke verklaring 
voor deze observatie ontbreekt nog, maar mogelijk speelt de correlatie tussen 
cholesterol en concentratie in het bloed van co-enzym Q10 een rol. Co-enzym Q10 
is een sterke anti-oxidant en elektronenacceptor voor het mitochondriële complex I, 
en zou volgens recente theorieën een gunstige invloed kunnen hebben op ziekten 
waarbij de functie van mitochondriën is gestoord.
Dieronderzoeken hebben aangetoond dat hoge concentraties van homocysteine het 
proces van dopaminerge celdood kunnen bespoedigen, mogelijk door een toename 
van oxidatieve schade. Om deze reden onderzochten we het effect op het risico op de 
ziekte van Parkinson van de TT variant van het methylenetetrahydrofolate reductase 
(MTHFR) C677T polymorfisme. Personen met deze genvariant hebben vaak een licht 
verhoogde homocysteineconcentratie in het bloed. In hoofdstuk 5.1 beschrijven we 
dat deelnemers met het TT genotype, met name rokers, een significant verhoogd risico 
hadden op de ziekte van Parkinson. Dit past bij eerder beschreven synergistische 
effecten van roken en het TT genotype op de homocysteine concentratie. In hoofdstuk 
5.2 beschrijven we de relatie tussen inname via de voeding van foliumzuur, vitamine 
B12 en vitamine B6 –vitaminen die nodig zijn om het homocysteine gehalte in het 
bloed laag te houden- en het risico op de ziekte van Parkinson. Een hogere consumptie 
van vitamine B6, maar niet van foliumzuur of vitamine B12, was gerelateerd aan een 
verlaagd risico op de ziekte van Parkinson. Dit wordt mogelijk verklaard doordat 
vitamine B6 niet alleen een rol speelt in het metabolisme van homocysteine, maar 
ook bij de synthese van dopamine, en daarnaast anti-oxidatieve eigenschappen 
vertoont. Om de mogelijke invloed van oxidatieve schade verder te onderzoeken, 
keken we vervolgens naar de invloed van de concentratie van urinezuur in het bloed. 
In hoofdstuk 5.3 presenteren we onze bevinding dat een hogere concentratie van 
urinezuur (een sterke anti-oxidant) gepaard gaat met een lager risico op de ziekte 
van Parkinson.
Hoofdstuk 6 behandelt de prognose van patiënten met de ziekte van Parkinson. 
Deelnemers met de ziekte van Parkinson hadden een significant groter risico om 
dement te worden en een significant verkorte levensverwachting vergeleken met 
deelnemers zonder de ziekte. Met name patiënten met het APOE ε2 allel hadden een 
sterk verhoogd risico op het ontwikkelen van dementie. De biologische verklaring 
voor deze bevinding is nog onduidelijk, hoewel een mogelijke invloed van het APOE 
genotype op de ziekte van Parkinson en dementie bij de ziekte van Parkinson eerder 
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beschreven is. Een verhoogde mortaliteit werd met name gezien onder patiënten 
die al langere tijd leden aan de ziekte van Parkinson en was minder uitgesproken 
na correctie voor het optreden van dementie, hetgeen suggereert dat de verkorte 
levensverwachting van patiënten met de ziekte van Parkinson gedeeltelijk is toe te 
schrijven aan een verhoogd risico om dement te worden. 
Tot slot probeer ik in hoofdstuk 7 onze observaties in een breder perspectief te 
plaatsen. Ik bespreek hoe onze bevindingen aansluiten bij de huidige inzichten 
omtrent de pathogenese van de ziekte van Parkinson en besteed aandacht aan 
mogelijke implicaties voor de huidige praktijk en toekomstig onderzoek. 
188
Dankwoord
Letterlijk duizenden personen verdienen een vermelding in dit naar verluidt meest 
gelezen deel van het proefschrift. Op de eerste plaats de bijna achtduizend deelnemers 
aan het ERGO onderzoek die zich in de afgelopen vijftien jaar herhaaldelijk en 
zeer uitgebreid lieten ondervragen, prikken, meten, wegen, testen en onderzoeken 
omwille van de wetenschap. 
Zonder hen geen data, geen analyses, geen resultaten, geen publicaties. 
Dit gaat evenzeer op voor vele collega’s: alle medewerkers van het ERGO centrum, 
het datamanagement, de mannen van de automatisering en de dames van de fup. 
Iedereen, maar in het bijzonder Corina, Henriëtte en Trudy (voor de Parkinson 
screening), Anneke, Lyda, Jolande en Anne-Monique (voor het doorploegen van alle 
huisartsenstatussen op jacht naar Parkinsoncases), Anneke (voor te veel om op te 
noemen) en Frank (voor de interview-PD-alerts en talloze variabelen en bestanden): 
duizendmaal dank voor de onmisbare hulp.
Uiteraard wil ik op deze plek mijn beide promotoren bedanken, prof.dr.M.M.B. 
Breteler en prof.dr.P.J.Koudstaal. Beste Monique, de afgelopen jaren ben ik in 
toenemende mate gegrepen door het onderzoeksvirus, en daarin heeft jouw kritische, 
maar inspirerende en motiverende begeleiding zeker een belangrijke rol gespeeld. 
Ik heb veel meer van je geleerd dan alleen het schrijven van mooie papers en 
het doet me daarom genoegen dat we de samenwerking de komende jaren zullen 
voortzetten. Beste Peter, van de Parkinson-consensusmeetings tot de beoordeling 
van de manuscripten; het verliep allemaal even vlot, efficiënt, en toch altijd in een 
ontspannen sfeer. Ik zal trachten daar gedurende de opleiding een voorbeeld aan te 
nemen.
Daarnaast bedank ik graag een aantal andere personen voor hun bijdrage aan dit 
proefschrift: 
Prof.dr. A. (Bert) Hofman, hoofd van de afdeling Epidemiologie en Biostatistiek en 
inspirator van het ERGO-onderzoek, voor het aanstekelijke enthousiasme voor de 
epidemiologie en het commentaar op de stukken. Marjolijn Bornebroek, voor het 
meedenken over de Parkinson diagnostiek, het samen schrijven van artikelen en het 
goede gezelschap op de kamer gedurende ruim twee jaar. Prof.dr. B. (Bruno) Stricker, 
voor de (Parkinson)medicatiegegevens. Frank Jan, Marieke, Michiel en Arfan voor 
hun bijdrage aan de Parkinson-workups. En Maarten Schipper voor de statistische 
hulp als de analyses al te gecompliceerd dreigden te worden. 
189
Omdat een promotietraject – zoals zo veel zaken - nu eenmaal een stuk beter verloopt 
in een aangenaam werkklimaat, wil ik alle personen bedanken die er mede voor 
hebben gezorgd dat ik in de afgelopen drieënhalf jaar nooit met tegenzin naar mijn 
werk gegaan ben:
Sjoerd, Miranda en Mendel, voor de prima sfeer op de kamer. 
De overige (ex-)lotgenoten uit de neuro-epidemiologie groep (Ewoud, Tom, Niels, 
Frank Jan, Marieke, Michiel, Arfan, Meike, Willemijn, Kamran en Mariëlle), voor de 
feedback tijdens het wekelijkse overleg en omdat de deuren aan de overkant altijd 
open stonden.
De borreldames  (Arlette, Dominiek, Sharmila en Marieke), voor de zinnige en zinloze 
maar bovenal gezellige cardiovasculair-radiologisch-oogheelkundig-neurologische 
kruisbestuiving op vrijdagmiddag (en -avond) en tussen de bedrijven door.
Vele andere huidige en voormalige medepromovendi (Cornelis, Claire, Albert Jan, 
Sabine, Annette, Hok Hay, Stephanie, Gysele, Mariëtte, Suzette, Isabella, Simone, 
Dika en Julia) voor alle adviezen, tips, goede gesprekken en zaken die wat minder 
met het werk te maken hadden.
Joke, omdat het leuk was tijdens de epidemiologie-cursussen, en dat sindsdien zo 
gebleven is. 
De ERGO-dames, in het bijzonder Anneke Korving, voor de gezelligheid op het 
centrum, de persoonlijke belangstelling en niet te vergeten alle vakliteratuur.
Marti, voor de secretariële ondersteuning maar niet minder voor alles daarnaast.
Gelukkig sta ik tijdens de verdediging niet alleen. Leonie, na bijna 20 jaar ben je nog 
steeds een geweldige vriendin. Steeds een stapje voor met alle life-events, maar nu 
mag ik een keer als eerste! Marieke (M.), jouw naam staat nu het meest genoemd in 
dit dankwoord, dat zegt hopelijk genoeg. Fijn dat jullie mijn paranimfen willen zijn.
Er is meer in het leven dan werk alleen, en dat is maar goed ook. Velen verdienen 
dan ook dank voor hun zeer indirecte maar niet onbelangrijke bijdrage aan dit 
proefschrift. Alle vrienden en vriendinnen uit Brabant, Maastricht, Nijmegen, Utrecht, 
Amsterdam, Den Haag, Haarlem en Leiden: ik ben heel blij met jullie.
Lieve pap en mam, Mathijs en Bas, fantastische familie. In Brabant voel ik me altijd 
thuis. Een betere basis kan ik me niet wensen. 
Tot slot het thuisfront, mijn man en meisje. Lieke, jij hebt de allerhoogste impactfactor! 
En Tijn, je bent steeds mijn rots in de branding, ook tijdens dit project. Je hints waren 
niet nodig: 
deze laatste regel is voor jou, je verdient hem om alle denkbare redenen.
190
List of publications
De Lau LML, Giesbergen PCLM, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MMB. Incidence 
of parkinsonism and Parkinson disease in a general population. The Rotterdam Study. 
Neurology. 2004; 63:1240-1244.
De Lau LML, Bornebroek M, Witteman JCM, Hofman A, Koudstaal PJ, Breteler MMB. Dietary 
fatty acids and the risk of Parkinson disease. The Rotterdam Study. Neurology. 2005; 64: 2040-
2045.
De Lau LML, Koudstaal PJ, van Meurs JBJ, Uitterlinden AG, Hofman A, Breteler MMB. Methyle
netetrahydrofolate reductase C677T genotype and PD.  Ann Neurol. 2005; 57: 927-30. 
De Lau LML, Schipper CMA, Hofman A, Koudstaal PJ, Breteler MMB. Prognosis of Parkinson 
disease: risk of dementia and mortality. The Rotterdam Study. Arch Neurol. 2005; 62: 1265-
1269.
De Lau LML, Koudstaal PJ, Hofman A, Breteler MMB. Serum uric acid levels and the risk of 
Parkinson disease. Ann Neurol. 2005; 58:797-800.
De Lau LML, Koudstaal PJ, Hofman A, Breteler MMB. Subjective complaints precede Parkinson 
disease. The Rotterdam Study. Arch Neurol. (in press).
De Lau LML, Koudstaal PJ, Witteman JCM, Hofman A, Breteler MMB. Dietary folate, vitamin 
B12, and vitamin B6 and the risk of Parkinson disease. Submitted.
De Lau LML, Breteler MMB. Epidemiology of Parkinson disease. Submitted.
De Lau LML, Koudstaal PJ, Hofman A, Breteler MMB. Serum cholesterol levels and the risk of 
Parkinson disease. The Rotterdam Study. Submitted.
Bornebroek M, de Lau LML, Hofman A, Koudstaal PJ, Stricker BHC, Breteler MMB. Non-
steroidal anti-inflammatory drugs and the risk of Parkinson disease. Submitted.
Frigerio R, Breteler MMB, de Lau LML, Sanft KR, Bower JH, Ahlskog JE, Grossardt BR, de 
Andrade M, Maraganore DM, Rocca WA. Fertility and Parkinson’s disease in men: independent 
replication in two studies. Submitted.
191
About the author
Lonneke de Lau was born on September 17th, 1973 in Middelburg, the Netherlands. 
In 1991, she graduated from secondary school (Strabrecht College, Geldrop) and 
started her medical training at the University of Maastricht. From 1994 to 1997 she 
studied cultural anthropology and Spanish at the Radboud University Nijmegen. In 
1996 she participated in a research project on microglial reactivity in rat brains at 
the Universitat Autònoma de Barcelona. After she graduated from medical school 
in 1999, she provided medical care to refugees from the Kosovo war in a center in 
Arnhem for 9 months and spent 3 months working as a primary care physician in 
a rural clinic in Las Palomas (Queretaro), Mexico. Subsequently, she worked as a 
resident in Neurology at the OLVG hospital in Amsterdam (2001) and the Erasmus 
Medical Center in Rotterdam (first half of 2002). In August 2002 she started the 
work described in this thesis in the Neuroepidemiology group of the Department 
of Epidemiology and Biostatistics (prof. dr. M.M.B.Breteler) in collaboration with the 
department of Neurology (prof. dr. P.J. Koudstaal) of the Erasmus Medical Center. 
In 2004 she received a Master of Science degree in Clinical Epidemiology at the 
Netherlands Institute of Health Sciences (NIHES). She will start her residency in 
Neurology at the Erasmus Medical Center (prof. dr. P.A.E. Sillevis Smitt) after her 
thesis defense on February 1st, 2006.

